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1. Abbrevations
A Alanine
A˚ Angstro¨m
Ala Alanine
Arg Arginine
AP-1 activator protein-1
Asp Aspartate
Asn Asparagine
ATP Adenosintriphosphate
C Cysteine
CD Crohn’s disease
DHFR dihydrofolate reductase
COX Cyclooxygenase
Cys Cysteine
D Aspartate
DMARDs Disease-modifying anti-rheumatic drugs
E Glutamate
EN Energy
ERK Extracellular signal-regulated kinase
F Phenylalanine
G Glycine
Glu Glutamate
Gln Glutamine
Gly Glycine
H Histidine
H-bond Hydrogen-bond
His Histidine
HTS High-Troughput-Screening
xx
I Isoleucine
IBD Inflammatory Bowel Disease
IL Interleukin
Ile Isoleucine
JNK c-Jun NH2-terminal kinase
JIP JNK-interacting proteins
K Lysine
L Leucine
LC/MS Liquid Chromatography/Mass Spectrometery
Leu Leucine
Lys Lysine
M Methionine
Met Methionine
MAPK Mitogen-activated protein kinase
MAPKAP K2 MAPK activated protein kinase 2
MAPKK Mitogen-activated protein kinase kinase
MAPKKK Mitogen-activated protein kinase kinase kinase
MIF Molecular Interaction Fields
MKK MAP Kinase Kinase
MKP MAP kinase phosphatase
mol2 mol2 (file format)
MTX Methotrexate
MW Molecular Weight
N Asparagine
NMR Nuclear magnetic resonance
NSAIDs Non-steroidal anti-inflammatory drugs
n.t. not tested
P Proline
p38 MAP kinase p38 mitogen-activated protein kinase
PDB protein database bank (file format)
PPAR-γ peroxisome proliferators-activated receptor ligand-γ
PGE2 Prostaglandine E2
Phe Phenylalanine
Pro Proline
Q Glutamine
R Arginine
RA Rheumatoide Arthritis
RDF Receptor description file
RMSD Root mean square deviation
RNA Ribonucleic acid
S Serine
SAR Structure Activity Relationship
Ser Serine
SP standard-precision (GLIDE)
T Threonine
TAB transforming growth factor-β-activated protein kinase binding protein
TAK transforming growth factor-β-activated kinase 1
Thr Threonine
TNF-α Tumor necrosis factor-α
Trp Tryptophane
Tyr Tyrosine
UC Ulcerative Colitis
V Valine
Val Valine
VS Virtual Screening
W Tryptophane
WT Wild type
XP extra-precision (GLIDE)
Y Tyrosine
2. Zusammenfassung
Die p38 MAP Kinase and JNK3 geho¨ren zur Familie der MAP Kinasen und steuern die
Freisetzung verschiedener entzu¨ndungsfo¨rdernder Zytokine, die bei chronisch entzu¨ndlichen
Erkrankungen wie Rheumatoide Arthritis, Morbus Crohn, Psoriasis, Asthma oder Alzheimer,
sowie Krebs eine entscheidene Rolle spielen. Die medikamento¨se Therapie ist in vielen Fa¨llen
noch unzureichend. Die Hemmung der p38 MAP Kinase mit sogenannten ”small molecule
inhibitors” stellt eine Kontrolle der Biosynthese und Freisetzung der entzu¨ndungsfo¨rdernden
Faktoren in Aussicht. Verschiedene pharmazeutische Unternehmen arbeiten an der Entwick-
lung derartiger Inhibitoren. In unserem Arbeitskreis wurden die ”Suberone”als neue Klasse von
Liganden entwickelt. Ihre Wirksamkeit wurde in verschiedenen Testsystemen nachgewiesen.
Da es sich hierbei um neue Leitstrukturen handelt, war bis jetzt der genaue Bindemodus
noch nicht bekannt und die Synthese verscheidener Derivate konnte noch nicht gezielt nach
Struktur-Aktivita¨ts-Beziehungen erfolgen. Die vorliegende Arbeit befasst sich mit der Unter-
suchung des Bindemodus der ”Suberone” mit verschiedenen Methoden des Molecular Model-
ing. Die von anderen Gruppen vero¨ffentlichten dreidimensionalen Ro¨ntgen-Kristallstrukturen
der p38 MAP Kinase und JNK3 wurden in Bezug auf ihre Qualita¨t verglichen. Die besten
verschiedenen Konformationen wurden ermittelt und fu¨r die weiteren Studien verwendet. Mit
dem Programm GRID wurden innerhalb der ausgewa¨hlten Proteinstrukturen die energetisch
gu¨nstigsten Positionen berechnet, an denen bestimmte Strukturfragmente, wie sie auch im
”Suberone”-Geru¨st (z.B. Carbonyle) vorhanden sind, am wahrscheinlichsten vorkommen wer-
den. Im Anschluss wurden verschiedene Dockingstudien durchgefu¨hrt. Mit jedem verwen-
deten Dockingprogramm wurde zuerst Re-Docking- und Cross-Docking-Versuche vorgenom-
men. Dafu¨r wurden die in den Proteinstrukturen vorhandenen Liganden unvera¨ndert in einer
Liganden-Datenbank gespeichert und zum Docking verwendet. Ausserdem wurde eine Daten-
bank von ”Suberone”-Strukturen erstellt, welche solche ”Suberone”, von denen bereits Hemmw-
erte bekannt sind, sowie solche, mit denen man mo¨gliche verschiedene Bindemodi untersuchen
ko¨nnte, beinhaltet. Diese Datenbank wurde mit Hilfe der Dockingprogramme FlexX, Flexidock,
GLIDE und eHITS in die verschiedenen inzwischen vorliegenden Kristallstrukturen gedockt.
Zusammen mit den Daten, die bei Studien mit GRID erstellt wurden, konnte dadurch nur
ein mo¨glicher Bindemodus ermittelt werden. Mit Hilfe einer Kristallstruktur einer p38 MAP
Kinase mit einer ”Suberone”-Struktur konnte der durch die Modeling Studien vorgeschlagene
Bindemodus inzwischen besta¨tigt werden.
3. Introduction
3.1. Proteins
3.1.1. Basics
Proteins are composed of amino acid which contain two functional groups: the amino group
(NH2) and the carboxyl group (COOH), which are connected via the alpha carbon (α-C)
atom. Normally amino acids exist as ”Zwitterions”, where the amino group is protonated and
the carboxylic group is in its carboxylate form. The side chains can be classified into three
major groups: charged polar, uncharged polar or nonpolar. The charged polar side chains can
be positively (Lysine, Arginine and Histidine) or negatively charged (Aspartate and Glutamate).
The uncharged polar side chains have hydroxyl (Serine and Threonine), phenolic (Tyrosine),
amide (Asparagine and Glutamine) or thiol groups (Cysteine). Nonpolar side chain residues
differ in shape and size. Glycine is the smallest, followed by Alanine, Valine, Leucine and
Isoleucine. Methionine has a thiol ether side chain, while Phenylalanine and Tryptophane are
aromatic. Finally Proline has a cyclic pyrrolidine side group.
The geometry of the side chains is determined by the torsion angles of the bonds coming from
the atoms of the side chains. The carbons of the side chain are called β-C, γ-C and δ-C.
The residues Glycine, Alanine and Proline do not have torsion angles, because in case of the
Glycine there is only a hydrogen, Alanine just has a methyl group as side chain, while the
Proline side chain is forming a ring. Due to this the side chains can not be regarded as flexible.
The amino acids in a protein are polymerized via the peptide bond which is created through
the elimination of water. A protein is made of more than 35 residues connected via the peptide
bond. A protein’s primary structure is the sequence of the residues in a polypeptide chain.
The residue with a free amino group is called the N-terminus, while the residue with a free
carboxylate group is called the C-terminus. The backbone of a protein just consists of the
atoms of the peptide bond. The conformation of the backbone is described by the torsion
angles around the α-C-N (measured in φ) and the α-C-C (measured in ψ) bond. These angles
are both defined as 180, when the polypeptide chain is in its fully extended conformation and
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increases clockwise when viewed from the α-C. Therefore the conformational freedom of the
backbone and the torsions are sterically constrained. Rotation around the α-C-N and the
α-C-C bonds to form certain combinations of φ and ψ angles may cause the amide hydrogen,
the carbonyl oxygen, or the substituents of α-C of adjacent residues to collide.
The interactions between different backbone residues create the secondary structure of a
protein. There are two immediately recognizable secondary structures: α-helix and β-sheet. In
the α-helix every ninth C=O backbone residue points along the N-H group of the fourth residue.
This results in a strong H-bond. The side chains project away from the helix. In β-sheets
H-bonds occur between neighbouring polypeptide chains. The β-sheet can be divided into
two varieties. In the antiparallel β-sheet the neighbouring chains run into opposite directions,
while in the parallel sheet they run in the same direction. There are often combinations of
parallel and antiparallel β-sheets. Many proteins surfaces contain variations of the secondary
structure. α-helices and β-sheets can be joined by stretches, which abruptly change direction,
the so-called loops. Loops play important roles in substrate recognition. Various other motifs
can act as binding sites. The rearrangement of several motifs folded into two or more global
clusters are called domains. Binding sites for natural substrates or small molecule inhibitors are
often located between two domains. So the substrate is bound by groups from both domains.
This allows flexible interactions between protein and substrate.
The tertiary structure describes the three-dimensional folding of the secondary structure and
specifies the position of the side chains. Proteins which consist of more than one polypeptide
chain, associate their subunits in a specific geometry; the quarternary structure (figure 3.1)[5].
Figure 3.1.: Protein structure, picture taken from www.contexo.info
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3.1.2. Determining Protein Structure
X-ray crystallography or nuclear magnetic resonance (NMR) can be used to obtain a three-
dimensional picture of a protein. For this study only protein structure models which were
obtained by X-ray crystallography were used.
3.1.2.1. X-ray crystallography
The first step is the production of crystals which is the rate-limiting step in the determination
of structures. The crystallization process has to produce crystals, that are large enough and
diffract sufficiently [6]. Then X-rays can make up an image of a molecule, because its wave-
length is comparable to covalent bond distances. When a crystal of a protein is exposed to a
parallel beam of X-rays, the atoms in the molecule scatter the X-rays, with the scattered rays
reinforcing each other. This results in a diffraction pattern, which is recorded. The intensities
of the diffraction maxima are used to calculate a three-dimensional image of the protein. The
X-rays only interact with the electrons and not with the atomic nuclei. The outcome is an
electron density map (figure 3.2).
Figure 3.2.: X-ray crystallography
Hydrogens are invisible, because they only have one electron. All of the protein crystals contain
water molecules, yielding to a disorder of the residues by a few Angstro¨m (A˚). This requires a
good resolution up to at most 2,5 A˚. On the other hand the hydration of the protein reproduces
the native conformation similar to that in cells. In the electron density map only the backbone
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atoms can be clearly traced. To deduce the position of the side chains, the sequence has to
be fitted on the electron density map [5].
3.1.2.2. NMR
Nuclear magnetic resonance (NMR) studies magnetic nuclei by aligning them with an applied
constant magnetic field and perturbing this alignment using an alternating electric field, those
fields being orthogonal. NMR spectroscopy handles the resulting response to the perturbing
magnetic field. Therefore it can be used to obtain physical, chemical, electronic and structural
information about molecules due to the chemical shift and Zeeman effect on the resonant
frequencies of the nuclei. It can provide detailed information on the topology, dynamics and
three-dimensional structure of molecules in solution. Commonly measured nuclei are hydrogen-
1 and carbon-13, along with nuclei from isotopes of many other elements (e.g. 15N, 14N, 19F,
31P, 17O, 29Si, 10B, 11B, 23Na, 35Cl, 195Pt). Since the mid-1980s NMR allows the determination
of three-dimensional structures of proteins in aqueous solution. These measurements yield the
inter-atomic distances between specific protons that are smaller than 5 Angstrom in a protein of
known sequence. Nuclear Overhauser effect spectroscopy (NOESY) or correlated spectroscopy
(COSY) can determine the inter-proton distances. Together with known geometric constraints
(e.g. van der Waals radii) these distances are used to calculate a three-dimensional structure
model. This structure can not be regarded as unique, because of the imprecision of the above
inter-proton distances. A NMR structure is therefore a representative sample of structures
that are consistent with the constraints. Another NMR technique is Transverse relaxation
optimized spectroscopy (TROSY) which is principally used for large proteins, because the
magnetization results in a shorter transverse relaxation times (T2). Therefore there is less
time to detect a signal [7]. Attenuated T2 relaxation by mutual cancellation of dipole-dipole
coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large
biological macromolecules in solution. TROSY selects the component for which the different
relaxation mechanisms have almost canceled, leading to a single, sharp peak in the spectrum.
This significantly increases both spectral resolution and sensitivity. In the end the NMR
structures are in the most favourable cases comparable to that of an X-ray structure with a
resolution of 2-2,5 Angstro¨m (A˚). Therefore, NMR methods provide a mutual crosschecking
with X-ray techniques and allow the determination of proteins which fail to crystallize [5].
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3.1.2.3. Protein Kinases
Protein kinases play a crucial role in many signal transduction pathways and therefore are very
important in biological processes such as cell growth, metabolism, differentiation and apop-
tosis. The development of small molecule inhibitors is a promising approach against many
diseases caused by a kinase malfunction. Glivec R© was the first kinase small inhibitor on the
market for the treatment of cancer. Other therapeutic targets connected to kinase malfunc-
tions are Psoriasis, Chronic Inflammatory Bowel Disease (CIDB) including ulcerative colitis
and Crohn’s disease, Rheumatoide Arthritis (RA) or Alzheimer’s Disease. All therapeutic ap-
proaches so far targeting the diseases above are unsatisfying, whether due to their side effects
(COX inhibitors) or high costs for the health insurance companies (figure 3.3).
Figure 3.3.: Rheumatoide Arthritis; picture taken from http://www.orthoteers.com
The Humane Genome Project identified over 518 genes which translate about 2500 protein
kinases [8]. Based on the catalytic specificity, they can be divided into those specific for
Tyr, for Thr/Ser and for both. This brought up the question, if there even can be any small
molecule inhibitors which measure up to the demands in regard to selectivity and specificity.
The crystallization of the first kinases identified the ATP-binding pocket as a suitable part
of the protein kinases for drug design. For all kinases bind ATP (Adenosintriphosphate) to
separate a phosphate of ATP to pass it to the next substrate for activation. In all kinases
the ATP cave is highly conserved and is situated between the two domains. The hinge region
which connects two domains allows donor-acceptor hydrogen-bonding, while the other parts
invite rather hydrophobic/van der Waals interactions. Figure 3.4 shows the ATP binding site.
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Figure 3.4.: ATP-binding site of protein kinases
In the adenine region ATP forms two H-bonds with the hinge region which connects the
N- and C-terminal domain. Many recently developed small molecule inhibitors form one or
more H-bonds to the hinge region of their target kinase as well. The hydrophilic sugar pocket is
also the target of some research [9]. ATP’s triphosphate group binds next to the sugar pocket
in the so-called phosphate-binding region and is considered to be a less important region to
target. The two hydrophobic regions are not occupied by ATP. The hydrophobic pocket I
plays an important role to achieve selectivity. The gate keeper residue which also presents
the beginning of the hinge region on the left side of the hydrophobic pocket I determines
the width of the entrance to this pocket (see next section for further explanations). Many
researchers try to gain selectivity and to improve solubility by adding substrates that occupy
the hydrophobic region II. It is more a slot and is opened to solvent[10].
3.2. The p38 MAP kinase
The p38 MAP kinase belongs to the family of mitogen-activated protein kinases (MAPK).
Those belong to the Serine/Threonine protein kinases, which play important roles in the
cellular response to different signals (figure 3.5).
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MAP kinases
Figure 3.5.: The Human Kinome Project, picture taken from www.kinase.com/human/kinome
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Cell growth, differentiation and apoptosis are regulated by extracellular signals. These signals
are transmitted to the inside of the cells, where signaling complexes are assembled for integra-
tion and processing, and lead to a response. MAP kinases, which integrate and process various
extracellular signals, are primary compounds of the intracellular signaling circuitry. The MAP
kinases mitogen-activated protein kinase kinase kinase (MAPKKK), mitogen-activated protein
kinase kinase (MAPKK) and MAP kinase create the MAP kinase cascade. In this cascade
three MAP kinase pathways have been described. The three kinases in mammalian cells are
extracellular signal-regulated kinase (ERK), c-JUN N-terminal kinase (JNK) and p38 MAP
kinase, which are to 65% identical, but differ in their sequences and the size of the activation
loop, as well as in their activation in response to different stimuli. Each MAP kinase is char-
acterized by the substrate it phosphorylates and by its activators. Those MAPK subfamilies
have different isoforms, which often have different functions. The p38 MAP kinase α isoform
which is the best characterized and perhaps most physiologically relevant kinase is involved
in the inflammatory process. The splice variants β, γ and δ have 60% identity to α and are
expressed in different more local tissues, whereas α is ubiquitously expressed. Until now little
is known about their function. All of these kinases are activated by dual phosphorylation of a
Thr-X-Tyr motif.
The p38 MAP kinase consists of two domains, a N-terminal domain with 135 residues and a C-
terminal domain of 225 residues. The N-terminus contains β-sheets, whereas the C-terminus
is largely helical. The active site is located at the junction between the two domains. The
domains are connected via the above mentioned hinge region [11]. The hinge region consists
in the case of the p38α MAP kinase of the following residues:
• Thr106, His107, Leu108, Met109, Gly110, Ala111 and Asp112
The N-terminal domain creates the upper part of the binding pocket for ATP, while the C-
terminal domain creates the loop, the catalytic base, the magnesium binding site (phosphate-
binding region) and the underground of the ATP binding pocket. The phosphate anchor,
which is composed of:
• Gly31, Ser32, Gly33, Ala34, Tyr35 and Gly36
and is therefore also called the Gly-rich loop (or Gly-X-Gly-X-X-Gly) which is highly mobile.
The phosphorylation loop, which is also highly mobile, consists of 14 residues:
• Gly170, Leu171, Ala172, Arg173, His174, Thr175, Asp176, Asp177, Glu178, Met179,
Thr180, Gly181, Tyr182 and Val183
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The p38 MAP kinase is dual-phosphorylated on Thr180 and Tyr182. In between lies Gly181.
Another important residue is Thr106 (hydrophobic pocket I), the so-called gatekeeper. The
residues in this position of the hinge region determines the size of the entrance of the hy-
drophobic pocket I and differ in the other isoforms and MAPKs. Other differences occur
concerning Gly110 (hinge region) [12] and Gly181 (phosphorylation loop). The hydrophobic
pocket I is constituted of the residues:
• Ala51, Lys53, Leu75, Ile84, Leu86, Leu104 and Thr106
whereas the hydrophobic region II consists of the following resides:
• Val30, Leu108, Met109, Gly110, Ala111, Asp112, Ala157 and Leu167
The phosphate binding region is created by the residues Arg67, Arg79, Arg149, Arg173, Arg186
and Arg189. Figure 3.6 shows the three-dimensional structure model of the p38α MAP kinase.
N-terminal 
domain
C-terminal 
domain
hinge region
phosphorylation loop
Gly-rich loop
Figure 3.6.: Structure of the p38α MAP kinase, PDB 2EWA [1]
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3.2.1. The p38 MAP kinase pathway
The p38 MAP kinase responds especially to environmental stress, including mechanical ex-
posure, UV-light, heat, osmotic shock and proinflammatory cytokines. The activation by
MAPKK, which in turn is phosphorylated by MAPKKK leads to the activation of p38 MAP
kinase. MAPKK3, MAPKK4 and MAPKK6 phosphorylate and therefore activate p38 MAP ki-
nase. Recently a MAPKK-independent mechanism by transforming growth factor-β-activated
protein kinase (TAK1) binding protein 1 (TAB1) was described. The dephosphorylation by var-
ious protein phosphatases regulates the activity of p38 MAP kinase. The activated p38 MAP
kinase phosphorylates and thus activates MAPK-activated protein kinase 2 (MAPKAPK2) in
response to chemical stress and thus plays an important role in the regulation of cytokine
expression. MAPKAPK2 regulates the production of Interleukin-6 (IL-6) and Tumor necrosis
factor-α (TNF-α) via messenger RNA turnover during transcription and protein translation.
Furthermore the p38 MAP kinase phosphorylates transcription factors such as ATF-2, which
is responsible for the production of mRNAs coding for the inflammatory cytokines IL-1β and
TNF-α. In addition the p38 MAP kinase controls the translation by phosphorylating an mRNA
suppressor protein (cytokine binding protein) and through interaction with p90rsk/S6 at a ri-
bosomal level (figure 3.7) [13].
Figure 3.7.: p38 MAPK pathway
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3.2.2. Inhibition of the p38 MAP kinase
The involvement of the p38 MAP kinase disclosed the search for selective p38 MAP kinase
inhibitors. As there are over 2000 kinases in human cells, the small molecule inhibitors have to
be selective for this special kinase. This is possible because the active sites of the kinases differ
in a small amount. All kinases bind ATP and it’s binding region is subdivided into six regions.
The hinge region connects the N-terminal with the C-terminal domain. Here, the adenine part
of ATP creates two H-bonds with the NH of Met109 and the amide C=O of Gly110. The
adenine binding region is created of the side chains of the N-terminal domain above and the
C-terminal domain below of adenine. In the sugar region the ribose is anchored over H-bonds
with the C-terminal domain. With the support of two magnesium ions the phosphate groups
are bound to the phosphate binding region. In addition to these hydrophilic regions the active
site is created by two hydrophobic regions. These regions are not occupied by ATP. The key
residue on case of the p38 MAP kinase is Thr106. The dimension of the its side chain defines
the enlargement of the region. The other MAP kinases have bigger residues in this position.
Many p38 MAP kinase inhibitors have a fluoro-phenyl to fit selectively in this region. That is
why the hydrophobic pocket I is also called the selectivity pocket. The hydrophobic region
II is more a groove, while the hydrophobic pocket I is deeply buried. Many small molecule
inhibitors have substituents to fit in that region. But occupying this pocket does not increase
selectivity, but helps to anchor the inhibitor in the active site, which may improve affinity [11].
Gly110 is a another specific residue of p38α MAP kinase. The selectivity of quinazolinones
and pyridol-pyrimidines results from a glycine in position 110, e.g. [14].
3.2.3. p38 MAP kinase as a target in the treatment of inflammatory
diseases
Although a variety of drugs is available for the treatment of inflammatory diseases, the therapy
is still unsatisfying. Many of the used drugs just work as analgetics (e.g. COX inhibitors) and
have just low or unspecific effects on the inflammation.
An alternative are the Biologicals such as the chimeric anti-TNF-α monoclonal antibody In-
fliximab or Adalimumab a recombinant human IgG1 monoclonal antibody which bind TNF-α.
Certolizumab pegol or CDP870 is a monoclonal humanized anti-TNF-α antibody Fab’ frag-
ment linked chemically to polyethyleneglycol. The IL-1 receptor antagonist Anakinra decrease
the effects of IL-1. IL-1 and TNF-α are the most important inflammatory cytokines in stim-
ulating the cascade of inflammation via the production of Prostaglandin E2 (PGE2), matrix
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metalloproteinases and adhesive molecules. Unfortunately their high price and difficult produc-
tion in addition to their need of parenterally administration prevent the Biologicals from being
optimal drugs. So there is still a need for orally available small molecules, which decrease
both IL-1 and TNF-α production at the same time [15], [16]. Feige et al. [17] showed that
targeting both IL-1β and TNFα exhibits in a synergistic capacity. Lately, Wijbrandts et al.
published that there are some patients who do not clinically respond to TNF-α blockade. Re-
cent studies have suggested that individuals predisposed to high TNF production could show
worse responses to anti-TNF-α therapy, while other studies propose exactly the opposite. It
can be assumed, however, that a patient’s baseline cytokine profile affects responding from
non-responding. Another explanation may be that other inflammatory mediators are responsi-
ble for pathogenetic subsets of RA. That implies the need for point of action somewhere in the
pre-TNF-α level, because the therapeutic effect can not be predicted. Thus p38α MAP kinase
is responsible for the TNF-α and IL-1β production, it is a reasonable approach to inhibit the
cytokine production rather at their starting point [18].
3.2.4. X-ray crystal structures of the p38α MAP kinase; DFG-IN
Binders
3.2.4.1. DFG motif
The DFG motif is composed of Asp168, Phe169 and Gly170 in case of the p38α MAP kinase.
This stretch of three amino acids is a widely conserved feature among the protein kinase
superfamily. Asp168 coordinates a magnesium ion for catalysis, thus is thought to be critical
for the activity of the hydrolysis of ATP. For the binding of the class of diarylurea inhibitors the
DFG loop undergoes a structurally dynamic response to create an otherwise hidden cavity [3].
The hydrophobic pocket DFG-OUT is composed of Arg67, Arg70, Glu71, Leu74, Leu75 (upper
part), Ile166, Leu167, Asp168, Ile141, Ile146, Ile147 and His148 (bottom). This conformation
is called the DFG-OUT conformation. Phe169 shifts from a buried position to a solvent
exposed position. It was also discovered during dynamic simulations and NMR studies. This
supported the idea of the existence of a dynamic equilibrium between DFG-IN and DFG-OUT
conformations of apo-p38α MAP kinase ([1], [19]). Vogtherr et al. even demonstrated that
the inhibitor SB203580 can bind during both conformations. Lately, Bukhtiyarova et al. ([20])
studied the role of Phe169 in p38α MAP kinase. They suggest it is mainly important for
catalytic stability. They discovered a new p38α DFG-OUT conformation which they termed
α-DFG-OUT to reflect the α-helix-like conformation of Asp168 which also allows the entrance
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to the Phe169 cavity mentioned above. In contrast the PDB entries 2EWA and 1KV1 ([3]
had observed a rather β-sheet-like conformation of Asp168. The values of the torsion angles
φ and ψ of Asp168 determine most of the local conformational differences between DFG-IN
and DFG-OUT. Figure 3.8 visualizes the DFG-IN and DFG-OUT conformations.
Figure 3.8.: Ligand L12 bound to p38α MAP kinasein DFG-IN conformation (PDB 1W84
coloured in blue) and ligand LI2 bound to p38α MAP kinasein DFG-OUT confor-
mation (PDB 1WBS coloured in red); the DFG-OUT loop is situated above the
DFG-IN loop
Bukhtiyarova et al. suggest that based on thermal stabilities and their structures that the
α-DFG-OUT state is allowed, but less energetically favourable than the DFG-IN. It may be
a intersection to the β-DFG-OUT state upon binding a diarylurea inhibitor. Taken together,
the position of Phe169 seems to have influence for structural activity and structural dynam-
ics, rather than for structural stability. Maybe the occurrence of different states represent a
mechanism for conformational auto-inhibition.
3.2.4.2. PDB 1W84
3-(2-(4-pyridyl)ethyl)indole (PDB 1W84, IC50 35 µmol) (figure 3.9) was optimized by using
X-ray crystallographic screening.
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NH
N
Figure 3.9.: Ligand of PDB 1W84
The inhibitor of PDB 1W84 binds to the ATP binding site between the N- and C-terminal
domains of the p38 MAP kinase and forms an H-bond with the backbone -NH of Met109 (hinge
region), while the hydrophobic pocket I contains the 3-indolyl group which forms contacts
with the side chain of Lys53. In addition the indolyl NH acts as an H-bond donor to the
backbone carbonyl of Ala51. PDB 1W84 was the first inhibitor which binds with both rings
(the indole) within the hydrophobic pocket I [4].
3.2.4.3. PDB 1OZ1
In this publication of this X-ray crystal structure a native unphosphorylated p38 MAP kinase
was solved with (3-(4-fluoro-phenyl)-2-pyridin-4-yl-1H-pyrrolo[3,2-B]pyridin-1-ol)(figure 3.10).
N
OH N
F
Figure 3.10.: Ligand of PDB 1OZ1
The 4-pyridyl moiety creates an H-bond with backbone -NH of Met109, the 4-fluoro-phenyl
group fills the hydrophobic pocket I and the nitrogen of the central imidazol ring forms
an additional H-bond with the terminal nitrogen of Lys53. This may be required for the
regioselective positioning of the pyridyl and the fluoro-phenyl group. The 4-azaindole binds
to the α- and β-isoforms (gatekeeper residue Thr106) to both the activated and inactivated
form. Other gatekeeper residues for example a larger Met106 in γ and δ isoforms prevents the
4-fluorophenyl group to get access to the hydrophobic pocket I [21].
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3.2.4.4. PDB 2GTN
The ligand in the X-ray crystal structure of PDB 2GTN is a C-2 tri-subsituted purine based
inhibitor of the p38α MAP kinase. The author’s efforts started with a co-crystal structure of a
precursor of the ligand in PDB 2GTN, when they first studied the binding mode of this series.
An inactive S180A and Y182F mutant of murine p38α MAP kinase was taken for SAR studies.
The 2-fluoro-substituent lies in the hydrophobic pocket I, whereas the di-fluoro-phenyl lies in
hydrophobic region II . A water molecule mediates an interaction between the NH of position
C-8 with Lys53. The N-1 of the purine ring forms an H-bond with the backbone -NH of
Met109. To establish this interaction the hinge region has to pass through a rearrangement.
A so-called ”flip” can be observed; the carboxyl of Gly110 turns away from the inside of the
ATP binding pocket, whereas the backbone NH turns towards the inhibitor. This torsional flip
allows an additional H-bond between the ligand’s ether oxygen and NH Gly110 in case of the
ligand of 2GTN. The replacement of the N-9 ethyl with an isopropyl led to the present ligand
in PDB 2GTN with an IC50 of 4nM (figure 3.11).
N
N
N
N
O
FF
NH
F
Figure 3.11.: Ligand of PDB 2GTN
3.2.4.5. PDB 2GFS
Compound RO3201195 of a series of 5-Amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones
shows a H-bond between the exocyclic amin with the side chain hydroxyl of Thr106 and
with the backbone oxygen of His107 in addition to a H-bond between the backbone HN of
Met109 and the benzoyl oxygen of the inhibitor. The interaction between the inhibitor and
Thr106 controls the high selectivity, because Thr106 is a rare residue at this position amongst
the kinases, as for the MAP kinases it is just present in the α and β isoforms of the p38
MAP kinases. In the other two isoforms and all JNKs Methionine occupies this position,
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whereas in ERK1 and ERK2 Gln and in ERK3 Phe, respectively [12]. Compound 63 [5-Amino-
1-(4-fluorophenyl)-1H-pyrazol-4-yl]-(2(S)- 3-dihydroxy-propyl)methanone has a IC50 value of
0,7+0,1µM (p38 α MAP kinase) and is selective apart from p38α and β MAP kinase (IC50
0,05µM), GAK (IC500,59µM) and PDGFRβ (IC500,61µM) (figure 3.12).
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Figure 3.12.: Ligand of PDB 2GFS (compound 63)
3.2.4.6. PDB 2I0H
Some known compounds [22] have shown a unique binding mode, where the hinge region
residues Met109 and Gly110 perform a ”flip” to be able to form two H-bonds with a ligand.
In other kinases the residues linked to Met109 have larger side chains which prevent the
”flip”. The first requirement to create this flip is that the ligand has to contain a carbonyl
oxygen as an anchor point. Secondly, the hydrophobic pocket I has to be occupied by an
aryl substituent, in this case bound via an amide linker to the 6-oxo-pyridazin scaffold. The
occupation of the hydrophobic region II enhances potency and allows the variation of physical
properties, because of its position in the front towards the solvent. 2-3-[(2-chloro-4-fluoro-
phenyl)-[1-(2-chlorophenyl)-6-oxo-pyridazin-3-yl]amino]propyl]isoindole-1,3-dione comes up to
the described requirements. SAR studies point to the importance of the carbonyl function (to
maintain a high dipole moment). The authors suggest that the introduction of a neighbouring
nitrogen negatively influences a dipole induced ”flip”and lowers the stability of that state. The
isoindole-1,3-dione optimal linked by a propyl did not create the expected H-bond to Asp168,
but enabled a - stacking with Tyr35 of the Gly-rich loop. The IC50 values for p38α MAP
kinase and p38β MAP kinase add up to 9nM and 20nM respectively. The ligand and it’s
analogues did show any significant activity against p38γ MAP kinase, p38δ MAP kinase,
JNKs or ERKs. Figure 3.13 shows the ligand of PDB 2I0H.
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Figure 3.13.: Ligand of PDB 2I0H
3.2.4.7. PDB 2QD9
Following the Scios concept [23] where the introduction of methyl groups on the piperidine
scaffold should prevent conformational mobility to increase potency, a series of imidazol[1,5-
a]pyrazines was synthesized. Here a ring constraint between a benyzlmethylene and a proximal
piperidine ring prevents conformational mobility. A second reason was to bury the arylgroup
into the hydrophobic pocket I and simultaneously increase the possibility of an H-bond between
Lys53 and nitrogen of the introduced ring. To improve the SAR data, an oxalamide side chain
was introduced which effectively improved potency. The ligand of PDB 2QD9 was chosen for
X-ray co-crystallographic studies with unphosphorylated p38α MAP kinase (figure 3.14).
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Figure 3.14.: Ligand of PDB 2QD9
The ligand’s central amide carbonyl forms two H-bonds with the backbone NH of Met109 and
Gly110. The imidazol nitrogen performs a water mediated H-bond with Lys53 and Asp168.
The hydrophobic pocket I is occupied by the 2,4-difluorophenyl group. The oxalamide side
chain lies between Val30 (Gly-rich loop) and the hinge region with no H-bonds. It’s value
lies in the improvement of binding affinity by the reduction of the network of bounded water
molecules, the authors assume.
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3.2.5. X-ray crystal structures of the p38 MAP kinase; DFG-OUT
Binders
3.2.5.1. PDB 1W82 and PDB 1WBS
Before the binding of this class of urea inhibitors (PDB 1W82 (N-[(3Z)-5-tert-butyl-2-phenyl-
1,2-dihydro-3H-pyrazol-3-ylidene]-N’-(4-chlorophenyl)urea) and PDB 1WBS (3-fluoro-5-
morpholin-4-yl-N-[3-(2-pyridin-4-ylethyl)-1H-indol-5-yl]benzamide) in figure 3.15) a significant
conformational rearrangement of the phosphorylation loop has to forego to open up a hy-
drophobic pocket, the so-called hydrophobic pocket DFG-OUT.
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Figure 3.15.: Ligand of 1WBS (left) and ligand of 1W82 (right)
Phe169 (F) changes its postion in a range of 10A˚. The ligand of 1W82 (IC50 196nM) was found
during the first case study of Gill et al., while obtaining the ligand of 1W84. In their second
case study they focused their efforts on indole-based compounds to bind in the DFG-OUT con-
formation and succeeded with the ligand of 1WBS (IC50 630nM). Like with other DFG-OUT
binders ([3], [14]) the amide forms H-bonds to Asp168 and Glu71, which is possible because
of the formation of the polar channel through the movement of Phe169. This polar binding
channel formed by Asp168 and Glu71 reaches from the ATP binding site to the hydrophobic
pocket DFG-OUT. One oxygen of the side chain of Glu71 forms two H-bonds to each nitrogen
of the urea group, while the backbone NH of Asp168 creates an H-bond with the oxygen
of the urea group. The t-butyl group is situated in the hydrophobic pocket DFG-OUT. The
hydrophobic pocket I is occupied by the indole, while the nitrogen of the pyridine interacts
with Met109. The morpholino group occupies the hydrophobic pocket DFG-OUT. Altogether,
the achieved X-ray crystal structures of this series (PDB codes 1Wx) are of very good quality.
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3.2.6. DFG-IN and DFG-OUT
3.2.6.1. PDB 2EWA
The aim of the author’s research was to study the role of different DFG conformations, which
was observed in many kinase complexes. As X-ray structures are static and just show snapshots
of a momentary state, the DFG movement from DFG-IN to DFG-OUT requires kinetic studies.
NMR therefore can complement these studies to characterize an inhibitor. The authors studied
the DFG-IN and DFG-OUT equilibrium of p38 MAP kinase with five well-characterized ligands
(two DFG-IN and three DFG-OUT binders). 2EWA was obtained by X-ray crystallography
with p38 MAP kinase and SB203580 (figure 3.16).
Figure 3.16.: SB203580 in PDB 2EWA
The pyridine forms an H-bond with Met109, whereas the nitrogen of the imidazol forms an
H-bond with Lys53 and the fluoro-phenyl occupies the hydrophobic pocket I. The DFG-IN
ligands bind to the DFG-IN conformation which was observed before in PDB code 1A9U [24].
Awkwardly, the NMR assignment is just to 79% complete for the N-terminal domain, while the
C-terminal domain notably the DFG motif is unassigned. The missing signal can be explained
by the mobility of the DFG loop during activation. To study the loop they used the 13 N-Phe-
labeled p38 MAP kinase phenylalanine residues. Apart from one they all appeared in a 1H,15H
TROSY spectrum. The missing one therefore is Phe169 which flows in case of no present
ligand or a DFG-IN binder such as SB203580. In the presence of a DFG-OUT ligand the DFG
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loop movement is restrained, resulting in the appearance of a thirteenth signal. Thus these
ligands do not interfere with the DFG loop and are uninvolved with the activation. DFG-OUT
binders block both the activity and the activation because they hinder the natural movement
of the DFG loop. Taken together a new approach to characterize new structures as DFG-IN
or DFG-OUT binders was introduced. [1]
3.2.7. X-ray crystal structures without a ligand
3.2.7.1. PDB 2FSO
The authors produced several intrinsically active D176A p38α MAP kinase mutants which
reveal local alterations in the L16 loop region. This conformational change to enhance acti-
vation seems to be similar to the one which occurs in the natural activation. The mutants
are in a constant active state and maintain all biochemical and pharmacological properties of
an active p38α MAP kinase. The L16 loop, normally stabilized by a hydrophobic core, is a
natural element maintaining the low basal activity of p38 MAP kinase (figure 3.17).
Figure 3.17.: L16 loop in PDB 2FSO
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Moreover, they suggested that the conformation of L16 loop in the p38α wild-type maintains
its basal activity [25]. Canagarajah et al. [26] and Zhang et al. [27] had observed this change
in ERK2 and Bellon et al. [28] in p38γ MAP kinase before. In PDB 2FSO the L16 loop residue
Glu328 forms a salt-bridge with Arg70, which interacts with the phosphorylated Thr180 upon
activation [28]. Both Arg70 and Glu328 are conserved in the MAP kinase family.
3.2.7.2. PDB 2PKJ
In this paper the authors studied the role of Phe169 in a p38 MAP kinase. They produced
five p38αMAP kinase DFG motif mutants and compared them to the wild-type especially
examining in vitro phosphorylation by MKK6, activity towards ATF2 and thermal stability.
2PKJ is a F169A (Phenylalanine to Alanine) mutant. This mutation showed decreased thermal
stability of p38αMAP kinase (1,3), while the phosphorylation loop occurs in the DFG-IN
conformation. In an in vitro kinase assay, using GST-ATF2 as substrate in the presence of
ATP, F169A was dually phosphorylated at Thr180 and Tyr182, but its enzymatic activity was
reduced in comparison to the wild-type. The other mutants showed different conformations
and properties, but were not chosen for the docking studies. Through the mutation originated
DAG conformation is similar to the DFG conformation in the wild-type, although the mutant
suffers from a loss of almost all side chain surface area, and a small change in φ and ψ angles
of Asp168 related to the shift in the positions of Asp168 atoms. PDB 2PKJ was chosen
because its good quality according to the quality standards.
3.3. JNK
The c-Jun terminal kinases are also members of the MAP kinase family and therefore, regulate
signal transduction in response to environmental stress. The focus of this work will just spot on
the JNK3 isoform which is selectively expressed in the brain and to a lesser extend in the heart
and the testis, whereas the other isoforms JNK 1 and 2 are widely expressed. The amino acid
sequence identity is greater than 90%, with more than 98% homology within the ATP-binding
site. The exchangement of Leu144 in JNK3 for Ile106 in JNK1, may along with different lobe
orientations, contribute to selektivity approaches among the JNK family [2], [29]. The hinge
regions contains the residues:
• Met146, Glu147, Leu148, Met149, Asp150, Ala151, Asn152
The hydrophobic pocket I is composed of:
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• Val78, Ala91, Lys92, Lys93, Met115, Ile124, Ile126, Leu144, Val145, Met146 (gate
keeper), Leu206
whereas the hydrophobic region II is composed of:
• Ile70, Ile148, Asp150, Ala151, Asn152, Gln155, Val196.
The Gly-rich loop contains the residues:
• Gly71, Ser72, Gly73, Ala74, Gln75, Gly76, Ile77, Val78
The phosphorylation loop is designed of the residues:
• Leu206, Asp207, Phe208, Gly209, Leu210, Ala211, Arg212, Thr213, Ala214, Gly215,
Thr216 , Ser217, Phe218, Met219, Met220 , Thr221, Pro222, Tyr223, Val224, Val225,
Thr226
The p38 MAP kinase and JNK3 share 51% sequence identity. Six residues differ in the ATP
binding site. p38 MAP kinase can accommodate lager ligands, because its gate keeper residue
(Thr106) is smaller than in JNK3 (Met146). Figure 3.18 shows the structure of JNK3.
N-terminal 
domain
C-terminal 
domain
hinge region
phosphorylation loop
Gly-rich loop
Figure 3.18.: Structure of the JNK3, PDB 2B1P [2]
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3.3.1. The JNK pathway
The JNK pathway mediates beta amyloid processing, Tau phosphorylation, neuronal apoptosis
and mediation of neurotoxicity, consequently the diseases caused by JNK3 include neurode-
generation, RA, inflammatory disorders, cancer and diabetes. In mammalian systems the
intracellular signaling controls cellular proliferation, differentiation, development, inflamma-
tory response and apoptosis. MAP kinases belong to these signaling proteins. One of these
signalling pathways is controlled by c-Jun NH2-terminal kinases (JNKs). It is activated by
Cytokines and environmental stress. These stimuli activate the MAP3Ks (MAPKKK) for ex-
ample transforming growth factor-β activated kinase-1 (TAK1) or Toll-like receptors (TLR-3,
TLR-4,TLR-9), which then activate the MAP2K (MAPKK) isoforms MKK4 and MKK7 via
phosphorylation. In turn these phosphorylate and activate JNK. The activation requires dual
phosphorylation of the phosphorylation loop residues Thr183 and Tyr185. A major target of
JNK is activator protein-1 (AP-1). The resulting phosphorylation of c-Jun on Ser63 and Ser73
results in the acquisition of enhanced transcription of AP-1. If the Serines are not activated
the c-Jun is degraded by another pathway. The MAPK phosphatase (MKP) deactivates the
JNK pathway. The JNKs signal transduction can be carried out by protein-protein interactions
or scaffold proteins (JNK-interacting proteins (JIPs)). The inhibition of the JNK pathway
can therefore be multiple accessed with small molecule inhibitors. SP-600125 was reported
as a selective inhibitor of JNK1, JNK2 and JNK3 [30] and provides a first potential therapy
approach for RA (figure 3.19).
Figure 3.19.: JNK pathway
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3.3.2. Inhibition of JNK
In 2001 Celgene discovered SP600125 (figure 3.20) as a small molecule inhibitor for autoim-
mune, anti-inflammatory and neurodegenerative diseases [31].
O
N N
H
N
R2R1
Figure 3.20.: First reported selective JNK small molecule inhibitor SP600125
It showed an IC50 of 110nM for JNK1 and JNK2, and 150nM for JNK3. The selectivity of
this compound is still not fully figured out yet. Over the years several other companies in-
troduced different kinds of compound selective for JNK2 and JNK3 or just JNK1 or JNK3
against stroke, neurodegenerative and inflammatory diseases, asthma and cancer [31]. Xie et
al. [32] first obtained a crystal structure of unphosphorylated JNK3 with a ATP analogue
(adenylylimidodiphosphate). It revealed that JNK3 has a typical kinase fold, with the ATP
binding site between the N- and C-terminal domains. The N-terminal domain is composed of
the residues 45-149 and 379-400, and is set up mostly of β-strands. It contains the Gly-rich
loop. The C-terminal domain is composed of the residues 150-374 and includes the phos-
phorylation lip with the two phosphorylation sites Thr221 and Tyr223 and is mainly α-helical.
Pro222 is situated between the two phosphorylation sites in the case of JNK3. The loop is
two residues longer than in p38 MAP kinase. The ATP binding site has a larger residue as the
”gatekeeper” (Met146) than p38α MAP kinase (Thr106) implying a possible approach for se-
lectivity against p38α MAP kinase by introducing large substituents to the p38α MAP kinase
scaffolds to address the hydrophobic pocket I. Met149 of the JNK3 hinge region corresponds
to Met109 of p38α MAP kinase. The other often addressed residue in p38α MAP kinase
Lys53 corresponds to Lys93 in JNK3 and guides the other side of the entrance (the right side)
of the hydrophobic pocket I .
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3.3.3. Ligands of JNK3
3.3.3.1. PDB 1PMN and PDB 1PMQ
The authors created a total of four crystal structures of JNK3 in complex with different
compounds. The chosen ligands in PDB 1PMN (N-cyclopropyl-4-[5-(3,4-dichlorophenyl)-2-
(1-methylpiperidin-4-yl)-3-propyl-imidazol-4-yl]pyrimidin-2-amine) and PDB 1PMQ (N-cyclo-
hexyl-4-[5-(3,4-dichlorophenyl)-2-piperidin-4-yl-3-propyl-imidazol-4-yl]pyrimidin-2-amine) are
not selective for JNK3 (IC50 7,1 nM and 1,6 nM respectively)(see figure 3.21).
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Figure 3.21.: Left: ligand of PDB 1PMN, right: ligand of PDB 1PMQ
The higher potency of the ligand in PDB 1PMQ is apparently due to the enhanced hydrophobic
interactions of the cyclohexyl ring. That p38 MAP kinase is also inhibited with IC50 values of
0,2 nM and 4,0 nM respectively, but not ERK, makes these ligands unsuitable as therapeutic
agents. Both inhibitors keep H-bonds with the nitrogen and oxygen atoms of Met149 in the
hinge region, while the di-chloro-phenyl moiety lies in the hydrophobic pocket I. The piperidine
ring occupies the phosphate binding area and is very much solvent exposed. The more potent
compound allows more contacts with the hydrophobic region II due to the replacement of
the cyclopropyl ring with a cyclohexylring [33].
3.3.3.2. PDB 2B1P
In this crystal structure the ligand is a 3-(4-pyridyl)indazole derivate. The scaffold was found
through HTS. The 6-anilino group was added to occupy selectively the hydrophobic pocket I.
The binding mode of this series was proved by X-ray crystallography, revealing, in addition to
the hydrophobic interactions within the hydrophobic pocket I, two H-bonds with the indazole
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nitrogens of the ligand with the backbone amino groups of the hinge region residues Met149
and Glu147 and a water mediated H-bond between Lys93 and the anilino NH of the ligand
(figure 3.22).
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Figure 3.22.: Ligand of PDB 2B1P
They achieved selectivity amongst other kinases apart from p38α MAP kinase. To prevent
this unintentional inhibition the 5-(4-dimethylaminobutanoylamino)benzoic acid derivate was
synthesized to address two residues (the 3-carboxylic acid-Asn152 and the 3-amide with long
chain bearing a basic amine-Asp150) on different sides of the hydrophobic region II , which
differ in p38α MAP kinase. [2]
3.3.3.3. PDB 2O0U
The JNK3 inhibitory activity of the scaffold of N-[3-cyano-6-(3-piperidin-1-ylpropanoyl)-5,7-
dihydro-4H-thieno[5,4-c]pyridin-2-yl]naphthalene-1-carboxamide was found in a binding assay
(figure 3.23).
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Figure 3.23.: Ligand of 2O0U
It shows pIC50 ([34]) values of 5,3 for JNK2 and 5,5 for JNK3 over JNK1 and the other
members of the MAPK family. The only residue that differs between JNK3 and JNK2 is
Met115 which corresponds to Leu77 in the latter. The obtained X-ray crystal structure reveals
that the napthyl substituent lies in hydrophobic pocket I, while the piperidine of the 6-amide
occupies the hydrophobic region II and the solvent exposed front. Met149’s backbone -NH
forms an H-bond with the 3-cyano substituent. Angell et al. also observed an H-bond between
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the amide nitrogen to the sulfur of Met146. They suggest that this interaction contributes to
the observed selectivity profile.The amide oxygen creates a water mediated H-bond to Lys93.
3.4. Ottosen et al.
In 2003 Ottosen et al. (LEO Pharma, Denmark) [35] reported the synthesis and SAR of a
series of 4-aminobenzophenones as inhibitors of the p38 MAP kinase. They used molecular
modeling to rationalize their SAR approach and suggested the following binding mode (see
next page figure 3.24) The carbonyl oxygen forms an H-bond with the NH of Met109, whereas
the ring A is situated in the hydrophobic pocket I and the aminophenyl (ring C) forms  
stacking interactions with Tyr35. Compound 45 inhibits the TNF-α production and the IL-1β
production with IC50 of 6 and 14 nM. The increased activity is supposed to be created by
the two lipophilic ortho substituents which force the benzophenone system to an energetically
favourable conformation. Modeling suggested that the ketone bridge is hindered in its rotation.
A variety of substitutions instead of a amino group at the ring C is accepted if possible. Only
a nitro group is objectionable. The ketone group is essential; any reduced analogues were
inactive. Alkylation at the secondary amino group which connects rings B and C is tolerated
to a certain extent without any great loss of potency. The compounds did not inhibit the kinase
activity of ERK1, ERK2 or JNK1 in a kinase assay. Compound 49 which has an additional
p-bromide in ring C in comparison to compound 45 inhibited in a panel of 60 kinases only
p38α MAP kinase, p38β MAP kinase and MKK6 at 1µM. The in vivo inflammatory effect of
the compounds was proved in tests of acute and chronic murine model of skin inflammation.
Energy analysis provides one possible explanation of the increased p38α MAP kinase activity
of the ortho-substituted compounds. The conformational restriction results therefore in a
lower loss of entropy upon protein binding and in the end to higher affinity (Menendez et al.
[36]). Their docking studies confirmed the binding of the ketone to Met109. Since compounds
without the secondary amino group have lower affinity, the amino group might form at least
an H-bond with another residue inside of the ATP binding site. However, the docking in
PDB 1A9U could not locate a possible binding partner. Although the position of the Gly-rich
loop in PDB 1A9U does not imply anything, the flexibility of the Gly-rich loop might form a
conformation which allows interactions with Tyr35.
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Figure 3.24.: Proposed binding mode of the Ottosen compound 45 in the ATP binding pocket
of the p38α MAP kinase
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3.5. Revesz et al.
The efforts to synthesize a p38 MAP kinase inhibitor first led to the identification of a
pyrido[2,3-d ]pyrimidine as a weak inhibitor [37]. The ring-opened analogues benzophenones
or benzoylpyridines are much more potent (figure 3.25); benzophenones were slightly more
potent.
N
N N N
H
R
R
O
X N
H
F
F
R
Figure 3.25.: Left: Revesz scaffold A, right: Revesz scaffold B
SAR studies demonstrated the necessity of the carbonyl oxygen, because any reduction led to
inactive molecules. The authors propose a binding mode where the carbonyl oxygen forms an
H-bond to the NH of Met109 and the difluorophenyl ring (ring C) occupies the hydrophobic
pocket I . Ring A lies in the solvent accessible hydrophobic region II. Modeling suggests that
the substituents on that ring for example a amino-dimethylpropynl lies near the DFG loop and
may form an additional H-bond to Asp168. This proposed binding mode is opposed to that of
the very similar compounds of Ottosen et al., where the hydrophobic pocket I accommodates
ring A instead of ring C in the case of Revesz et al. (see next page figure 3.26).
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Figure 3.26.: Proposed binding mode of compound 6b, which is the most potent benzoylpyri-
dine with an IC50 of 8 nM
This may be caused by the presence of the amino group encouraging the idea of an H-bond
between the amino group an Asp168 or any other residue with electron acceptor properties.
Further analysis disclosed that increased flexibility of the substituted side chain results in a loss
in potency. An amine group at the end of any chain is preferred over an alcohol group. Other-
wise the benzophenone analogue with a 1-methyl-4-hydroxy-4-vinylpiperidine in para position
to the methoxy group at ring A was with an IC50 of 1 nM one the most potent compound in
the series. The most potent compound with an IC50 of 0,7 nM is compound 19a; a benzoyl
substituted benzimidazole (see figure 3.27 on the next page).
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Figure 3.27.: Left: Revesz compound 19a, right: Revesz scaffold 3
Orally active compounds such as 6b and 19a were tested in vivo in the acute LPS induced
TNFα release model and in the acute LPS/TNFα model and showed good potency. In 2005
Revesz et al. introduced another series of inhibitors of the p38 MAP kinase. This series
also started with a modest pyrido[2,3-d ]pyrimidine leading to the ring-opened analogue which
was introduced in 2004. In this series further modifications led to pyrazolo[3,4-b]pyridines,
pyrazolo[3,4-d ]pyrimidines and pyrazolo[3,4-b]pyrazines. A 1,1-dimethylpropynylamino group
was introduced to all three scaffolds to permit a comparison of their p38 MAP kinase inhibitory
activity. Their potencies were very similar; the pyrazolo[3,4-b]pyridines slightly favoured. Fur-
ther analysis supported the preference of rigid substituents as described in the publication
of Revesz et al. a year before and points out the importance of the substitution of ring A.
Two compounds of the pyrazolo[3,4-d]pyrimidines series with a secondary or ternary nitrogen
(figure 3.28) on the next page inhibited the p38 MAP kinase at IC50 values of 0,6 and 0,9 nM
respectively.
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Figure 3.28.: Left: Revesz compound 18c, right: Revesz compound 18d
Beforehand mentioned interactions with Asp168 might be a possible explanation for the in-
creased inhibitory. These series was also tested in vivo for oral efficiency. Some compounds
showed less activity than against p38α MAP kinase, due to their inadequate pharmacological
properties (e.g. half-life, plasma concentration, bioavailability). The three scaffolds were also
tested against a panel of 13 kinases (>1000-100 fold) and for their ability to inhibit the cy-
tochrome P450 isoenzymes (no adverse inhibition). The proposed binding mode of this series
also includes an H-bond between the NH of Met109 in this case with the pyrazolo nitrogen
and the difluorophenyl ring accommodates the hydrophobic pocket. A rigid, long enough
substituent on ring A can form H-bonds to Asp168 (see next page figure 3.29).
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Figure 3.29.: Proposed binding mode of 18c
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3.6. The Suberones
The concept of Ottosen et al. was the staring point of our in-house synthesis strategies.
Ottosen and Revesz also belong to a new class of Linear Binders [38]. Vertex [39] introduced
the first compound of the new class, in which a pyrimidopyridazine bicycle interacts with
Met109. The bicycle is directly connected by a sulfur spacer to a phenyl ring that occupies
the hydrophobic pocket I. These linear arranged parts are required for the basic interaction.
The actual compound VX-745 has an additional 2,6-dichloro-phenyl substituent attached to
the bicycle, which lies in hydrophobic region II. Several other compounds also followed this
strategy ([40],[41]).
In our case the PhD thesis of R. Niess [42] and J. S. Hering [43] dealt with the synthesis of:
• 3-amino-6,11-dihydro-dibenzo[b,e]thiepin-11-ones
• N-substituted-3-amino-6,11-dihydro-dibenzo[b,e]oxepin-11-ones
• 2-amino-10,11-dihydro-dibenzo[a,d]cyclo-hepten-5-ones
• 2-amino-dibenzo[a,d] cyclo-hepten-5-ones.
The in-house term for the series is Suberone and for the general formula see figure 3.30 [44].
XY
O
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R
Figure 3.30.: Suberone scaffold: X=O,Y=CH2; X=CH2,Y=O; X=CH2, Y=CH2, X=CH,
Y=CH; X=S, Y=CH2
The idea of our concept was to restrict the conformational freedom by fixing the rings A and B
by introducing condensed ring systems. Our new class of ligands are only build up of fragments
that contribute directly to the binding. The Suberones are linear molecules (so-called Linear
Binders). As kinases are very flexible per se, flexible ligands may support many induced fits,
while a more rigid ligand, like a Suberone scaffold, may limit the number of these induced
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fits and increase selectivity. Ethano-, etheno-, methylenoxy- and methylsulfanyl-subsituents
were chosen as linkers for the ring systems to produce similar geometric and conformational
properties in comparison to the benzophenones. The synthesis is described in Laufer et al.
[44]. The compounds were tested in an isolated p38α MAP kinase assay described in Laufer
et al. [45] and revealed the following SAR results. An ortho-substitution at ring C of the 2-
amino-dibenzo[a,d]epines leads to potent inhibitors. Any isomeric structures ((8-amino-6,11-
dihydro-dibenzo[b,e]oxepin-11-ones)) of the 3-amino-6,11-dihydro-dibenzo[b,e]oxepin-11-ones
suffer from a so far unexplainable loss of potency. The position of the oxygen in the seven-
membered ring seems to be of high importance. Less potency was also achieved by moving the
amine to the meta- or para-position of ring C. A 2,4-diamino analogue also showed less potency.
This suggests the participation of the amino-group in an H-bonding system. An introduction
of the fluorine in the ortho-position in the presence of a para-substituents unexpectedly results
in better inhibitory activity. Following this the introduction of a fluorine at the para-position
of ring C resulted in a potent inhibitor. Choosing any bigger halogen resulted in increased
inhibitory activity. The most potent compound was achieved by combining the insight of the
amino and fluoride substitutions, resulting in JH31 with an IC50 of 38nM. First in vivo data
showed promising results in agreement to CYP P450 inhibition. A binding mode analogue to
the proposed to that of Ottosen et al. or Revesz et al. can be presumed.
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This study aims to find the binding mode of the Suberones mainly in the p38α MAP kinase.
Some structures of the JNK3 are also included, because the Suberones inhibit this kinase as
well. The Suberone belong to series of Linear Binders described in [38]. In this class the two
essential rings (in this case A, B and C) are connected by spacer atoms (a carbonyl oxygen
and an amine group). Therefore only the two rings and their substitutents form the required
interactions; H-bond-network to the hinge region (to Met109; there called the ”linker residue”)
and hydrophobic interactions with the hydrophobic pocket I. Whereas other ligands like the SB
compounds ([46]) have a central scaffold that connects the all the substituents which interact
with the hinge region and the hydrophobic pocket I. The Linear Binders represent a class of
ligands with minimized linear located interaction points. The Suberone’s structural similarity to
the Ottosen and Revesz compounds (also Linear Binders) suggests, that the Suberone binding
mode would be similar to theirs. Both groups propose that the carbonyl oxygen interacts with
the hinge region, but they are contradictory on the position of the amino-phenol (ring C).
Ottosen et al. believe that it will be situated in the hydrophobic region II, whereas Revesz
et al. propose a location where it will be situated on the opposite site, in the hydrophobic
pocket I to be precise (figure 4.1 on the next page). However none of them published a X-ray
structure yet, so it is not possible to work with a PDB structure that includes one of these
ligands.
36
X
Y
O
NH
F
R
HP I
HR II
DFG
Met109
hinge 
region Asp168
Tyr35
X
Y
NH
F
R
A
B
C
C
A
B
Figure 4.1.: Binding modes proposed by Ottosen et al. (in red) and Revesz et al. (in green)
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There is a great number of available X-ray structures of different ligands of the p38α MAP
kinase, but the compositions of these ligands are different, though some share the carbonyl
oxygen , that binds to the hinge region. This study uses established methods of molecular
modeling to get more information about the binding mode of the Suberones and tries to
connect them to already obtained SAR data. The study is divided into three parts. First, a
selection of usable PDB structures was chosen by several quality checks. This manageable
number of p38α MAP kinase (and JNK3) models of different conformations is loaded in GRID
afterwards. GRID is a molecular modeling programme, which calculates favourable positions
of chosen probes (e.g carbonyl oxygen or -NH2) in a PDB structure. Subsequent to this sev-
eral docking studies are carried out (with FlexX, Flexidock, GLIDE and eHITS). For this two
databank files are generated. The first one contains the ligands of the chosen PDB structures
and is used for evaluating the docking programmes. The second databank file is composed of
Suberone compounds which were already synthesized or were exclusively generated to answer
special questions concerning docking issues. The poses suggested by the docking programmes
together with such information as SAR data and GRID calculation will make up the base for
a binding mode prediction for the Suberones. A X-ray crystallization attempt is also carried
out in parallel, so that the results gained by the molecular modeling study can be checked and
discussed. The general workflow of this study is presented in figure 4.2 on the next page.
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All X-ray structures: p38 α MAP kinase and JNK3
Quality Check: WHAT IF, PDBSUM
p38 α MAP kinase: 1OZ1, 1W84,  
2GTN, 2GFS, 2FSO,2PKJ, 2I0H, 2QD9
Binding Mode 
of the Suberones
?
GRID
Docking
FlexX, 
GLIDE, 
eHITS
Ottosen et al. Revesz et al.
JNK3: 2B1P,2O0U,
1PMN, 1PMQ
Figure 4.2.: Workflow: Aim of the study
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5. Results
5.1. Validation of X-ray crystal structures: What is a
good model?
Until November 2007 nine X-ray crystal structures of JNK3 (see Table 5.1) and 56 of p38α
MAP kinase (see Table 5.2) have been deposited at the RCSB protein databank [47].
No. PDB Resolution in A˚ Authors Year
1 1PMN 2.20 Scapin et al. [33] 2003
2 1PMQ 2.20 Scapin et al. [33] 2003
3 1PMU 2.70 Scapin et al. [33] 2003
4 1PMV 2.50 Scapin et al. [33] 2003
5 2B1P 1.90 Swahn et al. [2] 2006
6 2EXC 2.75 Swahn et al. [2] 2006
7 2O0U 2.10 Angell et al. [29] 2007
8 2OK1 2.40 Aronov et al. [48] 2007
9 2P33 2.40 Alam et al. [49] 2007
Table 5.1.: PDB structures of JNK3 (Status: November 2007)
No. PDB Resolution in A˚ Authors Year
1 1A9U 2.50 Wang et al. [46] 1999
2 1BL6 2.50 Wang et al. [46] 1999
3 1BL7 2.50 Wang et al. [46] 1999
4 1BMK 2.40 Wang et al. [46] 1999
5 1DI9 2.60 Shewchuk et al. [50] 2000
6 1IAN 2.00 Tong et al. [51] 1998
7 1KV1 2.50 Pargellis et al. [3] 2002
8 1KV2 2.80 Pargellis et al. [3] 2002
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9 1LEW 2.30 Chang et al. [52] 2002
10 1LEZ 2.30 Chang et al. [52] 2002
11 1M7Q 2.40 Stelmach et al. [41] 2002
12 1OUK 2.50 Fitzgerald et al. [53] 2003
13 1OUY 2.50 Fitzgerald et al. [53] 2003
14 1OVE 2.10 Fitzgerald et al. [53] 2003
15 1OZ1 2.10 Trejo et al. [21] 2003
16 1P38 2.10 Wang et al. [54] 1997
17 1R39 2.30 Patel et al. [6] 2004
18 1R3C 2.00 Patel et al. [6] 2004
19 1W7H 2.21 Hartshorn et al. [55] 2005
20 1W82 2.20 Gill et al. [4] 2005
21 1W83 2.50 Gill et al. [4] 2005
22 1W84 2.20 Gill et al. [4] 2005
23 1WBN 2.40 Gill et al. [4] 2005
24 1WBO 2.16 Hartshorn et al. [55] 2005
25 1WBS 1.80 Gill et al. [4] 2005
26 1WBT 2.00 Gill et al. [4] 2005
27 1WBV 2.00 Gill et al. [4] 2005
28 1WBW 2.41 Gill et al. [4] 2005
29 1WFC 2.3 Wilson et al. [56] 1997
30 1YQJ 2.00 Tamayo et al. [57] 2005
31 1YW2 2.01 Laughlin et al. [58] 2005
32 1YWR 1.95 Golebiowski et al. [59] 2005
33 1ZYJ 2.00 Michelotti et al. [60] 2005
34 1ZZ2 2.00 Michelotti et al. [60] 2005
35 1ZZL 2.00 McClure et al. [61] 2005
36 2BAJ 2.25 Sullivan et al. [14] 2005
37 2BAK 2.20 Sullivan et al. [14] 2005
38 2BAL 2.10 Sullivan et al. [14] 2005
39 2BAL 2.80 Sullivan et al. [14] 2005
40 2EWA 2.10 Vogtherr et al. [1] 2006
41 2FSL 1.70 Diskin et al. [62] 2007
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42 2FSM 1.86 Diskin et al. [62] 2007
43 2FSO 1.83 Diskin et al. [62] 2007
44 2FST 1.45 Diskin et al. [62] 2007
45 2GFS 1.75 Goldstein et al. [63] 2006
46 2GHL 2.10 Brugel et al. [64] 2006
47 2GHM 2.35 Maier et al. [65] 2006
48 2GTM 1.90 Sabat et al. [66] 2006
49 2GTN 1.80 Sabat et al. [66] 2006
50 2I0H 2.00 Natarajan et al. [67] 2006
51 2PKJ 2.00 Bukhtiyarova et al. [20] 2007
52 2PTJ 2.20 Bukhtiyarova et al. [20] 2007
53 2PTO 2.30 Bukhtiyarova et al. [20] 2007
54 2PV5 2.10 Bukhtiyarova et al. [20] 2007
55 2PV8 2.20 Bukhtiyarova et al. [20] 2007
56 2QD9 1.70 Dhar et al. [68] 2007
Table 5.2.: PDB structures of the p38α MAP kinase (Status: November 2007)
The first step to gain inside of the binding mode of the Suberones was to choose a sample of
structures in that bulk of available structures, because docking in all 65 structures would be
too time consuming and would not be reasonable. The next step was to compare the available
structures in respect to their quality. JNK3 was also chosen for the studies to examine the
binding mode there as well, because JNK3 is also inhibited and there are enough structures
available that are of good quality [42]. A structure should be regarded as a model, because
it is just a hypothesis of a simplified representation of a molecule (a collection of coordinates
representing the atoms). Kleywegt observed in this review [69] that errors in models based
on crystallographic data is unavoidable. Since any subjective pitfalls of model building and
refinement can be expelled (e.g. an unexperienced crystallographer) the possible types of
error should be considered carefully. Several tools can be used to get an overview about the
quality of a X-ray structure. Assessing the quality of a model is called validation. Validation
needs to be done by both producers and users. It should always be considered that a model
is gained through subjective interpretation of the experimental data. The first step for the
user is to check the crystallographic data. The first clue of the quality a crystallographer
offers the user is the resolution. A high resolution is obviously the most useful, represented
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through small numbers. Models of high resolution have value of 2,5 or better. Altogether the
model has to follow the concepts of chemical sense (bond lengths and angles, chirality, flat
aromatic rings etc.), physical sense (favourable packing of the molecules in the crystal etc.),
crystallographic sense (model agrees with the experimental data), statistical sense, protein-
structural sense (good Ramachandran plot, usual main-chain and side-chain conformations)
and biological sense (model explains activity, specificity, effect of mutations or inhibitors).
5.1.1. WHAT IF
WHAT IF identified the following PDB structures as good models for docking studies in
comparison to other PDBs. The calculated results are shown in tables 5.3 and 5.4 on the next
two pages.
In comparison to other PDB structures (for example PDB 1YWR which was used in the
previous Diploma thesis [70] just because of its good resolution) those present in the tables
above have better overall data. A closer look on the data was performed by checking the
full output reports, identifying some ”false” warnings or errors. Many warnings or errors did
not occur anywhere near the ATP binding pocket or could be identified as irrelevant. For
example all ligands appeared in the bond-distance check. The lower distances between special
ligand atoms and residue atoms could be explained by the existence of possible H-bonds
between them. Even the programme suggested this as a possible explanation. This is why the
programme demands a closer look to the results. In the end the overall quality and the manual
check identified the best X-ray crystal structures of p38α MAP kinase and JNK3. After the
WHAT IF check all PDB structures underwent further quality tests.
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5.1.2. Experimental data check: R-value, ProSA, PDBSUM,
Ramachandran plot
After this first validation with WHAT IF, all available models underwent further following
quality checks.
5.1.2.1. R-Value
Apart from the resolution the R-Value also offers evidence of the quality of a model. The
crystallographic R-value (or R-factor) is defined as: R=Sum jF (obs) F (calc)j
Sum F (obs) . This R-factor
is a measure of the level of disagreement between the (properly scaled) observed structure
factors (Fobs) and calculated structure factors (Fcalc). It is usually reported in %, i.e. a
R-value of 0.18 is reported as 18%. This R-factor is distinct from the calculation of Rmerge
or Rsym values which are used to report the quality of the experimental diffraction data as
the average discrepancy of multiple measurements of the same reflection. These R factors are
based on diffraction intensities: R=Sum jI(obs(i)) I(mean)j
Sum I(mean) . The crystallographic R-factor is an
attempt to report with a single number the degree to which a complex atomic model with
four or more parameters per atom agrees with a large set of individual diffraction observations.
Typically, thousands of atoms give rise to thousands of computed structure factors which are
then compared to the observed structure factors to yield a single R-factor. This R-factor is
not very sensitive to errors, especially in case of:
• low-resolution structures with a low observations-to-parameters ratios
• overall good structures with few localized errors
• structures with distorted geometry
Structures with a resolution at or better than 2.5 A˚ with R-factors below 25% tend to be largely
correct [71]. The more recent advances in the field of macromolecular refinement has been
the introduction of the free R-factor or R-free [72]. It is based on the statistical method called
cross-validation. The free R-factor was introduced because it shows greatly reduced coupling
to the target function used during minimization (the residual) than the R-factor. It measures
the degree to which the atomic model predicts a subset of the observed diffraction data that
has been omitted from the refinement. So instead of letting the minimizer refine against the
complete dataset (all Fobs), a random subset (5-10%) of the dataset is set aside and labeled
the free or test set. The remaining 90-95% of the dataset (working set) are used to form the
target function for refinement and to compute the traditional crystallographic R-factor. The
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free R-factor is commonly 2-8% higher than the regular R-factor. In table 5.7 all R-factors are
displayed. PDB 2QD9 (0,252) slightly lies above 0.25 and PDB 2PKJ (0.280) is even higher.
The other PDB structures fulfill the above mentioned expectations. In all cases the value of
R-free is acceptable.
Another column of table 5.7 displays the number of water molecules in the crystal structure.
A very low number is unusual. WHAT IF also includes a check of the positions of the water
molecules. Water molecules are not visible in the X-ray structure and have to be positioned
by the depositer anywhere he thinks it is wise. This subjective placement may not be the best
objective.
5.1.2.2. ProSA
ProSA can reveal if the overall structure is correct and can identify faulty parts. Table 5.5
shows the ProSA calculations of the JNK3 models; the lower the Z-Score the better.
ProSA Overall model quality Z-Score
2B1P -8.32
2O0U -7.57
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1PMN -7.43
1PMQ -7.12
Table 5.5.: Overall model quality of JNK3 models expressed by the Z-scores
The calculated values for the overall model quality range between -8.3 and -7.1. Altogether
they are much better than those of p38α MAP kinase. The local model quality reveals high
energy values for the phosphorylation loop regions. Their state seems to be energetically
unfavourable according to this calculation. Table 5.6 on the next pages shows the values of
the overall model quality calculated for p38α MAP kinase models.
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ProSA Overall model quality Z-Score
1W84 -8.02
1W82 -7.98
1WBS -7.92
2GFS -7.75
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2I0H -7.64
1OZ1 -7.37
2PKJ -6.93
2GTN -6.55
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2FSO -6.00
2QD9 -5.99
1YWR -6.65
Table 5.6.: Overall model quality of p38α MAP kinase models expressed by the Z-scores
All values are situated in the normal field; some in the middle (e.g. PDB 1W84), while others
(e.g. PDB 2PKJ) are situated at the frame. The local model quality shows bad values in the
sequence sector of the loop residues 210-220 (exemplified by figures of PDB 1OZ1 5.1 on the
next page). PDB 1YWR [59] that was used in the Diploma thesis [70] has acceptable Z-scores
as well.
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Figure 5.1.: Local model quality of PDB 1OZ1, red: areas of high energy, blue: areas of low
energy
The folding of the phosphorylation loop arouses suspicion and should be therefore regarded
with caution. Many loop regions have very high energy values, affecting adversely the over-
all model quality. Excluded PDB 1YWR, due to other validation tools, shows not the worst
overall model quality here in comparison to others (PDB 2GTN). PDB 2QD9 has a very low
overall model quality, because many residues in the loop sections have very high energy values
(phosphorylation loop and Gly-rich loop (residues 30-38)). The pose of the phosphorylation
loop of PDB 2GTN is highly unusual and was only seen in the PDB 2GTN model. It lies in
the ATP binding pocket and may therefore cause heavy problems during the docking studies
(Figure 5.2). Just like a missing loop may have a not-wanted influence on the docking.
Figure 5.2.: Local model quality of PDB 2GTN, red: areas of high energy, blue: areas of low
energy
The best values of p38α MAP kinase models were calculated for the PDB 1Wx series, support-
ing their usage in the study. The state of the phosphorylation loop seems to be energetically
disadvantageous apart from the DFG-OUT states and PDB 1W84 (see figure 5.3).
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Figure 5.3.: Local model quality of PDB 1W84, red: areas of high energy, blue: areas of low
energy
Surprisingly the local model quality of the DFG-OUT models have very low energy values in
the phosphorylation loop section (Figure 5.4).
Figure 5.4.: Local model quality of PDB 1W82, red: areas of high energy, blue: areas of low
energy
The state of the DFG-OUT conformation seems to be not unusual. Since just the beginning
of the phosphorylation loop (residues 167-170) lies at the frame of the ATP binding pocket,
the unfavourable energy state may not have influence on further modeling studies.
5.1.2.3. PDBSUM
PDBSUM [73] provides an at-a-glance overview of all PDB structures of the p38α MAP kinase
and JNK3 in the Protein Data Bank (PDB). There is a link to the PROCHECK, where the
Ramachandran plots in the next section come from.
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5.1.2.4. Ramachandran Plot
The Ramachandran plot indicates allowed conformations of proteins. The conformation of the
backbone of a residue is determined by three torsion angles, called φ(C[i-1]-N[i]-CA[i]-C[i]),
ψ(N[i]-α-C[i]-C[i]-N[i+1]), and ω(α-C[i]-C[i]-N[i+1]-CA[i+1]) (figure 5.5 below).
Amide plane
α-Carbon
Amide plane 
Side group
Figure 5.5.: Torsion angles of protein backbone
Proteins mainly are trans-peptides, so that the omega angle is restrained to values near 180.
Cis-peptides are rare and if they occur, the next residue is a Proline. The omega angle
therefore offers little in the way of validation checks. Due to steric hindrance there are several
clearly preferred combinations of φ and ψ values. The Ramachandran plot is therefore an
useful indicator of model quality. Most areas of the Ramachandran plot represent forbidden
conformations (coloured in white). Three regions are physically accessible to most residues. If
the model was determined accurately, most of the angels fall in the so-called allowed regions
(coloured in red, orange and yellow). Any residues which occur in the forbidden regions
should not have adopted the observed conformations and would have required a check by the
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crystallographer. The two residues Glycine and Proline are exceptions in that point. Proline is
the most restricted residue and φ can only range around -6, while the values of φ and ψ for
Glycine, the only amino acid without any Cβ atom, cover a larger area on the Ramachandran
plot. The Ramachandran Plot statistics of PROCHECK [74] demonstrate a easy overview
(Check table 5.7). Good models have at least 90% (based on an analysis of 118 structures
of resolution of at least 2.0 A˚ and R-factor no greater than 20.0) of their residues in most
favoured regions. The G-factors provide a measure of how out-of-the-ordinary a property is.
The overall average of the G-Factors should be above -0.5. A value below -1.0 is highly
unusual. Below are shown the Ramachandran plots of the JNK3 models (Figures 5.6 and 5.7
on the next page).
Figure 5.6.: Ramachandran plot of PDB 1PMN (left) and PDB 1PMQ (right) created by
PROCHECK
Figure 5.7.: Ramachandran plot of PDB 2B1P (left) and PDB 2O0U (right) created by
PROCHECK
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Apart from PDB 1PMQ all JNK3 models have over 90% of the residues in the the allowed
regions (see also table 5.7). PDB 2O0U has one outlier (Glu384), what is of little importance,
because it is outside of the interesting areas. The following two Ramachandran plots show the
DFG-OUT p38α MAP kinase models (Figure 5.8).
Figure 5.8.: Ramachandran plot of PDB 1W82 (left) and PDB 1WBS (right) created by
PROCHECK
The two have no outliers and a very good score, see also table 5.7. Figures 5.9, 5.10 and 5.11
show the Ramachandran plots of the DFG-IN p38α MAP kinase models.
Figure 5.9.: Ramachandran plot of PDB 1OZ1 (left) and PDB 1W84 (right) created by
PROCHECK
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Figure 5.10.: Ramachandran plot of PDB 2GFS (left) and PDB 2GTN (right) created by
PROCHECK
Figure 5.11.: Ramachandran plot of PDB 2QD9 (left) and PDB 2I0H (right) created by
PROCHECK
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The majority of the Ramachandran plots have no outliers and have over 90% of their residues
in the favoured regions. Only PDB 2GTN has two outliers near the ATP binding site, but
they are of little importance. PDB 2IOH has only 89.2% of its residues in the most favoured
regions, but this small deviation can be overlooked. The Ramachandran plots of the DFG-IN
p38α MAP kinase models without ligands are present in figure 5.12.
Figure 5.12.: Ramachandran plot of PDB 2FSO (left) and PDB 2PKJ (right) created by
PROCHECK
PDB 2PKJ has below 90% of his residues in the favoured regions and several outliers (see
also table 5.7). But it was neccessary to use another unliganded PDB apart from 2FSO, the
deviations of PDB 2PKJ were accepted. PDB 2PKJ was still the best of its series and the
deviations do not concern any important residues for this study. The in the diploma thesis
used PDB 1YWR is of much less quality. It contains many outliers and only has 86,1% of its
residues in the most favoured regions.
5.1.3. Chosen PDB structures
In the end the following PDB structures of JNK3: PDB 1PMQ, PDB 1PMN, PDB 2B1P, PDB
2O0U and p38α MAP kinase: PDB 1OZ1, PDB 1W82, PDB 1W84, PDB 1WBS, 2FSO, PDB
2GFS, PDB 2GTN, PDB 2I0H, PDB 2PKJ and PDB 2QD9 were chosen for the further analysis
(see table 5.7).
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This selection of models of good quality represent all the available conformations of the two
kinases. JNK3 is just available in the DFG-IN conformation, while the models of p38α MAP
kinases show the different conformations. PDB 1OZ1, PDB 1W84 and PDB 2GTN represent
the DFG-IN conformation, whereas PDB 2GFS, PDB 2I0H and PDB 2QD9 also are DFG-IN
representatives, but have a special conformation of the Gly-rich loop and/or the hinge region
(PDB 2I0H). PDB 2GTN contains mouse p38α MAP kinase instead of human expressed in
E.coli respectively. PDB 2FSO and PDB 2PKJ do not contain any ligand. PDB 1WBS and
PDB 1W82 are models of the DFG-OUT conformation and make sure that the small possibility
of the Suberones being DFG-OUT binders, is not overlooked. They were included after first
in-progress reports during the crystallisation process, suggested the DFG-OUT pocket as a
possible area for the binding of the Suberones.
5.1.4. Alignments by homology of the models
All PDB structures were aligned by homology with the Biopolymer)Compare Structures)Align
by Homology panel of SYBYL to compare the differences. The four JNK3 models were aligned
by homology on their C-α atoms (Figures 5.13, 5.14, 5.15 on the next pages).
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Figure 5.13.: Alignment of PDB 1PMQ, PDB 2O0U is fixed, RMSD 0.6043
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Figure 5.14.: Alignment of PDB 1PMN, PDB 2O0U is fixed, RMSD 0.5922
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Figure 5.15.: Alignment of PDB 2B1P, PDB 2O0U is fixed, RMSD 0.6206
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In all cases the relevant residues (residues of the ATP-binding site) are very similar; the Root
mean square deviations (RMSDs) are below 1. The overall RMSDs are also below 1 and differ
little. The four JNK3 models were also aligned by homology on all atoms (figures 5.17, 5.16,
5.18).
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Figure 5.16.: Alignment of PDB 1PMN, PDB 2O0U is fixed, RMSD 1.1179
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Figure 5.17.: Alignment of PDB 1PMQ, PDB 2O0U is fixed, RMSD 1.1158
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Figure 5.18.: Alignment of PDB 2B1P, PDB 2O0U is fixed, RMSD 1.0904
The RMSD values are higher, but that is due to the inclusion of the side chain atoms. Side
chain conformations can differ among the protein models. The appearance of different side
chain conformations is possible. But an unfortunate conformation may have influence on the
docking, because during all dockings the model is treated as rigid. The concerning residues
here is the side chain of Glu147 differs in PDB 2O0U in comparison to the others. The overall
RMSD values are acceptable and all other important residues have a RMSD around 1. Figure
5.19 shows the alignment by the C-α atom of the four JNK3 PDB structures.
Figure 5.19.: Alignment of PDB 1PMN (green), PDB 1PMQ (blue) and PDB 2B1P (red);
PDB 2O0U (yellow) is fixed
The chosen PDB structures of p38α MAP kinase were also aligned by homology. PDB 2PKJ
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was fixed and all the other PDB structures were aligned on the PDB 2PKJ coordinates. The
RMSDs of Lys53 are not presented, because the conformations do not differ significantly
among the PDBs. Figure 5.20 visualizes the data of table 5.8. Unfortunately many atoms of
the Gly-rich loop atoms are missing in several PDB structures. Still recognizable is that Gly31
(5) and Gly36 (2) have high RMSD values, especially in PDB 2I0H and PDB 2GFS. The
other residues have lower RMSD values and do not differ among the PDB structures.
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Figure 5.20.: Alignment the Gly-rich loop atoms of PDB 2PKJ to all other chosen PDBs of
the p38α MAP kinase
No. Residue 1OZ1 1W84 2I0H 2GFS 2QD9 2FSO 1WBS
1 VAL38 N 1.02 1.34 1.28 0.78 0.84 0.80 0.64
2 VAL38 CG2 0.93 1.22 0.99 0.76 0.81 0.92 0.77
3 VAL38 CG1 0.85 1.03 0.44 0.54 0.87 0.80 0.74
4 VAL38 CB 0.92 1.17 0.81 0.66 0.86 0.82 0.74
5 VAL38 O 0.76 1.06 1.12 0.61 1.13 0.51 0.56
6 VAL38 C 0.89 1.08 0.95 0.64 0.92 0.69 0.58
7 VAL38 CA 0.93 1.09 0.92 0.71 0.87 0.77 0.58
8 SER37 N 1.14 1.18 1.39 1.11 1.05 0.79 0.57
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9 SER37 OG 2.20 1.77 1.89 2.24 1.91 2.20 0.82
10 SER37 CB 0.86 1.62 1.77 1.28 0.99 0.66 0.85
11 SER37 O 0.91 0.98 0.69 0.77 0.75 0.88 0.53
12 SER37 C 0.97 1.24 1.13 0.74 0.87 0.82 0.59
13 SER37 CA 0.90 1.45 1.53 0.63 1.00 0.74 0.66
14 GLY36 N 2.71 1.14 4.72 4.57 0.61 1.07 1.44
15 GLY36 O 2.87 1.29 3.51 2.80 0.45 0.78 1.69
16 GLY36 C 2.13 1.10 2.65 2.23 0.72 0.81 0.92
17 GLY36 CA 2.33 0.83 3.36 3.35 0.84 0.87 0.62
18 GLY31 N 1.47 1.60 2.30 2.14 5.94 1.60 1.22
19 GLY31 O 3.06 3.32 3.69 4.04 6.52 2.80 2.29
20 GLY31 C 1.53 2.29 3.66 3.55 7.00 1.34 1.22
21 GLY31 CA 1.09 1.27 2.22 2.67 7.01 1.28 1.17
22 VAL30 N 1.36 1.59 1.34 0.91 0.97 1.17 0.99
23 VAL30 CG2 1.11 3.22 0.49 1.38 1.03 2.08 1.51
24 VAL30 CG1 1.29 1.75 0.97 0.95 0.99 2.97 3.32
25 VAL30 CB 1.30 1.55 0.90 1.02 0.95 1.26 1.36
26 VAL30 O 1.40 3.69 3.05 2.72 1.91 1.26 1.41
27 VAL30 C 1.42 1.74 1.43 0.97 0.95 1.30 1.25
28 VAL30 CA 1.38 1.55 1.24 0.92 0.94 1.19 1.11
Average 2.24 2.13 1.59 1.89 1.11 1.25 3.77
Table 5.8.: Data of the alignment of the Gly-rich loop atoms of PDB 2PKJ to all other chosen
PDBs of the p38α MAP kinase
Figure 5.21 visualizes the data of table 5.9 (see the next pages). Noticeable are the high RMSD
values of the PDB 1W84 and PDB 1OZ1. The side chains of Met109 in these structures differ
greatly to that of the others. Here the side chain of Met109 extends to the ground of the
ATP binding side, limiting the accessible space in front of the hinge region considerably. The
side chain of PDB 1WBS also has high values, representing the changes which occur in the
hinge region during the DFG-OUT conformation. The three PDB structures also step forward
when taking a look at Gly110. Next to Met109 on the opposite side of Gly110, Leu108
does not show such high RMSD values. This may indicate that any ”flip” in the hinge region
happens exclusively at the residues Met109 and Gly110. The side chain of His107 also shows
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different conformations, but thus it is not directed into the ATP binding pocket, it is of little
consequence. Much more important is Thr106. The side chain’s oxygen in the PDB 2GFS,
PDB 2FSO and PDB 2I0H has another conformation (PDB 2QD9 with it’s RMSD of 1 lies in
the middle). The side chain of Asp112 in PDB 2GFS is the only one which is similar to PDB
2PKJ. All the other hinge region atoms are very similar.
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Figure 5.21.: Alignment the hinge region atoms of PDB 2PKJ to all other chosen PDBs of
the p38α MAP kinase
No. Residue 1OZ1 1W84 2I0H 2GFS 2QD9 2FSO 1WBS
1 ASP112 N 0.88 0.64 1.44 0.79 0.69 0.56 0.75
2 ASP112 OD1 3.10 2.79 1.80 1.17 2.47 2.37 3.09
3 ASP112 OD2 1.31 1.72 2.86 0.69 2.16 1.93 1.28
4 ASP112 CG 0.93 0.79 1.30 0.91 0.80 0.35 0.87
5 ASP112 CB 0.77 0.68 1.43 0.96 0.85 0.41 0.69
6 ASP112 O 0.89 0.46 1.52 0.67 0.15 0.49 0.86
7 ASP112 C 0.72 0.47 1.37 0.73 0.53 0.59 0.63
8 ASP112 CA 0.73 0.56 1.41 0.84 0.73 0.53 0.63
9 ALA111 N 1.13 1.12 1.76 0.52 0.81 0.54 0.93
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10 ALA111 CB 1.24 0.93 1.59 0.88 0.66 0.52 1.04
11 ALA111 O 0.42 0.48 1.91 0.70 1.33 0.50 0.44
12 ALA111 C 0.76 0.64 1.68 0.71 0.94 0.41 0.63
13 ALA111 CA 1.17 1.00 1.68 0.63 0.68 0.52 0.91
14 GLY110 N 1.39 1.53 1.50 0.77 0.72 0.79 2.32
15 GLY110 O 2.41 2.14 1.76 0.39 0.60 0.80 2.27
16 GLY110 C 1.46 1.49 1.80 0.52 0.82 0.70 1.49
17 GLY110 CA 1.68 1.79 1.89 0.94 1.08 0.82 2.12
18 MET109 N 2.52 2.22 0.69 1.27 0.11 1.95 2.12
19 MET109 CE 10.00 10.04 1.25 2.21 0.61 2.35 9.26
20 MET109 SD 8.14 8.10 1.32 2.45 0.89 2.71 7.74
21 MET109 CG 5.85 5.54 1.28 2.36 0.73 2.68 5.18
22 MET109 CB 3.53 3.19 1.32 2.04 0.52 2.93 3.83
23 MET109 O 5.41 5.36 1.62 3.71 0.82 5.06 2.25
24 MET109 C 3.27 3.19 1.36 1.68 0.59 2.81 2.39
25 MET109 CA 2.95 2.74 0.95 1.52 0.34 2.43 2.70
26 LEU108 N 1.10 0.96 0.68 0.49 0.68 0.71 0.73
27 LEU108 CD1 1.89 1.92 1.37 1.50 0.83 1.65 1.32
28 LEU108 CD2 1.11 1.39 1.65 1.00 1.15 0.60 0.81
29 LEU108 CG 1.30 1.32 1.24 0.90 0.75 0.83 0.81
30 LEU108 CB 1.02 1.07 1.13 0.69 0.69 0.63 0.75
31 LEU108 O 1.34 0.81 0.95 0.71 0.94 1.01 1.10
32 LEU108 C 1.63 1.22 0.38 0.60 0.47 1.20 1.18
33 LEU108 CA 1.35 1.15 0.75 0.66 0.63 0.96 0.85
34 HIS107 N 0.59 0.59 0.51 0.29 0.71 0.43 0.53
35 HIS107 ND1 1.46 1.06 1.13 1.76 1.18 2.10 2.12
36 HIS107 CE1 1.65 1.26 0.33 0.83 1.76 1.35 1.05
37 HIS107 NE2 1.18 0.85 2.71 1.83 1.81 1.77 1.71
38 HIS107 CD2 0.64 0.50 3.17 2.60 1.51 2.56 2.21
39 HIS107 CG 0.78 0.43 0.89 0.42 0.97 0.90 0.49
40 HIS107 CB 1.01 0.88 0.38 0.24 0.56 0.83 0.88
41 HIS107 O 1.09 0.89 0.50 0.87 0.50 0.94 0.62
42 HIS107 C 1.00 0.86 0.53 0.55 0.56 0.74 0.67
67
CHAPTER 5. RESULTS
43 HIS107 CA 0.81 0.73 0.54 0.24 0.61 0.55 0.67
44 THR106 N 0.39 0.19 0.45 0.27 0.70 0.35 0.30
45 THR106 CG2 0.14 0.15 2.31 2.45 1.18 2.37 0.60
46 THR106 OG1 0.30 0.46 2.04 2.41 1.26 2.86 0.70
47 THR106 CB 0.14 0.31 0.46 0.15 1.08 0.44 0.51
48 THR106 O 0.57 0.45 0.73 0.43 0.84 0.46 0.37
49 THR106 C 0.48 0.44 0.58 0.34 0.82 0.43 0.36
50 THR106 CA 0.32 0.30 0.46 0.24 0.84 0.40 0.31
51 VAL105 N 0.44 0.26 0.29 0.23 0.47 0.20 0.43
52 VAL105 CG2 0.49 0.18 0.69 0.44 0.58 0.05 0.48
53 VAL105 CG1 0.30 0.18 0.77 0.41 0.68 0.19 0.46
54 VAL105 CB 0.45 0.15 0.61 0.36 0.63 0.12 0.45
55 VAL105 O 0.46 0.25 0.36 0.28 0.56 0.41 0.27
56 VAL105 C 0.44 0.18 0.39 0.27 0.63 0.31 0.33
57 VAL105 CA 0.44 0.21 0.41 0.28 0.60 0.19 0.43
58 LEU104 N 0.54 0.49 0.39 0.45 0.35 0.39 0.21
59 LEU104 CD1 0.49 0.50 0.42 0.42 0.40 0.52 0.32
60 LEU104 CD2 0.44 0.33 0.21 0.30 0.21 0.53 0.09
61 LEU104 CG 0.52 0.44 0.29 0.37 0.47 0.48 0.20
62 LEU104 CB 0.64 0.53 0.23 0.38 0.37 0.46 0.24
63 LEU104 O 0.75 0.53 0.35 0.51 0.45 0.60 0.37
64 LEU104 C 0.54 0.42 0.28 0.36 0.43 0.33 0.33
65 LEU104 CA 0.54 0.44 0.20 0.36 0.36 0.34 0.23
Average 1.44 1.31 1.08 0.89 0.78 1.05 1.27
Table 5.9.: Datatable: Alignment of the hinge region atoms of PDB 2PKJ to all other chosen
PDBs of the p38α MAP kinase
Figure 5.22 visualizes the data of table 5.10 (see also the next pages). The DFG region is
represented by Asp168 and Gly170, while Phe169 is unfortunately missing in some structures.
Hence Leu167 was included, but does not show any notable differences among the PDB
structures. PDB 1WBS certainly has very high RMSD values in that region. PDB 1W84 and
PDB 1OZ1 have more moderate high values. PDB 2I0H has also high RMSD values at the
position of Asp168. Altogether all RMSD values of the side chain of Asp168 are fairly high.
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Figure 5.22.: Alignment the DFG atoms of PDB 2PKJ to all other chosen PDBs of the p38α
MAP kinase
No Residue 1OZ1 1W84 2I0H 2GFS 2QD9 2FSO 1WBS
1 GLY170 N 4.48 3.71 1.49 - 0.90 - 10.40
2 GLY170 O 5.89 2.95 2.01 - 0.81 - 10.90
3 GLY170 C 5.12 3.46 1.87 - 0.84 - 11.00
4 GLY170 CA 5.23 4.82 1.68 - 0.81 - 11.50
5 ASP168 N 1.31 1.58 1.46 1.75 0.63 1.07 1.70
6 ASP168 OD1 3.41 3.02 3.67 2.88 1.17 1.40 3.64
7 ASP168 OD2 2.64 2.14 1.23 3.08 1.11 1.52 3.35
8 ASP168 CG 2.59 2.61 2.15 2.94 1.11 1.39 2.14
9 ASP168 CB 1.73 2.84 1.66 2.92 1.06 1.35 0.43
10 ASP168 O 1.30 3.32 1.74 3.48 1.40 1.60 5.85
11 ASP168 C 1.72 2.83 1.66 2.95 1.28 1.48 5.23
12 ASP168 CA 1.79 2.48 1.66 2.61 1.09 1.29 2.73
13 LEU167 N 0.50 0.44 0.96 0.51 0.39 0.73 0.31
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14 LEU167 CD1 2.14 1.59 2.39 1.76 3.82 1.63 0.63
15 LEU167 CD2 1.06 0.84 0.64 1.28 1.88 1.9 1.57
16 LEU167 CG 0.84 0.65 1.17 0.73 2.19 1.28 0.26
17 LEU167 CB 0.72 0.72 1.13 0.79 0.17 0.92 1.35
18 LEU167 O 0.84 0.9 1.01 1.01 0.59 0.75 1.12
19 LEU167 C 0.89 1.04 1.18 1.13 0.57 0.88 1.05
20 LEU167 CA 0.56 0.60 1.11 0.46 0.40 0.83 0.28
Average 1.42 1.58 1.80 1.63 1.78 1.19 1.08
Table 5.10.: Data of the alignment of the hinge region atoms of PDB 2PKJ to all other chosen
PDBs of the p38α MAP kinase
5.1.5. PDB 2GTN
As mentioned above the genetic source of the p38α MAP kinase of PDB 2GTN is of murine
origin. However, the differences between PDB 2GTN and the other humane models are not
significant.
Table 5.11 shows the RMSD values of PDB 2GTN in comparison with PDB 2I0H, PDB 1W84
and PDB 1OZ1. RMSD values lower than 3 Angstro¨m are acceptable.
PDB 2GTN PDB 2I0H PDB 1OZ1 PDB 1W84
Backbone atoms 2.0965 1.6844 1.7914
C-alpha atoms 2.0950 1.6765 1.7670
Side-chain atoms 2.7280 2.4183 2.5960
All Atoms 2.4372 2.0883 2.2347
Table 5.11.: RMSD values of all atoms of PDB 2GTN aligned by homology to all atoms of
PDB 2I0H, PDB 1W84 and PDB 1OZ1
Figure 5.23 on the next page shows the detail of the RMSD values of all atoms of the hinge
region (residues 104-112). The calculated RMSD values are acceptable. The highest RMSD
values occur at the side chain atoms of Met109, what is of little matter, because they also
vary in all the humane p38α MAP kinase models.
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Figure 5.23.: Alignment by homology in SYBYL of PDB 1W84 to PDB 2GTN (fixed)
5.2. Creating databases for Docking
5.2.1. The ligands for the docking studies
Selected molecules according to Ottosen et al., Revezs et al. and Suberone-scaffolds were
built with SYBYL7.2 and minimized with MMFF94s. The database includes active (OTTO1-
OTTO3 and REV1-REV8) and those with less activity (OTTO4 and REV9-10), so-called
decoys. Suberone-scaffolds which were already tested (JH’s and RN ’s) were included, as
well as newer ones (GA). The GA Suberones include both possible positions of the oxygen.
The small Suberones (SK1-32) were built to examine the different position of a nitrogen in
the rings. Later added SK and GA followed by three number represent the newest synthesized
Suberones which were synthesized and tested recently. During the docking studies several other
Suberones were built to test the first binding mode suggestions (MORE, MORE2). Some of
these structures were exclusively built to check if the docking can find false positives (e.g.
MO9min, MO10min, MO15min, MO16min); the decoys. All molecules were minimized under
the conditions seen in figure 7.1 in Materials and Methods and therefore share the common
ending -min. Conformations of molecules minimized in SYBYL7.2 are rarely distinguishable
from to those determined by X-ray crystallography [75]. If the conformation is identical to
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the conformation in a small molecule-protein complex is not clear. All compounds with their
two-dimensional structures, energies, molecular weight and IC50 values can be found in the
appendix tables A.2, A.3, A.4, A.5, A.6, A.7, A.8, A.9, A.10.
5.2.1.1. Ligands of the chosen PDB structures
The ligands of the chosen PDB structures of the p38α MAP kinase and JNK3 were extracted
to a database. They were not minimized further, but were kept in the exact conformation that
has been found in the X-ray structure. All ligands bind to p38α MAP kinase, apart from the
ligand of PDB 2B1P, which is supposed to be only selective for JNK3 according to Swahn et
al.. The other ligands should therefore show reasonable binding poses in the docking studies.
For some ligands the author did not publish a selectivity profile. The ligand of PDB 2GFS
is reported to be less active on JNK3, whereas the ligand of PDB 2I0H should not have any
activity against JNK3 at all. PDB 2FSO and PDB 2PKJ contain no ligand. The energies and
molecular weights were calculated with SYBYL and can be seen in table A.1 in the appendix.
5.2.2. Properties of the Compounds
The position of the oxygen in the 3- or 8-amino-6,11-dihydro-dibenzo[b,e]oxepin-11-ones suffer
from an unexplainable loss of potency. A clue might be given from the properties. In SYBYL
all distances and angles of the Suberones were determined with the ”Measure” panel. All the
distances and angles are displayed in tables A.11, A.12, A.13, A.14, A.15, A.16, A.17, A.19,
A.18, A.20, A.21, A.22, A.23, A.24, A.25, A.26, A.27, A.28, A.29, A.30, A.31, A.32, A.33,
A.34, A.35 in the appendix. Figure 5.24 (next page) describes where which measurements
were carried out. In some cases no data could be collected, because the composition of the
molecule was too different to the Suberone scaffold (e.g. the missing seven-membered ring in
REV or OTTO compounds or the missing aminophenyl substituent of SK1-32). The θ and
accordingly the ι account for the hydrogen which points on the direction of the viewer, if the
amino-phenyl is on the right side.
Figure 5.25 on the next page represents the distances that occur in the Suberone database.
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Figure 5.24.: Measurement of distances in A˚ (a-f) and angles in  (α-κ), B=C and A=0 or
B=O and A=C
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Figure 5.25.: Measurement of distances
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The values of the distances a, b and c vary little. Just JH46min is an outlier, due to the
sulphur in the seven-membered ring (orange square above at position 64). No differences
between the GAmin and the JHmin molecules can be observed. In the MOREmin group
MO1min, MO2min, MO25min-30min, and MO39min and MO40min stand out as outliers, in
comparison to the other MOREmin compounds, but differ little from the GAmin or JHmin
compounds. MO7min and MO8min are above all others, due to their additional fused ring.
The OTTOmin compounds 1 and 2 are a little shorter than 3 and 4. The same occurs in
the case of REV1min-6min, which are shorter than REV7min and REV8min. RN14min and
RN14amin have longer distances from one end to the other than RN13amin and RN15min.
The SK with three identification numbers differ little. For SK1-SK32 no measurement was
possible. Figure 5.26 visualizes the first six values of the angles.
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Figure 5.26.: Measurement of the angles in  (α-&)
The molecules of the GAmin group do not show any conspicuousness. Only GA16min and
GA17min are outliers. Their values of  and & are very similar. The other angles differ
in some degrees to their constitution. The JHmin compounds are nearly indistinguishable
from GA5min-GA9min or GA425min, GA430min or GA553min. The first three angles of the
MOREmin compounds differ little from the GAmin and JHmin’s, but the following angles
show great differences. This can be explained by e.g. the substituents above the amino-phenyl
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group, which force different conformations. The  and & values of the OTTOmin and REVmin
compounds are also very similar to those of JHmin and GAmin. The other angles could not be
determined due to the composition of the OTTOmin and REVmin compounds. Compounds
of the RNmin series have similar values there. The angles differ from the JHmin and GAmin
series, notably having higher values for α-γ and values a little lower for δ. In the series of
the small SKmins many variations occur. Any SKmin molecules with the three numbers (e.g.
SK318min) follow in some degree the examples of the JHmin and GAmin series again once
again. Figure 5.27 shows the second part of the angles.
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Figure 5.27.: Measurement of the angles in  (η-κ)
The values of the η angles are in general very similar (above 130). Only in some cases
they stick out, e.g. MO29min or MO30min, which rings B and C are bounded by a ternary
amine instead of a secondary; or RN14min which rings are bound via an ethylamine instead
of a methylamine. All the other θ values take up around 120. Only REV7min, REV8min
and SK22min are outliers. For ι nothing significantly occurs. All GAmin, JHmin and MOmin
compounds have very similar κ values. Only JH46min, MO1min, MO2min, MO3min and
MO4min-MO12min lie below the others. The OTTOmin and REVmin compounds have also
very similar κ values. Outliers are here OTTO3min, REV7min and REV8min. In case of the
RN series RN14amin lies above the others of that series. In the SKmin series more variations
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of the κ values can be observed. SK316min, SK345min and SK362min lie a little above the
other three-numbered SKmins. The compounds of figure 5.28 were selected to to take a more
accurate look at the the different scaffolds.
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Figure 5.28.: Angles of selected compounds GA1min, GA430min, JH30min, MO15min,
MO16min, RN13amin, RN14amin, SK288min, SK362min
The differences that emerge of the oxygen position in GA1min (bad inhibition) in comparison
that in JHmin or GA430min (very good inhibition) is striking. All angles of active compounds
rather have a similar arrangements or order. MO15min is very similar, but has a lower 
than e.g. GA430min. It’s isomer MO16min with the alternative oxygen position in the seven-
membered ring is very similar to GA1min. RN14amin represents an outlier which differs greatly,
but has shown activity against p38α MAP kinase in biologicals tests. SK288min is less active
than SK362min in the test and varies a little in the arrangements of the angle values. By this
diagram the following order of the angle values can be proposed to create active compounds
(from top to bottom):
• η
• κ
• δ
76
5.3. GRID
•  or & or θ
• ι
• β
• α
• γ
5.3. GRID
The following PDB structures were loaded in GREATER. The calculated GRIN charges are
displayed in table 5.12.
PDB GRIN Charge PDB GRIN Charge
PDB 1PMN -1.16 PDB 1W84 -9.08
PDB 1PMQ -1.04 PDB 1OZ1 -9.00
PDB 2B1P -1.00 PDB 2GFS -8.00
PDB 1WBS -8.89 PDB 2GTN -5.00
PDB 1W82 -9.08 PDB 2I0H -9.96
PDB 2PKJ -3.63 PDB 2QD9 -6.00
Table 5.12.: Calculated GRIN charges
While loading the PDB structures all of them received GRIN warnings, because they had
missing atoms e.g somewhere at the N- or C-terminal domain and the hydrogens could not
be added. However these warnings can be overlooked, because no atoms in the ATP binding
site were concerned, using the ”accept all errors” button. The probes which were chosen to
calculate the Molecular Interaction Fields (MIF) can be divided into two groups. Probes which
can be found in the Suberones (such as carbonyl or amine) and probes to proof the reliability
of the GRID calculations. For example the phosphate groups were chosen to check if GRID
finds MIF where the phosphate groups of ATP would be originally situated. Water probes
were found in all PDB structures everywhere near hydrophilic residues. The probes are display
in table 7.1 in Materials and Methods. For a better overview they were divided into groups as
follows:
• DRY, C3 : hydrophobic interactions
• N2, N:, N1:, N2: : nitrogen probes
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• O, O::, OC=, OH : oxygen probes
• STH : sulphur
• F : fluoride
• PO4, PO4H : phosphate
• MG+2, AR.COO-, AR.CONH2 : others
The probes in the others group were not permanently calculated. The sulfur probe was
exclusively chosen, because of JH46 which contains a sulphur in the seven-membered ring. If
any highlights occurred within the groups they will be discussed in particular. The usefulness
of the programme was positively tested among other studies (e.g. [76]). Only the MIFs with
the lowest energies for the probes (the more negative the better) are described below. The
regions what are used for describing the positions of the MIF below correspond to the naming
according to [10] in the introduction. In the PDB JNK3 structures of PDB 1PMN, PDB
1PMQ and PDB 2B1P GRID calculated the following MIFs:
• hydrophobic interactions in hydrophobic pocket I and hydrophobic region II and hy-
drophobic pocket DFG-OUT (only PDB 2B1P)
• nitrogen probes around Asn152 and next to the hinge region inside of the ATP pocket
• oxygen probes next to hinge region in hydrophobic region II, next to Lys93, Asn152
(OC= only in PDB 2B1P)
• sulphur in hydrophobic pocket I and hydrophobic region II
• fluoride in hydrophobic pocket I (only PDB 1PMN)
• others: magnesium next to hydrophobic region II (sugar pocket), aromatic probes
situated exactly where the aromatic parts of the ligand of PDB 2B1P are
The results of the MIF calculation vary. In some cases (the magnesium or the hydrophobic
interactions) the calculation are comprehensible, but in other cases they are surprising. No
MIF was found e.g. for the fluoride in hydrophobic pocket I in PDB 1PMQ and PDB 1B1P.
For the DFG-OUT p38αMAP kinase PDB structures PDB 1W82 and PDB 1W84 the following
MIFs were calculated:
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• hydrophobic interactions in hydrophobic pocket I, hydrophobic region II and hydropho-
bic pocket DFG-OUT, and between the the Gly-rich loop and the DFG residues
• nitrogen probes next to Glu71, Met109, Asp112, Asp168 and Phe169
• carbonyl oxygen exactly at the position of the oxygen of the ureayl part of the ligand
• sulphur in hydrophobic pocket I, hydrophobic region II and hydrophobic pocket DFG-
OUT
• fluoride in hydrophobic pocket I (only PDB 1WBS), hydrophobic pocket DFG-OUT and
between the the Gly-rich loop and the DFG residues (only PDB 1WBS)
• phosphate in the ATP binding pocket and between Glu71 and the Gly-rich loop
Many results here are very good, e.g. the exact position of the oxygen and the hydrophobic
interactions. Again the fluoride calculations were unexpected. The phosphate calculation
revealed, that the phosphate may not be able to bind in the so-called phosphate binding
region during the DFG-OUT conformation.
The MIF calculations for the p38α MAP kinase PDB structures yielded in the following results:
• hydrophobic interactions in hydrophobic pocket I, hydrophobic region II and sometimes
along the hinge region (PDB 2QD9, PDB 2PKJ) or between Lys53 and Tyr35 (2IOH)
• nitrogen probes chiefly near Asp112 and Asp168, and sometimes near Tyr35 (PDB
1W84), near Lys53 (PDB 2I0H) or between both (PDB 2GFS)
• oxygen probes next to the hinge region, Thr106 (PDB 2GFS), chiefly Met109 (PDB
1W84) and/or Gly110 (both PDB 2QD9)
• sulphur in hydrophobic pocket I and hydrophobic region II or in some cases next to
hinge region (Thr106 in 2FSO, Met109 in PDB 1OZ1, Met109/Gly110 in PDB 2QD9
and Asp112 in PDB 2PKJ)
• fluoride in hydrophobic pocket I and/or near Asp112 (hydrophobic region II), in front
of Asp168 (2FSO) and between Tyr35 and Lys53 (PDB 1W84)
• phosphate in the phosphate binding region (PDB 2PKJ, PDB 2QD9)
• others: magnesium in the phosphate binding region, the aromatic carboxyl next to
Met109/Gly110 and the aromatic amine next to Asp168 and His107 (PDB 2QD9)
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The oxygen calculations on one hand found perfect posed MIF near Met109/Gly110 in PDB
2QD9 (figure 5.29), but on the other hand in case of PDB 2I0H only in the sugar pocket.
Figure 5.29.: GRID: Calculated MIF of oxygen probe in PDB 2QD9
Many nitrogen positions were situated next to Asp168 or Asp112 as expected. But the results
varied and no prediction can be made which is the more likely position of the amine. Both
results tend to both proposed binding modes and therefore can not help at all in this case.
In figure 5.30 (next page) it can be assumed that the position near Asp168 is more likely,
because the field is much more bigger than that of Asp112. When examining even more
negative ranges, only the field around Asp168 remains.
The results for fluoride and sulphur were also not ideal. The hydrophobic pocket I was
obviously identified by the hydrophobic probes and the fluoride probe as an area of hydrophobic
interaction. As a surprise came the identification of another hydrophobic area between Tyr35
and Lys53. The phosphate probes were placed in the phosphate binding regions in many cases
but sometimes next to the hinge region (PDB 2QD9). Figure 5.31 visualizes the position of
the phosphate probe in PDB 2QD9.
Also the magnesium showed unusual positions, e.g. next to Asp112 (PDB 2PKJ). The multi-
atom aromatic probes showed good positions, even suggesting that an aromatic amine is more
likely next to Asp168 than next to Asp112. In the end there are a few hints that a carbonyl
is very likely around Met109, as some X-ray crystal structures proofed before (PDB 2QD9).
That ring C of the Suberones is more likely to bind in the hydrophobic pocket I and its amine
substituents may form interactions with Asp168 is still very unsecure.
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Figure 5.30.: GRID: Calculated MIF of amine probe in PDB 2QD9
Figure 5.31.: GRID: Calculated MIF of phosphate probe in PDB 2QD9
81
CHAPTER 5. RESULTS
5.4. Docking
The docking studies are used to predict the binding orientation or pose of a ligand in a
protein receptor [77]; in this case the Suberones in p38α MAP kinase. Re-docking and cross-
docking methods were used, before the actual docking of the Suberones. During re-docking
the ligand of a PDB structure is extracted and the docking programme is challenged to pose
the ligand as closely as possible to its experimental structure [78]. In this study cross-docking
included docking of ligands of the p38α MAP kinase and ligands of JNK3 into the PDB
structures PDB 1PMN, PDB 1PMQ, PDB 2B1P and PDB 2O0U (JNK3) and PDB 1W84,
PDB 1OZ1, PDB 2GTN, PDB 2GFS, PDB 2FSO, PDB 2PKJ, PDB 2QD9, PDB 1WBS and
PDB 1W82 (different conformations of p38α MAP kinase). This is the real challenge for
a docking programme: to dock a ligand into a structure with which it was not crystallized
[79]. The re-dockings were not carried out independently, thus the ligand database included
all ligands of the PDBs. Several conformations of the p38α MAP kinase could be used,
whereas the PDB structures of the JNK3 are very similar among one another. Many papers
(e.g. [80, 81, 82]) deal with pose prediction and the finding of active in a set of compounds
(termed Virtual Screening (VS)). The sorting of active and inactive was not part of this study;
it might be a task for further studies. Cole et al. describe in their review [83] the difficulties
of pose-prediction. The measurement they introduce critically is the RMSD [84], which needs
visual inspection, for it is just a geometric measure between two poses, so it only compares
the atomic positions. Such accurately examination was not invested here. The usage of the
docking programmes was examined before. Several programmes were used to strengthen the
proposed docking poses in the end. The chosen docking programmes work with different
algorithms. Choosing enough residues to cover the whole of the binding sites ensures that the
correct ligand-protein-interactions are found. Water molecules are also a great uncertainty.
The exclusion from the docking, which is sometimes necessary, because the algorithm can not
cope with them, may result in wrong docking poses. This is very likely in case the ligand is
bound to the protein via water molecules. The quality check to choose the best models was
necessary to make sure that possible docking failures are not the result of a inapplicable docking
algorithm. For example some docking programmes are influenced by the molecular weight [85].
These programmes favour compounds with a higher molecular weight, because they have more
atoms that interact with the target molecule and this increase the interaction energy. This may
also have influence on pose-prediction. Another often described is the inadequacy of docking
programmes to cope with ligand-induced changes in the protein conformation (induced-fit),
which is highlighted by several cross-docking studies [83].
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5.4.1. FlexX
All PDB files were examined in SYBYL7.2 with the protein preparation tool, to identify bond
orders or clashes and to add hydrogens. The appearance of any inadequacies fortunately did
not concern any residues of the binding sites. Thus the ligand and if present any crystallization
artefacts (such as sulphate) were extracted. For the dockings the native PDB structures were
used, because any inadequacies outside of the binding pocket were irrelevant for the docking.
The re-docking studies of the preceding diploma thesis demonstrated that FlexX is not as
applicable for the p38α MAP kinase as Flexidock. However for this study it was still used,
because docking of large databases is very easy with FlexX [70].
5.4.1.1. Re-docking
More re-docking studies following the diploma thesis had been carried out with more PDB
structures (data not shown). It showed that FlexX should be able to propose suitable binding
poses. For further evaluation cross-docking studies were executed (see next chapter). The
ligand database for cross-docking also included the native ligands of the used PDB structures,
so another re-docking is also included in the cross-docking studies.
5.4.1.2. Cross-docking
The first cross-dockings were carried out with the JNK3 models (apart from PDB 2O0U which
was lately published). FlexX put the three JNK3 inhibitors on the first three ranks (AIZ501,
Q880-501, Q984-501) in the PDB 1PMN docking. The majority of the poses were alike the
poses in their native crystal structure (apart from 5 outliers out of 50 poses). The p38α MAP
kinase inhibitors appeared in the the order PQB1, LIE301, Q222-400, L12 and FPH. Just in
case of LIE301, L12 and FPH some (5-10) poses were relatively similar to the pose of their
native structures. The rest was posed rather insignificantly. The ranking of the three JNK3
inhibitors was alike in PDB 1PMQ, but the poses for the first ranked AIZ501 were not even
similar to the native pose. However the poses of Q880-501 and Q984-501 were very much
alike. PQB1, Q222-400, LIE301, FPH and L12 on the next ranks were slightly different to
PDB 1PMN, but FPH was the only one which pose was comprehensible.
PDB 2B1P own native ligand was rank on one and its posed was very similar to the one
in PDB 2B1P. The second rank was occupied by PQB1 and its pose was also very alike its
native X-ray structure (PDB 2GFS). The rest of the ligands (in the order LIE301, Q880-501,
Q984-501, L12, Q222-400 and L12) had no acceptable poses, some of them were even posed
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outside of the ATP binding pocket.
PDB 1OZ1’s cross-docking yielded to AIZ501 on the first rank with many alike poses out of
the fifty possible poses. This also applied for FPH (the native ligand of PDB 1OZ1), Q880-
501, Q222-400 and L12. Therefore LIE301 and PQB1’s poses at the bottom ranks were very
unrealistic (no traceable interactions).
Most of the PDB 1W84’s cross-docking results did yield to reasonable poses. Only Q984-501
(rank 2) was posed alike in its PDB structure (PDB 1PMN). Some poses of FPH (rank 3)
and L12 (rank 7 and the native ligand of PDB 1W84) were acceptable. All other poses were
outside if the ATP binding site or positioned without any interactions (rank one AIZ501, rank
4 PQB1, rank 5 LIE301, rank 6 Q222-400 and rank 8 Q880-501).
AIZ501 also appeared on the first rank in the cross-docking to PDB 2GFS. Its binding pose
was alike the one in PDB 2B1P, although this ligand is supposed to be selective for JNK3. For
second ranked PQB1 half as much good and non-acceptable poses were found. Q22-400 was
next, but was not posed suitable (most outside of the ATP binding site), as was next FPH.
LIE301 binding pose was found in some solutions, but in the majority of the poses it was not.
With L12 it was the same. Between them was Q880-501 posed mainly outside of the ATP
binding site, as was Q984-501 on the last rank.
AIZ501 was only on the second rank in the PDB 2GTN cross-docking and its pose was all
the time about-faced. PDB 2GTN own native ligand was situated on the first rank alike the
X-ray structure in the majority of the solutions. All the other ligands were posed outside of the
ATP binding pocket. Very few were posed in the inside and if the poses were unacceptable.
The order was PQB1, FPH, LIE301, Q222-400, L12, Q984-501 and Q880-501. AIZ501 was
then again on the first rank when docked in PDB 2I0H. LIE301’s pose on the next rank was
also in many solutions much alike in (PDB 2GTN). With the next ranked ligands Q880-501,
Q222-400, FPH, PQB1, L12 and Q984-501 it was not as good. Only very few poses could be
considered a little similar to their native poses. The rest was posed unacceptable.
For the last cross-docking COM2000 the native ligand of PDB 2O0U was included in the
docking database. AIZ501 was on the first rank alike in PDB 2B1P. The majority of the poses
of Q984-501 on the next rank were also acceptable. However, for the rest of the ligands no
suitable poses were found (PQB1, FPH, Q880-501, LIE301, COM2000, L12 and Q222-400).
Because some in-between results from the crystallization team hinted that the Suberones might
bind in the DFG-OUT conformation, subsequently DFG-OUT cross-dockings were executed
with PDB 1W82 and PDB 1WBS. The following DFG-OUT ligands were chosen (figure 5.32
on the next page).
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Figure 5.32.: Ligands (from left: BMU (PDB 1KV1 [3]), B96 (PDB 1KV2 [3]), LI2 (PDB
1WBS [4]), L10 (PDB 1W82 [4])
The ligands were taken out of the PDB structures, the atom types checked, modified when
necessary and saved in a separate file. All ligands were docked in PDB 1W82 and PDB
1WBS. In both cases very good poses were found for LI2 (PDB 1WBS). Only the position
of the morpholino substituent varied slightly. The four ligands appeared on the same ranks
in both PDB structures. But just in case of PDB 1W82 some poses of L10 were correctly
docked (approximately 50%). In most cases for all the other ligands not even poses inside of
the binding site were found.
In the end the cross-docking results were not very promising. The outcome can not be
connected to any ligand properties or IC50 values, because they are too inhomogeneous and
irreproducible. However, FlexX was used for the docking of the Suberone database.
5.4.1.3. Docking of the Suberones
The first dockings were carried out for PDB 1PMN and PDB 1PMQ. In both cases REV6min
was on the first rank. The poses were alike: the carbonyl oxygen pointed to the hinge region
and the amino-phenol was in the hydrophobic region II. Second ranked was REV4min, also
in both cases. REV4min of PDB 1PMN took up the binding pose, whereas REV4min of PDB
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1PMQ lay across the ATP binding pocket. In PDB 1PMN next ranked REV9min’s carbonyl
oxygen had an H-bond to backbone -NH of Met149 and its amino-phenol in the hydrophobic
pocket I (see figure 5.33) and an additional H-bond to the backbone oxygen of Asp150.
Figure 5.33.: Docking of PDB 1PMN, pose of REV9min, left: stick representation, right:
MOLCAD surface representation
From now on different Suberone compounds appeared in the rankings. In case of PDB 1PMN
next were more REV compounds (REV3min, REV5min) which took up the observed pose
alike the other REV compounds. GA7min’s carbonyl oxygen pointed to Lys93, whereas the
amino-phenol was situated in the hydrophobic region II. This pose was also chosen by all the
following GA compounds (and most of the RN compounds). The REV and OTTO compounds
were posed alike the poses of rank one. An outlier was OTTO4min which took up a pose alike
REV9min. All JH compounds were posed around Lys93 (rather like shielding it). RN15min’s
carbonyl oxygen pointed to the hinge region and formed H-bonds to the backbone atoms
of Met149 and Asp150, whereas the amino-phenol lay in the hydrophobic region II. This
binding pose would be correspond to the binding mode proposed by Ottosen et al. (see figure
5.34 on the next page).
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Figure 5.34.: Docking of PDB 1PMN, pose of RN15min, left: stick representation, right:
MOLCAD surface representation
The first SK compound that appeared was SK10min, posed alike the GAmin compounds. The
last ranks were exclusively reserved for the SK compounds. The further docking results of
PDB 1PMQ were marked by many poses which lay across the ATP binding pocket, what
seemed not very likely, because they had no interaction sites. The GA compounds took up
their pose alike in PDB 1PMN, just like RN15min. The REV compounds appeared much later
in the ranking and took up also this rather unlikely poses. The SK compounds followed their
precursor poses, if they were even positioned in the ATP binding site at all. The results of
this docking were rather useless. The docking results of PDB 2B1P were focused on the side
chain -NH2 of Gln155. Most of the carbonyl oxygen of the Suberone compounds pointed
and formed H-bonds to that residue. The position of the amino-phenol varied, either it was
positioned in front of the hydrophobic pocket I or it was solvant exposed left above the hinge
region. Likely poses were rare. REV7min and REV2min were one of the few exceptions. Their
pose was similar to that proposed by Revesz et al.. However many other rather unlikely poses
occurred. For example GA15min, which carbonyl oxygen pointed to the hinge region, but
without any H-bonds to it, whereas the ether oxygen of the seven-membered ring formed one
to the side chain -NH2 of Gln155. Additionally the pyridazin nitrogens interacted with the
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side chain nitrogen of Lys93. The SK compounds took up the pose which allowed interactions
with Gln155 and again could only be found at the bottom of the ranking. PDB 2O0U results
also focused on Gln155 as a possible interaction partner for the Suberone compounds. Many
unlikely poses occurred as presented in figure 5.35.
Met146
hydrophobic
pocket I
Met149
Gln155
hinge 
region
Lys93
Met146
hydrophobic
pocket I
Met149
Gln155
hinge 
region
Lys93
Asp150
Asp150
Figure 5.35.: Docking of PDB 2O0U, pose of REV10min in stick representation
REV10min is pictured, which carbonyl oxygen formed an H-bond to Lys93; also never observed
before. Few acceptable poses were obtained. An example is shown in figure 5.36.
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Figure 5.36.: Docking of PDB 2O0U, left: pose of REV6min in stick representation, right:
pose of OTTO4min in stick representation
REV6min’s carbonyl oxygen formed an H-bond to the backbone -NH of of Met149 and
the -NH to the backbone oxygen of Asp150. However, this binding pose conflicts with the
proposed binding mode of Revesz et al.. Right pictured OTTO4min in contrast supported it
again. The ranking or any other properties could not be connect to any docking results. So,
in the end docking to the JNK3 models could not give any new insights which binding mode
of the Suberones is the most probable.
The first dockings to the p38α MAP kinase were carried out with PDB 1W84. GA11min
was on the first rank. The amino-phenol lay in front of the hydrophobic pocket I and both
the -NH and -NH2 formed H-bonds to the side chain oxygens of Asp168. The carbonyl oxygen
pointed to the Gly-rich loop and had two H-bonds to the backbone -NH of Tyr35 and Gly36.
GA10min on the next rank lay outside of the ATP binding pocket (between Lys53 and Tyr35).
OTTO4min on rank three took up the binding pose of GA11min again, as did the following
compounds. The two poses that had appeared on the first rank dominated the ranking and
were also observed for the RNmin and REVmin compounds. GA14min was different, but the
backbone -NH of Tyr35 and Gly36 also were the main binding partners (in this case with the
nitrogens of the pyridazin ring). The rest of GA14min lay across the entrance of the ATP
binding pocket. JH31min’s pose (alike all other JH compounds) was also posed in front of
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the entrance of the ATP binding site. The lower a compound appeared the more unlikely
its pose. RN15min’s carbonyl oxygen had an H-bond with the side chain hydroxyl group of
Tyr35, whereas the amino-phenol lay in front of Lys53. The SK compounds which of course
appeared at the bottom of the ranking took up the first observed pose (figure 5.37).
Figure 5.37.: Docking of PDB 1W84, pose of GA11min, left: stick representation, right: MOL-
CAD surface representation
This docking was dominated by Gly-rich interactions. The observed binding poses can not be
regarded as very likely, because the loop is such a high mobile region, that its position in this
X-ray structure can not be treated as certain.
Docking to PDB 1OZ1 yielded to REV6min on the first rank. The pose was similar to the
pose proposed by Ottosen et al.. The amino-phenol lay in hydrophobic region II and the -NH
formed an H-bond to the backbone oxygen of Met109 and the nitrogen of the pyridin formed
another one to the backbone -NH of Met109. The sp2 nitrogen of the imidazol subsituent
formed a third H-bond to the backbone -NH of Asp168. The carbonyl oxygen pointed to
back of the ceiling of the ATP binding pocket. The pose is visualized in figure 5.38.
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Figure 5.38.: Docking of PDB 1OZ1, pose of REV6min, left: stick representation, right: in
MOLCAD surface representation
GA4min on rank 3 was posed as proposed by Revesz et al.. The carbonyl oxygen formed an
H-bond to Met109 and the amino-phenol was situated in the hydrophobic pocket I. Though
the position is not optimal. The -NH interacted with a side chain oxygen of Asp168 (figure
5.39).
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Figure 5.39.: Docking of PDB 1OZ1, pose of GA4min, left: stick representation, right: in
MOLCAD surface representation
The following compounds took up either the pose of the first or of the third rank. Only the
OTTO compounds were positioned differently, where the carbonyl oxygen was situated in the
hydrophobic pocket I. This docking again showed that both binding poses of Ottosen et al. and
Revesz et al. are possible, but none was preferred and no connection between the composition
of the Suberone compounds (e.g. the position of the oxygen of the seven-membered ring)
could be identified.
In the PDB 2GFS docking REV6min was on rank one again, however this time the carbonyl
oxygen formed an H-bond to Thr106. The subsituents were posed alike PDB 1OZ1, but
formed several additional H-bonds to the hinge region (-NH and -NH2 to the backbone oxygen
of Met109 and -NH2 to the backbone oxygen of Gly110 (pose of OTTO1min see figure 5.40)
on the next page).
92
5.4. DOCKING
Figure 5.40.: Docking of PDB 2GFS, pose of OTTO1min, left: stick representation, right: in
MOLCAD surface representation
The carbonyl oxygen of GA7min on rank 5 again pointed to Met109, while the amino-phenol
was situated in hydrophobic region II (figure 5.41).
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Figure 5.41.: Docking of PDB 2GFS, pose of GA7min, left: stick representation, right: in
MOLCAD surface representation
The amino-groups formed two H-bonds to the backbone oxygen of Gly110 and one nitrogen
of the pyrazin formed an additional H-bond to the side chain hydroxy group of Thr106. Most
of the compounds had their carbonyl oxygen directed to Thr106 and their amino-phenol in
the hydrophobic region II. Some few AD compounds had their carbonyl oxygen about-faced
to the hinge region, but these were just few exceptions. The SK compounds appeared again
on later ranks.
PDB 2GTN was modified before it was used. The phosphorylation loop lies partially in the
ATP binding pocket (parallel to the hinge region). First dockings yielded in very bad results.
FlexX could not find any poses, because the residues and the ligand atoms constantly clashed.
For further usage it was decided to delete the residues that extend to the ATP binding pocket;
so Phe169-Ala172 were removed. The position of Asp168 is unusual in PDB 2GTN. It is
situated in the back of the hydrophobic pocket I, whereas in all the other PDB structures it
is if at all present a little right below of Lys53. Altogether the position of the phosphorylation
loop has to be treated with care. In the following docking all OTTO compounds appeared in a
row (OTTO1min, OTTO4min, OTTO2min and OTTO3min) and all shared the same binding
mode. The carbonyl oxygen had two H-bonds to the backbone -NH of Met109 and to the
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backbone -NH of Gly110. The amino-phenol was situated in the hydrophobic pocket I and
its -NH2 formed an H-bond to the side chain oxygen of Asp168 (see figure 5.42).
Figure 5.42.: Docking of PDB 2GTN-modified (without Phe169-Ala172), pose of OTTO1min,
left: stick representation, right: in MOLCAD surface representation
Most of the database compounds took up the same binding pose, but sometimes only an
H-bond to either Met109 or Gly110. Only a few outliers appeared (most of them later in
the ranking), for example GA6min, GA7min or the RN compounds. The amino-phenol was
situated in the hydrophobic region II or the pose was across the entrance of the ATP binding
pocket. JH126min was posed alike but had no H-bonds to the hinge region. Again all SK
compounds appeared at the bottom with their carbonyl oxygen pointing to the hinge region
and their amine subsituent situated in the hydrophobic region II.
In the PDB 2I0H docking GA15min was on rank one. It lay across the ATP binding site and
the nitrogens of the pyridazin formed two H-bonds to the backbone -NH of Met109 and
Gly110. Meanwhile the amines of the amino-phenol interacted with the side chain oxygens of
Asp168. Second ranked was again REV6min. The amino-phenol was situated in the hydropho-
bic pocket I and the pyridine interacted with the side chain of Thr106. The sp3 hybridized
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nitrogen of the imidazol formed an H-bond with the backbone oxygens of Gly110, whereas the
carbonyl oxygen formed two H-bonds to the backbone -NH of Met109 and Gly110 (figure
5.43).
Figure 5.43.: Docking of PDB 2I0H , pose of REV6min, left: stick representation, right: in
MOLCAD surface representation
Apart from REV2min all REV compounds had the same binding mode, as had OTTO2min
and OTTO3min. The GAmin compounds were found across in the entrance of the ATP bind-
ing pocket. The SKmin compound’s carbonyl oxygen also interacted with both Met109 and
Gly110. However the amino-phenol was situated in the hydrophobic region II and the -NH
formed an H-bond to a side chain oxygen of Asp112 at the end of the hinge region as always
found at the bottom of the ranking. The docking to PDB 2I0H supported the binding mode
proposed by Ottosen et al..
The docking to PDB 2FSO which does not contain a ligand put REV6min on the first rank.
Its carbonyl oxygen formed an H-bond to Thr106 alike in PDB 2GFS. Only the pose of the
benzyl-imidazol varied. In PDB 2FSO parts of the Gly-rich loop are missing. So the benzyl-
imidazol has enough free space to lie in front of Lys53. From there it formed two additional
H-bonds; the sp3 nitrogen to the side chain oxygens of Asp168 and the sp2 nitrogen to the side
chain of Lys53. This pose was often took up the other REVmin compounds. Many GAmin,
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OTTOmin and RNmin compounds on the following ranks were even positioned outside of the
binding pocket. The amino-phenol groups of the compounds were mainly situated in the hy-
drophobic region II. JH30min’s carbonyl oxygen formed an H-bond to the hydyoxy group of
Thr106 and the -NH and -NH2 formed H-bonds to Glu71, which is situated behind Lys53 and
normally forms a salt-bridge with it. All the SKmin compounds, again ranked at the bottom,
formed H-bonds to the hinge region (Met109 mainly). The absence of parts of the Gly-rich
loop seem to have a negative influence on the docking results.
Subsequent the MORE database was generated and added to Suberone database. Several of
the MORE compounds were exclusively build to fail in the docking attempts (e.g. MO15min).
An additional phenyl substituent may help to decide if one or the other proposed binding
mode is more likely. The proposed binding mode of Revesz et al. would not allow the a phenyl
substituent in that position, whereas an additional amino substituent may form additional
H-bonds (e.g. to Thr106). However PDB 2QD9 was the only PDB structure, where the
MORE compounds were included. For the so far practical PDB structures PDB 2I0H and
PDB 2GTN they were carried out later exclusively with the MORE compounds. FlexX posi-
tioned in both cases some of the MORE compounds which had to fail the docking (MO9min,
MO10min, MO15min, MO16min, MO19min, MO20min, MO21min and MO22min) with the
added phenyl/benzyl rings outside of the ATP binding pocket. The main pose was the one
according to Ottosen et al., or with the carbonyl oxygen about faced of the hinge region
or complete outside of the ATP binding pocket. Nevertheless no connection to the MORE
compound’s compositions or properties could be found. The poses seemed to be accidental.
Some poses of FlexX were extremely bad. Figure 5.44 shows two poses the left in PDB 2GTN
and right in PDB 2I0H, which can not be realistic at all.
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Figure 5.44.: Docking of the MORE database to PDB 2GTN (left stick representation) and
PDB 2I0H (right stick representation). The distance between Thr106 and the
amine of MO25min (0.4 A˚) and the way MO9min is posed are unrealistic.
Docking the Suberone database to PDB 2QD9 yielded to OTTO2min on the first rank. Its
pose was characterised through three H-bonds. Two between the carbonyl oxygen and the
backbone -NH of Met109 and Gly110 and the third was formed between the -NH2 and the
backbone oxygen of Leu104. The amino-phenol was situated in the hydrophobic pocket I,
so that this pose comes up to the proposed binding mode of Revesz et al. (see figure 5.45 on
the next page).
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Figure 5.45.: Docking to PDB 2QD9, pose of OTTO2min, left: stick representation, right:
MOLCAD surface representation
Many of the following compounds (e.g. REV6min, REV1min, OTTO3min, OTTO4min) until
rank 15 took up this pose. The rest of the poses were dominated by the pose according to
Ottosen et al.. Only now and then some compounds were posed alike the pose proposed
by Revesz et al.. As was RN14min (see figure 5.46 on the next page), where the carbonyl
oxygen formed an H-bond to the backbone -NH of Met109 and the amino-phenol in the
hydrophobic pocket I was anchored there with an H-bond between -NH2 and the backbone
oxygen of Ala51.
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Figure 5.46.: Docking to PDB 2QD9, pose of RN14min, left: stick representation, right: MOL-
CAD surface representation
Docking of the Suberones into PDB 1W82 ranked MO11min first, but was posed outside of
the binding pocket, alike MO17min on the next rank. Next was OTTO3min, where the -NH2
and NH of the amino-phenol formed H-bonds to the side chain oxygen of Glu71. The carbonyl
oxygen interacted with side chain of Arg70 and the methoxy oxygen was supposed to form
H-bonds to the side chain of Arg67 (figure 5.47).
Figure 5.47.: Docking of PDB 1W82, pose of OTTO3min, left: stick representation, right:
MOLCAD surface representation
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Next ranked REV10min took up the Glu71-H-bond-interaction, whereas the -NH formed an
H-bond to Asp168, which is situated on the opposite side of Glu71. The sp3 thiazol nitrogen
of REV7min on rank six formed an H-bond to Arg70, whereas the methoxy oxygen formed
one to the side chain of Arg67. All the others compounds took up the two binding modes of
OTTO3min (e.g. MO38min, GA13min, MO4min) or REV10min (e.g. MO19min, MO27min,
MO21min, MO35min, MO22min, MO4min, MO15min, MO32min, REV9min, MO31min,
REV1min, JH31min). The second pose appeared less often, though. The pose seems com-
prehensible. However, the preference of some MO compounds for the second pose cannot be
explained. The last ranks were all lined up by SK compounds.
REV6min was ranked first on the docking studies with PDB 1WBS. The thiazol was situated
next to the hinge region and formed an H-bond with Met109. No part of the molecule was
situated the DFG-OUT binding site. The amino-phenol was situated in the hydrophobic pocket
I, neither was next ranked REV10min. The di-fluoro-phenyl was situated in the hydropho-
bic pocket DFG-OUT. The pyridine nitrogen had an H-bond with the backbone nitrogen of
Asp168. The chloro-phenyl occupied the hydrophobic pocket I. REV5min on the third rank
detained also only the ATP binding pocket. The di-fluoro-phenyl occupied hydrophobic pocket
I, the carbonyl oxygen formed two H-bonds to the hinge region (the backbone -NH of Met109
and Gly110) and the benzyl-thiazol occupied hydrophobic region II. This is clearly the binding
mode according to Revesz et al.. and even in the DFG-OUT conformation (figure 5.48).
Figure 5.48.: Docking of PDB 1WBS, pose of REV5min, left stick: representation, right:
MOLCAD surface representation
REV4min and REV3min took up the same binding mode. Many other compounds had one
of the two binding modes alike in PDB 1W82 (OTTO1min, GA7min, RN14amin). Noticeable
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was that the majority of the GA compounds were docked outside of the ATP binding site. In
the end the REV5min-alike poses were outstanding and the poses which were obtained with
PDB 1W82 were found as well. But more unusual poses appeared. The docking yielded to
the result that the Suberones may also bind in the DFG-OUT conformation.
The docking with FlexX was not capable to determin which of the binding poses (Ottosen or
Revesz et al.) would work for the Suberones. Above that many poses FlexX suggested, did
not seem correct. As described above FlexX has problems to treat ligands of small molecular
weight alike ligands with a high molecular weight. This was shown that the SK compounds
were always found at the bottom of the ranking.
5.4.2. Flexidock
Flexidock’s main failure is the inability to dock large databases. In the diploma thesis [70] it
was identified to deliver good re-docking results for X-ray crystallographic structures of the
p38α MAP kinase. For the further studies is was simply not useful, because all Suberones
had to be positioned manually, which would have required a lot of time. Therefore Flexidock
was just applied to check mainly FlexX results. Proposed good or bad poses were used as
input for Flexidock to check if Flexidock agrees or disagrees to the proposed binding mode.
For example the dockings to PDB 2I0H, PDB 2GTN, PDB 2QD9 resulted in very acceptable
binding modes. They were saved and docked with Flexidock, which confirmed the good poses.
The DFG-OUT FlexX docking of PDB 1W82 identified a pose (type OTTO3min) as very
potential. The coordinates of the docking result of RN14amin were saved and transfered to
Flexidock. The Flexidock dockings (with the parameters described in Materials and Methods)
confirmed the pose as comprehensible.
5.4.3. GLIDE
Due to the cooperation with the Wilhelm Schickard Institute for Computer Science, Div. for
Simulation of Biological Systems, University of Tuebingen is was possible to work with GLIDE
(Schro¨dinger). All the databases which were created in SYBYL7.2 were used. All parameters
and pre-docking-preparations of the GLIDE dockings are described in Materials and Methods.
Before using GLIDE it was evaluated by re-docking and cross-docking studies. The focus
on the binding pose in any JNK3 models was neglected in the GLIDE docking study due
to in-between results of the crystallization team that the Suberones might bind in the DFG-
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OUT conformation. So the docking was more concentrated on the different conformations of
exclusively the p38α MAP kinase. Any further studies may include dockings to JNK3 models.
5.4.3.1. Re-docking
The re-docking was not carried out separately, it was included in the cross-docking studies.
However two ligand databases were generated, one which is the original SYBYL7.2 and a
Maestro-LigPrep-database. The last one contained more conformations of the nine ligands
from the start. It was generated to find out, if more ligand conformations (in the LigPrep-
database) yield to better poses. Additionally the differences between docking with contraints
or not as well as the two screening modes (SP or XP) were compared and tested for their
applicability.
5.4.3.2. Cross-docking
Thus the number of possible poses was set to 50, the ligand’s first appearance in the ranking
will be described or if any specialties arose. It occurred that the first appearance resulted
in good/similar poses and others later ranked were less similar. The first cross-docking was
carried out with PDB 1OZ1 (SP mode). AIZ501 was on rank one. But its binding mode was
not similar to the native in PDB 2B1P, except for the chloro-phenol which was situated in
hydrophobic pocket I. The next ligand that appeared was PDB 1OZ1 own ligand FPH (rank
7) and was very much posed alike. Next ranked was Q222-400 (rank 20) and its pose was
similar to PDB 2I0H. This also applied for L12 (PDB 1W84) on rank 24. The next ligand
that appeared in the ranking was PQB1 on rank 50; its pose also very similar to that in PDB
2GFS. The other ligands were situated on ranks above 100 (132: COM2000 (PDB 2O0U),
238: Q880-501 (PDB 1PMQ), 259: LIE301 (PDB 2GTN) and 337: Q984-501 (PDB 1PMN))
and their poses were very unlike to their native poses.
For the next docking studies the XP mode was used. FPH was here on rank one and very
similar posed, followed by also good poses for AIZ501 (rank 3), Q984-501 (rank 6), Q222-400
(rank 7) and L12 (rank 8). The poses for Q880-501 (rank 15), COM2000 (rank 21) and
PQB1 (rank 23) seemed not correct then again. However the calculations were even more
time consuming (70 minutes for 9 ligands).
The docking of the LigPrep database (SP mode) resulted in a slightly different ranking
(AIZ501, FPH, Q222-400, L12, Q984-501, Q880-501, PQB1, COM2000, LIE301). For
AIZ501, FPH, L12, Q984-501 and Q880-501 good docking poses were found. The dock-
ing was much more time consuming, however. The same docking in the XP mode resulted
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in the following ranking: FPH (rank one), Q984-501 (rank 3), COM2000 (rank 22), AIZ501
(rank 23), L12 (rank 26), Q222-400 (rank 31), Q880-501 (rank 41), LIE301 (rank 43) and
PQB1 (rank 51), where all proposed binding poses were acceptable.
The next docking was carried out with the contraints (con) option in the SP mode. It yielded
in the following ranking: AIZ501 (rank one), FPH (rank 6), Q222-400 (rank 10), PQB1 (rank
11), L12 (rank 14), COM2000 (rank 66), LIE301 (rank 92) and Q984-501 (rank 260). From
including L12 on the poses were not good, while Q880-501 was not even ranked at all. Docking
the database in the XP mode scored FPH hightest, followed by AIZ501 (rank 3), Q880-501
(rank 4), L12 (rank 10), Q222-400 (rank 12), COM2000 (rank 20), PQB1 (rank 23) and
LIE301 (rank 35). The last three poses were not alike those of their X-ray crystal structures.
The docking in the SP mode of the LigPrep database yielded to the following ranking (with
constraints) : FPH (rank one), Q222-400 (rank 5), AIZ501 (rank 6), L12 (rank 7), Q984-501
(rank 9), Q880-501 (rank 14), COM2000 (rank 22), PQB1 (rank 47) and LIE301 (rank 236).
The last two ligand’s poses were not good. Starting the same docking in the XP modes led to
a modified ranking: Q984-501 (rank one), FPH (rank 2), Q222-400 (rank 6), L12 (rank 20),
Q880-501 (rank 35), LIE301 (rank 30), AIZ501 (rank 37), COM2000 (rank 39) and PQB1
(rank 47). All binding poses were similar to those observed in the PDB structures.
In the end the native ligand FPH was found in a similar pose on the first two ranks at least.
Reasonable poses for AIZ501 were also surprisingly found as for all ligands. LIE301 was al-
ways situated at the bottom of the ranking, but even there some good poses were found, but
only when the XP mode was used. The LigPrep database was not superior to to the normal
database, even worse especially looking at the calculation time. XP was a little superior to
SP, but also is much more time consuming. When docking a large database the time, that
is needed, is a huge factor. Perfect results, but generated with more time consuming meth-
ods, are less worthwhile than only good results with less time consuming methods. The use
of SYBYL7.2 generated databases for docking studies in the SP mode so seems be a good
compromise for finding the correct binding mode of the Suberones.
Another evalution was carried out with PDB 2B1P. The appearance of the ligands in the
ranking during the different modes can be seen in table 5.13.
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All the dockings found very good poses with high scores for the JNK3 inhibitors (Q984-501,
Q880-501 and AIZ501). However, GLIDE had some problems with the posing of COM2000.
Its interactions were not often found. No difference between the quality of the SP and XP
modes could be observed. When the normal ligand database was used in the SP mode GLIDE
found reasonable poses for most of the other compounds, apart from LIE301. Good poses for
that ligand were hardly found. When the LigPrep database was used, the results for the JNK3
inhibitors became even more accurate, whereas good poses for the other ligands were found
to a less extent.
So far it seemed that docking with normal databases in the SP mode are useful for finding the
correct binding mode for the Suberones. The next part will present the results of the Suberone
docking.
5.4.3.3. Docking of the Suberones
The first docking was carried out with PDB 1OZ1, where RN14min was ranked first. The
carbonyl oxygen pointed to the hinge region, but without any H-bonds, whereas the amino-
phenol was situated in the hydrophobic pocket I. The -NH formed an H-bond to the backbone
oxygen of Ala51. The MOmin compounds like MO40min (rank 30) which had in some cases
their amino-phenol in the hydrophobic region II as well (MO37min rank 24, MO2min rank
40). Other MO compounds followed the pose on rank one (MO27min on rank 20). On rank
19 GA17min even was posed in this manner. It had appeared first on rank 6 with another,
even stranger pose (amino-phenol in the hydrophobic pocket I, whereas the oxygen of the
seven-membered ring pointed to the hinge region and the hydroxy groups of the substituents
had H-bonds with Met109 and Gly110). The SK compounds appeared very early in the
ranking (SK9min rank 14) and their carbonyl pointed to Lys53. JH30min was on rank 35 and
its analogue JH126min was on rank 42 and their oxygen in the seven-membered ring were
supposed to form an H-bond with Lys53. However, an H-bond with a ether oxygen which is
situated between two aromatic rings is very unlikely. In the end the docking studies with PDB
1OZ1 were not very successful, because they did not clearly prefer any pose.
The next docking was carried out with PDB 2GFS. REV9min was situated on rank one. Its
amino-phenol lay in the hydrophobic pocket I and the -NH2 formed H-bonds to the backbone
oxygen of Ala51. The carbonyl oxygen group formed an H-bond to the hinge region and
interacted with the backbone -NH of Met109. OTTO3min and REV5min on the next ranks
also took up the pose of rank one, apparently forming H-bonds with their carbonyl oxygen
to the backbone -NH of of Met109. All the compounds that followed (exclusively REVmin
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compounds) took up the observed binding poses. The first change happened with OTTO4min
on rank 15. While the carbonyl oxygen maintained the H-bond to Met109, this time the -NH2
formed an H-bond to the side chain oxygen of Asp168 instead of Ala51. The amino-phenol
remained in the hydrophobic pocket I. The next rank was occupied by MO3min. Here the
carbonyl oxygen pointed to the free space between Lys53 and Tyr35 (approximately the DFG
loop). The amino-phenol was still situated in the hydrophobic pocket I and the backbone
oxygen Ala51 formed an H-bond to -NH2. The rest of the ranking was ruled by the binding
pose of rank one (or rank 4 when regarding the carbonyl oxygen) e.g. MO13min (rank 18)
and MO1min (rank 26). The binding mode of rank 15 also appeared several times (REV2min
on rank 20 and OTTO1min on rank 31). In some cases no H-bond between the oxygen and
the hinge region was observed (RN14min rank 42). REV9min on rank 40 showed a special
binding pose. The carbonyl oxygen still pointed to the hinge region, whereas the amino-phenol
occupied the hydrophobic pocket I and the amine substituent formed an additional H-bond to
the backbone oxygen of Gly31 (part of the Gly-rich loop). The Revesz and Ottosen compounds
were often found in the top 100. On rank 70 GA17min appeared and was posed alike rank 4. It
again was ranked on 103, where the hydroxy group formed additional H-bonds to the hydroxy
group of Tyr35 (also Gly-rich loop). JH126min (rank 89) and GA6min (rank 105) took up the
binding pose of rank one, but their carbonyl oxygen rather pointed below the hinge region and
therefore did not form any H-bonds. The SK compounds only appeared above rank 200. The
poses on the ranks above 50 became more and more useless. But taken together the poses
obtained with PDB 2GFS strongly hinted at the pose according to Revesz et al..
The modified PDB 2GTN (with the deleted residues Phe169-Ala172) was used for the dockings.
OTTO1min was on the first rank. The carbonyl oxygen formed to H-bonds to backbone -NH
of Met109 and Gly110, whereas the amino-phenol was situated in the hydrophobic pocket
I and the -NH2 formed an H-bond with the side chain amines with Asp168. OTTO2min was
next and posed alike. REV3min occupied the next rank and also took up the pose. Fifth
ranked GA17min’s binding pose was alike, but the H-bonds to the hinge region were missing.
Instead the two hydrogens of the -NH2 formed in the hydrophobic pocket I two H-bonds
to the backbone oxygens of Ala51 and Leu104. Besides its hydroxy subsitutents formed two
additional H-bonds. One to the backbone oxygen of Val30 (beginning of the Gly-rich loop)
and the other to the side chain oxygen of Asp112 (at the end of the hinge region). Figure
5.49 shows the observed binding mode.
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Figure 5.49.: Docking to PDB 2GTN (green stick representation): GA17min; rank 5; (grey
stick representation), Val30 was left out to ensure a clear view, its position is
represented by the label
The following compounds all took up the pose. Sometimes they formed two H-bonds to
the hinge region (REV2min), or only one to Met109 or Gly110 or only pointed to the hinge
region, but had no H-bonds at all. From rank 14 on more unusual poses appeared. For
example JH126min’s carbonyl oxygen pointed to Lys53 (as did RN13amin, JH46min, MO3min,
MO4min, MO13min).The first SK compound appeared on rank 37, but its pose was negligible,
as those SK compounds that followed. Altogether it could be observed that the amino-phenol
was preferably posed in the hydrophobic pocket I (so alike Revesz et al.), whereas the pose
of the carbonyl oxygen and its H-bonds varied more.
Apart from one outlier all compounds of the Suberone database on the first 100 ranks had
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the same binding pose when docked in PDB 2I0H. MO4min on rank 65 had its carbonyl
oxygen pointed to Lys53, whereas all other compounds pointed with their carbonyl oxygen to
the hinge region. The first compounds formed H-bonds to Met109 and Gly110 (OTTO2min,
OTTO1min and OTTO3min). OTTO4min (rank 22) formed an H-bond to backbone -NH of
Gly110. All amino-phenol of the compounds were situated in the hydrophobic pocket I. The
amino-phenol on rank 44 was situated in hydrophobic region II. Several different H-bonds of
the aminogroups of the amino-phenol were found in the hydrophobic pocket I, e.g. with the
backbone oxygen of Ala51, with the backbone oxygen of Leu104 or with both or with none of
them. So this docking also supports the binding mode proposed by Revesz et al..
The GLIDE docking to PDB 2QD9 was carried out twice. Once with the normal database
and an extra docking with the then newly generated SG compounds. The first docking study
yielded to the REV compounds on the top ranks. REV9min was first and its carbonyl oxygen
formed two H-bonds to the backbone -NH of Met109 and Gly110 and the amino-phenol in
the hydrophobic pocket I. The -NH2 substituent formed an additional H-bond to the backbone
oxygen of Gly110. Until rank 44 all compounds were conformations of the REV compounds
apart from REV7min which did not appear at all. Rank 44 was occupied by SK510min which
took up the pose of the REV compounds, but only formed an H-bond to the backbone -NH
of Gly110. Both poses are displayed in figure 5.50.
Figure 5.50.: Docking to PDB 2QD9 (green stick representation): left REV1min; rank one;
(grey stick representation), right SK510min; rank 44 (grey stick representation)
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From then on more Suberones (not only REV compounds) appeared with similar poses (rank
one-44) appeared. An outlier was SK468 which lay across the ATP binding pocket in front
of the entrance. The OTTO compounds were primary ranked from rank 109 on. All poses
until the rank 160 were rather good and took up the poses alike the first ranks. Normaly
there was at least one H-bond either to Met109 and /or Gly110. And the amino-phenol
was positioned in the hydrophobic pocket I. There also the additional H-bonds to e.g. the
backbone oxygen of Leu104 appeared now and then. An extra docking of only the SGmin
compounds yielded to SK510min on the first rank. The pose was alike the one on rank 44 in
the previous docking. Next was SK318min, but had no H-bonds to the hinge region. Apart
from SK288min all SG compounds took up the pose, just varied in the formation of the H-
bonds (Met109 and/or Gly110 or no H-bond). Unlike the rest SK288min’s amino-phenol was
in the hydrophobic region II, and its carbonyl oxygen pointed to Lys53. The appearance of
the SG compounds was as follows: SK510min, SK318min, SK539min, SK558min, SK345min,
SK468min, SK568min, SK508min, SK541min, SK383min, GA430min, SK362min, SK316min,
SK288min, GA425min, SK436min and GA553min. The ranking could not be connected with
the binding affinity (if IC50 values existed, see also appendix). However, the results strongly
support the binding mode proposed by Revesz et al..
The docking of PDB 1W84 yielded in REV3min on the first rank. Its amino-phenol was
situated in the hydrophobic pocket I, but the pose of the carbonyl oxygen was unusual. It
pointed to the ceiling of the ATP binding pocket and did not form any H-bonds (figure 5.51).
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Figure 5.51.: Docking to PDB 1W84 (green stick representation): REV3min; rank one; (grey
stick representation)
SK345min appeared on rank 2 (in this docking the SGmin compounds were already added to
the Suberone database). Its carbonyl oxygen pointed to the hinge region, but no H-bonds
could be formed. SK318min pose on the next rank was partly posed outside of the ATP binding
site. The next compounds (SK508min, SK362min and SK468min) were posed alike rank one.
MO23min’s pose (rank 7) was very unusual; the ether oxygen of the seven-membered ring
formed an H-bond to Lys53 and the amino-phenol lay across in front of Tyr35. An unlikely
pose is demonstrated in figure 5.52.
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Figure 5.52.: Docking to PDB 1W84 (green stick representation): MO23min; rank 7; (grey
stick representation)
Many of the following poses were in fact not as unlikely as those of rank 7 and 9. While they
kept their amino-phenol in the hydrophobic pocket I, the rest of the molecule lay across the
binding pocket as well. No interactions between the carbonyl oxygen and the hinge region
were found. This docking was rather unsuccessful, because the poses were unlikely.
In PDB 2PKJ, one of the two unliganded PDB structures, RN14amin was put on rank one.
Its carbonyl oxygen pointed to the hinge region, but without any H-bonds. The amino-phenol
was situated in hydrophobic pocket I and the -NH2 formed H-bonds to the backbone oxygen
of Ala51. OTTO1min was next and its pose alike, but it formed an H-bond to backbone
-NH of Met109. The -NH2’s H-bond partner this time was the backbone oxygen of Leu104.
Third ranked GA17min’s amino-phenol was situated in hydrophobic region II (and the -NH2
formed an H-bond with Gly110), whereas the hydroxy substituents lay in the hydrophobic
pocket I and formed H-bonds to Asp168. This pose was very unlikely. GA1min’s carbonyl
oxygen on rank 5 pointed to Lys53, but still had its amino-phenol in the hydrophobic pocket
I. Another conformation of GA17min appeared in the exact pose on rank 9. The majority of
the results was posed alike the first rank, the only other alternative pose which occurred was
the one alike GA1min or OTTO1min (MO18min, MO28min, MO24min, GA2min, MO40min,
another conformation of RN14amin (rank 41) and MO12min) for the first 50 ranks. The SK
compounds appeared in this docking very late (rank 372, SK26min). Altogether the poses
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were very homologue and also hinted to the binding mode according to Revesz et al..
PDB 2FSO’s dockings came to the same result, if regarding the actual poses. But here the
first 50 ranks included no OTTOmin or REVmin compounds, but even there their poses took
up the two often poses that occurred most. The SK compounds were also only found on later
ranks. GA17min’s amino-phenol on the second rank was anchored by an H-bond to Asp168
in the hydrophobic pocket I, but its carbonyl oxygen pointed to Lys53. The hydroxy-groups
of the substituent had H-bonds to Gly110 and Asp112 (figure 5.53).
Figure 5.53.: Docking to 2FSO (green stick representation): GA17min; rank 2; (grey stick
representation)
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Many of the GA compounds had the same pose and even once a conformation of RN14amin.
Other compounds were situated with the amino-phenol in the hydrophobic pocket I anchored
with the H-bond to Ala51 and the carbonyl oxygen connected to Met109 with an additional
H-bond , but sometimes chose Asp168’s side chain oxygen instead of Ala51’s backbone oxygen
as an H-bond binding partner or alternatively Gly110 instead of Met109 or both at the same
time. Taken together docking to 2FSO also supports that the Suberones rather bind to the
p38α MAP kinase in the manner proposed by Revesz et al..
PDB 1W82 (DFG-OUT conformation) first rank was occupied by OTTO1min. The carbonyl
oxygen formed an H-bond with Met109 and the amino-phenol lay in the hydrophobic pocket
I. The other OTTO compounds followed this example on later ranks. In case of OTTO3min
the -NH2 was also anchored in hydrophobic pocket I by an additional H-bond with Ala51. The
other compounds were all posed alike the poses FlexX had suggested. The -NH2 and NH of
the amino-phenol formed H-bonds to the side chain oxygen of Glu71 or Asp168. However the
carbonyl oxygen had no interactions. The SK compounds appeared very early in the ranking
(rank 41 SK23min), but also without any H-bonds. On rank 46 MO4min was posed again in
the ATP binding pocket alike OTTO3min.
MO39min was on the first rank in the PDB 1WBS (also DFG-OUT conformation) dock-
ing. The pose was also alike the OTTO3min in PDB 1W82. But even with fewer H-bonds.
OTTO1min (rank 9) had the first of a small number of outliers. The carbonyl oxygen pointed
to Lys53, whereas the amino-phenol was directed to the hydrophobic pocket DFG-OUT and
the -NH formed an H-bond to a side chain oxygen of Glu71. The next ranks (e.g. REV1min)
took up the pose. Another conspicuity was situated on rank 16, where SK26min’s pose was
across the ATP binding pocket. Many other SK compounds on the next ranks, but their poses
were as unusual as the first one. In the end the pose that allowed H-bonds between the -NH2
to Glu71 or Asp168 was the preferred one. So alike FlexX GLIDE suggests that the Suberones
may also bind during the DFG-OUT conformation.
Further studies were carried in the XP mode and with contraints. The data is not presented
here. However the results did not alter much from the SP/without constraints studies, but
took much more calculation time. The results of the SP dockings were able to consider the
binding mode according to Revesz et al. as the more probable binding pose. Taken together
Glide docked the Suberones in very many acceptable poses, so it seems that it is more ap-
plicable for the p38α MAP kinase and a more reliable docking programme in comparison to
FlexX. Further docking was carried out next with eHITS to hopefully find more proof for the
GLIDE results.
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5.4.4. eHITS
5.4.4.1. Defining the docking options
With PDB 1OZ1 and PDB 1W84 the first re-dockings were carried out to decide if the accurate
or standard option produces results of different quality. Any fast docking is preferred over an
accurate if no loss of the quality of the poses can be observed. The standard option was
chosen, because it resulted in more similar results (17 of 32 instead of 7 of 32 in case of PDB
1OZ1) and altogether just three proposed binding modes of which two were nonsense (to four
of which three were unacceptable (PDB 1OZ1)) occurred. For PDB 1W84 only two poses
were proposed; the standard option resulting in more similar poses. The removal of the existing
water molecules of the PDB structures resulted in both PDB structures in more worse poses.
With eHITS it was apparent that low RMSD values refer to the right pose. Very similar poses
had RMSD values between 0,5000 and 1,0000 while any other positions had obviously higher
RMSD values (4,500 or more). The first good poses had high scores and therefore appeared
among the first ranks, but could also to be found in higher ranks (32 poses were calculated).
5.4.4.2. Re-docking
After choosing the right options more re-docking were carried out. The re-dockings in PDB
2GFS were worse in comparison to those done before. Overall the RMSD values were higher
and the binding modes varied considerably to the one in the X-ray structure. In general the
calculated orientations were very similar, but in many cases the position was shifted (e.g. flu-
orophenyl not buried in the inside of hydrophobic pocket I, but rather in front of it).
Re-docking of PDB 2GTN resulted in very many similar poses with low RMSD values. In case
of PDB 2GTN is was of no consequence if water molecules were present or not. Docking
first PDB 2I0H led to some difficulties, because two ligands are present in the X-ray crystal
structure. To enable an eHITS docking one of the ligands of the ATP binding pocket had to
be removed. The re-docking yielded in different results as mentioned before. Similar poses
were rare and were ranked lower than other totally unacceptable poses. Here the removal of
the water molecules resulted in more similar poses. But the RMSD values were higher (above
1,600 at least). PDB 2QD9 was also tested. Most of the binding poses were very similar to
the crystallized. The RMSD values are a little bit higher (most of them above 1), but that
comes from the size of the ligand with more large substitutents. The pose per se is correct,
but small variations in the substituents result in higher RMSD values in comparison to smaller
ligands (e.g. PDB 1W84). Completely wrong poses occurred rarely.
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To test eHITS on the re-docking of DFG-OUT conformations PDB 1WBS was chosen. The
poses here were also very similar, unveiled by the low RMSD values of 0,500-3,600 at most.
Small variations of the morpholine substituent yielded to RMSD values around 3. Figure 5.54
shows two re-docking results (PDB 1W84 (left) and PDB 1WBS (right)).
Figure 5.54.: Left re-docking of ligand L12 (pink stick representation) of PDB 1W84, rank
9(green stick representation) and right re-docking PDB 1WBS, native ligand pose
(pink stick representation) and docked ligand pose (green stick representation)
5.4.4.3. Cross-docking
During the cross-dockings eHITS does not calculate any RMSD values anymore. The poses
are judged visually and compared to the pose in their own X-ray crystal structure. If no rea-
sonable pose is expected, eHITS would hopefully not be able to find a pose at all. The first
cross-dockings included the refined water molecules. L12 the ligand of PDB 1W84 was found
on rank one in a very similar pose to the X-ray crystal structure and shared the same interac-
tions (pyridine-Met109, and indole in the hydrophobic pocket I). But altogether eHITS only
found poses for three other ligands (LIE301 (PDB 2GTN), FPH (PDB 1OZ1) and PQB1(PDB
2GFS)) which were positioned very unusual (not the expected H-bonds or even H-bonds at
all). For the next docking all water molecules were deleted. Here all ligands were docked and
they were all posed in the ATP binding site. Surprisingly the original ligand of PDB 1W84 was
only on rank 6. On the first rank was Q984-501 (PDB 1PMN), followed by Q880-501 (PDB
1PMQ). Their poses were very similar to the poses in their JNK3 X-ray structures. Positioned
on the next ranks were FPH (PDB 1OZ1), Q222-400 (PDB 2I0H) and LIE301 (PDB 2GTN),
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which are also very closely posed in comparison to their X-ray crystal structures. For PQB1
(PDB 2GFS) it is all the same. On the last ranks AIZ501 (PDB 2B1P) and COM2000 (PDB
2O0U) are located. Their poses are unusual, what goes along with their selectivity for JNK3
against p38α MAP kinase.
2FSO was also provided with SB203580, as mentioned before to ensure that eHITS finds the
ATP binding site. The cross-docking placed Q984-501(PDB 1PMN) on the first rank, but
the pose was unusual. The hydrophobic pocket I accommodated the cyclo-propyl-substituent,
whereas the di-chloro-phenyl was positioned in the hydrophobic region II. On the second rank
FPH is situated also differently, as well as LIE301 which is about-faced, Q222-400 (totally
different as well), L12 and Q880-501 (outside of the ATP binding site). The seventh rank is
occupied by PQB1 which position is also not similar to the native position in the X-ray struc-
ture. This also applies for COM2000 and AIZ501. For them it is not unexpected however,
because they should not be able to bind in regard to their selectivity profile.
In case of PDB 2GFS LIE301 was on the first rank and its pose was very similar to that of the
native structure. The second rank was occupied by COM2000 which pose was also very alike.
PQB1’s position on the third rank was less alike its crystal structure, followed by AIZ501 which
was again very much alike. In contrast to AIZ501 the five remaining ligands had very unusual
poses. The cross-docking of PDB 2GTN also set LIE301 on the first rank, but the pose was
about-faced from the crystal structure. Second ranked was Q222-400, but also in a different
orientation. PDB 1OZ1’s FPH on the third rank was posed alike its crystal structure, whereas
next ranked Q880-501 was not. On rank five AIZ501 is situated very much alike its pose in
JNK3. JNK3 structure PDB 1PMN’s ligand Q984-501, however, was posed very dissimilar to
native pose. On the last three ranks L12, PQB1 and COM2000 were situated. None of their
prosposed poses was similar to those of their crystal structures.
In case of PDB 2I0H ligand LIE301 was ranked best. Its pose was very similar. Second ranked
Q880-501’s position was about-faced to its observed in JNK3. PDB 2I0H own ligand Q222-
400 was ranked third best and in a very similar pose. COM2000’s naphtylene on the fourth
rank positioned in hydrophobic pocket I like in its crystal structure, but the rest of the ligand
was posed unusual. Next ranked FPH’s pose was also similar in regard to the substituent in
hydrophobic pocket I, but the pose of the rest of the molecule was twisted. The same applies
to Q984-501, followed by PQB1, L12 and the last ranked AIZ501.
The last cross-docking studies were carried out with PDB 2QD9. Q222-400 was best ranked
and its pose was alike the one in its crystal structure. Second ranked LIE301 was about-faced,
as well as Q984-501 on rank three. Fourth scored COM2000’s pose was very similar to its
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observed in PDB 2O0U, only the piperidin substituent is slightly different. Next ligand PQB1
was also very much alike, just like L12. On the seventh rank Q880-501 was situated, but not
very good posed. Eighth ranked FPH was very good posed again. The pose of AIZ501 on the
last tank was also very similar to that in its X-ray crystal structure.
The cross-docking studies showed that eHITS is able to find the right poses, but the user has
to check the results carefully, because there may be false results in between. In the end eHITS
seems to be as applicable for the docking studies as the other programmes. Figure 5.55 shows
a result of the cross-docking study of PDB 2QD9.
Figure 5.55.: Cross-docking study: ligand LIE301 (pink stick representation) of PDB 2GTN in
PDB 2QD9 (ligand LGF in green stick representation), rank 2
5.4.4.4. Docking of the Suberones
The first docking was carried out with PDB 2IOH (options standard accurancy, no water
molecules). On the first rank was REV8min in an orientation according to Ottosen et al.. The
sp2nitrogen of the pyrazol formed an H-bond to Thr106’s side chain oxygen. The amino-phenol
lies to the right of hydrophobic region II. The second rank was occupied with REV4min. Its
pose refers to the Revesz et al. binding mode. The carbonyl oxygens form two H-bonds to the
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backbone nitrogens of Met109 (distance 2,6187 A˚) and Gly110 (distance 1,9603 A˚) and the
amino-phenol lies in the hydrophobic pocket I (figure 5.56).
Figure 5.56.: Docking to PDB 2I0H: left proposed pose of REV8min rank one and right pro-
posed pose of REV4min rank 2 (no hydrogens were added for this representation)
REV10min (rank 3) formed again the H-bonds to the backbone nitrogens of Met109 (distance
2,2435 A˚) and Gly110 (distance 1,8263 A˚) and additionally the pyridine nitrogen to the side
chain oxygen of Thr106 (distance 3,0814 A˚) (these three H-bonds also occur with Q22-400, the
native ligand). Next ranked REV1min formed then again only two H-bonds to the backbone
nitrogens of Met109 and Gly110 (distance 2,4370 A˚ and 1,8540 A˚ respectively). However,
in both cases the amino-phenol was situated in the hydrophobic pocket I. Next compound
which stepped out was on rank 11 (MO15min). The amino nitrogen formed an H-bond with
the side chain oxygen of Thr106 (distance 2,8647 A˚). The amino phenol was situated in the
hydrophobic pocket I, but the carbonyl oxygene was far away from the hinge region, although
it still pointed to it. The additional phenol substituent should have prevented any posing, but
it was posed surprisingly anyway (figure 5.57).
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Figure 5.57.: Docking to PDB 2I0H: proposed pose of Mo15min rank 11
On the next rank was OTTO1min. The carbonyl oxygen formed two H-bonds to the backbone
-NH of Met109 (distance 2,2789 A˚) and Gly110 (distance 1,6181 A˚) and an additional H-bond
between the nitrogen of the amine to the backbone oxygen of Leu104 (distance 1,9050 A˚). The
amino-phenol occupied the hydrophobic pocket I and binds therefore according to the Revesz
et al. binding mode. Next eHITS ranked MO10min and MO16min. This time opposed to the
similar compound MO15min on rank 11 their pose was very unusual as it would have been
expected, due to their composition. Many other MO compounds were ranked subsequently,
but their carbonyl oxgen was about-faced and pointed rather to Lys53 instead of the hinge
region, whereas the amino-phenol was situated in the hydrophobic region II. Sometimes the
carbonyl oxygen even pointed to the hinge region, but formed no H-bonds to it and had the
amino-phenol situated in the hydrophobic region II (MO33min on rank 18). An exception
was MO29min on rank 19, where the oxygen pointed again to the hinge region. RN15min’s
(rank 21) binding pose also followed the unusual binding poses of the MO compounds. The
higher the rank the more unusual poses appeared. OTTO2min appeared on rank 27, had its
amino-phenol situated this time in the hydrophobic region II. The carbonyl oxygen pointed to
the hinge region, but was too far away posed to form any H-bonds. The REVmin compound’s
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poses remained traceable. GA16min was ranked on the 37th place; the oxygen only pointed to
the hinge region, whereas the amino-phenol was situated in hydrophobic region II, while its
amine formed an H-bond to the side chain oxygen of Asp112 (atom OD2, distance 2,0318 A˚).
JH31min’s oxygen (rank 46) pointed again rather to Lys53, while keeping the amino-phenol
in the hydrophobic pocket I, where the amine formed an H-bond to the backbone oxygen of
Leu104 (distance 1,5072 A˚). This pose and the one of OTTO1min are demonstrated in figure
5.58.
Figure 5.58.: Docking to PDB 2I0H: left proposed pose of OTTO1min rank 12 and right
proposed pose of JH31min rank 81
The first SK compound appeared on rank 103 (SK29min), but not comprehensible posed.
GA17min (rank 137 and 148) poses were acceptable. In both cases the carbonyl oxygen
formed two H-bonds to the backbone nitrogens of Gly110 (distances 3,0354 A˚ and 2,4073 A˚
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respectively) and Ala111 (distances 2,4759 A˚ and 2,1366 A˚ respectively) (figure 5.59).
Figure 5.59.: Docking of the Suberones in PDB 2I0H: proposed pose of GA17min rank 137
(left) and rank 148 (right)
PDB 2GTN’ first rank was occupied by MO35min which pose was alike JH31min in PDB 2I0H
(the carbonyl oxygens points to Lys53 instead of the hinge region, while keeping he amino-
phenol in the hydrophobic pocket I). The next ranked ligands shared this pose. MO37min’s
amino-phenol (rank 8) was situated in hydrophobic pocket I and its -NH2 formed two H-
bonds; one to the backbone oxygen of Phe169 (distance 2,1882 A˚) and another to the side
chain oxygen of Asp168 (distance 1,4197 A˚). REV9min is on rank 12 and the carbonyl oxygens
formed an H-bond to backbone -NH of Gly110 (distance 2,5406 A˚) and the -NH2 of the
substitent to the backbone oxygen of Gly110 (distance 2,0254 A˚) (figure 5.60).
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Figure 5.60.: Docking of the Suberones in PDB 2GTN: proposed pose of REV9min rank 12
Most of the following compounds pointed with their carbonyl oxygen to Lys53, whereas the
amino-phenol was situated in the hydrophobic pocket I. RN15min (rank 16) had its carbonyl
oxygen to the hinge region, but without any H-bonds. The amines in hydrophobic pocket I
had two H-bonds to the side chain oxygen of Asp168 (distance 2,8234 A˚) and to the Glu71
(distance 2,3819 A˚) in the meantime. The OTTO compounds (OTTO3min (rank 37) and
OTTO1min (rank 41)) were posed according to the Revesz et al. binding mode; on rank 43
RN13amin as well. Poses on the following ranks resulted in less good or acceptable poses.
The first SK compound was on rank 100 (SK12min), JH30min was unusual posed on rank 55,
whereas a good pose of GA17min was on rank 101. Altogether the eHITS docking to PDB
2GTN supported the theory that the amino-phenol would occupy the hydrophobic pocket I
rather than hydrophobic region II (so alike Revesz et al.). Several H-bonds of the amines
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were discovered, but the carbonyl position was often unusual (no pointing to the hinge region,
but in the other direction).
Docking the Suberones to PDB 2QD9 resulted in MO38min on the first rank. The amino-
phenol was in hydrophobic pocket I, whereas the carbonyl oxygen pointed to the hinge region,
but there no H-bond interactions were found. Analogue MO36min was on rank 2 and took
up the same pose. Many of the following compounds were about faced. They maintained
the amino-phenol position in hydrophobic pocket I, while sometimes forming an H-bond to
the backbone -NH of Met109 with the amino-phenol in the hydrophobic pocket I. Very few
were posed about-faced alike this with the carbonyl oxygen pointing to Lys53 (MO35min). In
the first twenty ranks almost exclusively MOmin compounds could be found. OTTO21min
on rank 21 was posed according to the Revesz et al. proposed binding mode. It formed three
H-bonds: the carbonyl oxygen to the backbone nitrogen of Met109 (distance 2,1560 A˚) and
Gly110 (distance 1,7916 A˚) and the -NH2 to the backbone oxygen of Leu104 (distance 1,8317
A˚). Two ranks later JH46min was positioned alike, but with only an H-bond to the backbone
nitrogen of hinge region residue Met109 (distance 3,0168 A˚). eHITS offered two additional
H-bonds between the -NH2 and the backbone oxygens of Ala51 and/or Leu104 (distances
2,2977 A˚ and 1,5705 A˚). The carbonyl oxygen of GA14min on the next rank pointed again
to Lys53, also RN15min on rank 28. REV4min on rank 37 shares the same hinge regions
interaction like GA17min of PDB 2I0H (Gly110 2,1685 A˚ and Ala111 2,0904 A˚). Figure 5.61
shows the proposed binding poses of REV9min and REV4min.
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Figure 5.61.: Docking to PDB 2QD9: left proposed pose of REV9min rank one and right
proposed pose of REV4min rank 37
In the following poses the Suberone’s carbonyl oxygen mostly pointed to Lys53, or if not it
did not form any H-bonds to the hinge region atoms. The first SK compound was found on
rank 115 (SK9min), but the oxygen pointed again to Lys53.
This docking study strengthens that the amino-phenol is situated in the hydrophobic pocket
I (Revesz binding mode). It also introduced a new binding partner to anchor the amino-
phenol there (Ala51). Thus, the SG compounds were added later to a separate database,
they were exclusively docked in PDB 2QD9, because it had shown very good docking results.
The first rank was occupied with SK568min. The hydrophobic pocket I accommodated the
amino-phenol, but the oxygen pointed to Lys53 instead to the hinge region. Next ranked
GA425min’s also had its amino-phenol in hydrophobic pocket I, while forming two H-bonds to
the hinge region.The backbone nitrogens of Met109 and Gly110 had each an H-bond with the
carbonyl oxygen (distances 2,2036 A˚ and 1,9980 A˚). Figure 5.62 on the next page illustrates
the proposed binding mode.
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Figure 5.62.: Docking to PDB 2QD9: proposed pose of GA425min rank 2
Third ranked SK539min was similar posed, but did not form any H-bonds. The following
ranks followed the poses which had been found on the first three ranks: rank one (SK383min,
GA553min, SK318min, SK468min), rank 2 (SK316min, SK288min) and rank 3 (SK541min,
SK558min). On the ranks 13-17 eHITS calculated for GA430min, SK508min, SK436min,
SK345min and SK362min the same pose. The amino-phenol was situated in the hydrophobic
pocket I, and the carbonyl oxygen pointed approximately to the DFG area. No correlation
between IC50, rank or composition could be observed.
PDB 1W84’s first rank was occupied by MO15min, but its pose was according to Ottosen et
al., placing the amino-phenol to hydrophobic region II. The carbonyl oxygen pointed to Lys53.
Besides MO15min was built to fail in the docking studies, because of the large substituent next
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to the amino-phenol. MO38min on rank 4 is the only one until rank 13 where the carbonyl
oxygen pointed to the hinge region and had its amino-phenol in the hydrophobic pocket I,
but did not form any H-bonds. MO38min pops up three time during the eHITS docking
studies (rank one PDB 2QD9 and later (278SLS)), although it has the wrong position of the
oxygen in the seven-membered ring. Its pose was hardly obtained by docking the suberones
in PDB 1W84 (exceptions MO36min (rank 21), MO35min and MO7min (rank 25-rank 26)).
The other compounds (GA, JH, OTTO or REV) have their amino-phenol in the hydrophobic
region II and/or their carbonyl oxygen pointing to Lys53. On rank 87 the first SK compound
was situated (SK9min), but with no comprehensible pose.
Altogether two poses appeared. In case of pose one the compounds were situated outside of
the ATP binding pocket and did not have any H-bonds. Or their amino-phenol was situated in
the hydrophobic pocket I, while the carbonyl oxygen pointed to Lys53 or the amino-phenol
was situated in the hydrophobic region II instead. PDB 2FSO yielded to very poor results
(figure 5.63).
Figure 5.63.: Docking to PDB 2FSO yielded in very poor results, left RN14min, middle
GA17min, right MO23min
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The first rank in PDB 1WBS (DFG-OUT conformation), the X-ray structure of the DFG-OUT
conformation, was REV6min. The pose is visualized in figure 5.64.
Figure 5.64.: Docking to PDB 1WBS, REV6min, rank one
The interaction file revealed only one H-bond interaction between the lone pair of the -NH
linker atome of the amino-phenol and the -NH3+ of Lys53. The amino-phenol was situated in
hydrophobic pocket I, while the carbonyl oxygen pointed to the DFG loop region, but formed
no H-bond interactions. All the following poses of all left Suberone compounds were found as
pictured below (figure 5.65).
Figure 5.65.: Docking to PDB 1WBS, left docked binding poses are all alike MO39min (rank
7) and right MO36min (rank 8)
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In both cases the amino-phenol was situated in front of the hydrophobic pocket I. Then either
the Suberone were posed similar to MO39min, where the carbonyl oxygen pointed to DFG loop
or similar to MO36min, where the carbonyl oxygen was about faced. Two additional H-bonds
were found in these poses. The amine linker formed one to H-bond to the side chain oxygen
of Glu71 (distance 2,6759 A˚) and in case of MO36min the -NH2 to the backbone oxygen of
Asp168 (distance 2,2258 A˚).
Neither of these poses seemed likely however and was supported by the results in the following
section. But in the end eHITS supported the results GLIDE had given, so that the Suberones
may rather take up the binding pose proposed by Revesz et al..
5.5. X-ray crystal structure 278SLS
In cooperation with the biochemistry department (Prof. Stehle, J. Romir) a X-ray crystal
structure was obtained with NR13a as ligand in September 2007. It revealed that the sus-
picions of the binding mode suggested by the docking studies are correct. The oxygen of
NR13a binds to the hinge region residues Met109 (NH) and Gly110(NH) (distances 1,920A˚
and 2,063A˚). For this the hinge region performed a ”flip”, so that the NH of Gly110 is able
to form the H-bond. The amino-phenyl lies in the hydrophobic pocket I just as the docking
studies and Revesz et al. had proposed (figure 5.66 on the next page).
Figure 5.66.: Binding mode of NR13a in 278SLS, shot taken in SYBYL7.2
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In the end the refined structure revealed two additional water mediated H-bonds.The H of the
amine linker formed an H-bond over the oxygen of water1 with a hydrogen of Lys53, while the
H of the amino-phenol formed over the oxygen of water2 an H-bond with the backbone NH
of Asp168 (figure 5.67).
Figure 5.67.: Binding mode of NR13a in the refined 278SLS (now MK38), shot taken in GLIDE
The next step was to compare 278SLS with the chosen PDB structures to identify the differ-
ences. The alignments by homology may explain the problems which occurred in the docking
studies (see table 5.14).
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The alignments reveal that only PDB 2I0H, PDB 2GTN and PDB 2QD9 share the observed
”flip” of Met109 and Gly110 (atoms 14-25) in the hinge region which is required for the
binding of the Suberones. Others like PDB 1W84 or PDB 1OZ1 do not include the required
flip and therefore the dockings with those resulted in wrong docking poses. In figure 5.68 the
differences can be observed. PDB 2GTN shares the flip with 278SLS, while the hinge region
of PDB 1W84 does not perform a flip.
Figure 5.68.: Left: 278SLS (colored by atom) and PDB 2GTN (purple) aligned by homology;
right: 278SLS (colored by atom) and PDB 1W84 (orange) aligned by homology,
shots taken in SYBYL7.2
The loop regions, especially the Gly-rich loop, point at major differences. The real state can
not be determined, because the electron density was very low in that regions and was only
assumed by the depositer. The conformation of the backbone of Thr106 (atoms 44, 48, 49,
50) which limits the left side of the hydrophobic pocket I is not relevant for it does not take
part in the flip, indicated by the fact that all PDB structures have very low RMSD values
there. The position of the oxygen of the side chain (atom 46 (OG1)) on the other hand
differs greatly. There are some PDB structures where the oxygen points into to the ATP
binding pocket, in some cases also forming an H-bond with the ligand. Docking can therefore
be influenced by the different conformations of the oxygen which can lead to wrong docking
poses. That fact makes PDB 2QD9 the more similar PDB structure in comparison to PDB
2I0H and PDB 2GTN, where the oxygen points into the ATP binding pocket, when compared
to 278SLS (figure 5.69).
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Figure 5.69.: Lys53, Thr106, Met109 and Gly110 of PDB 2I0H (red), PDB 2QD9 (green) and
278SLS (colored by atom) aligned by homology, shot taken in SYBYL7.2
Figure 5.70 shows the results of the alignment by homology in a diagram.
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Figure 5.70.: Alignment by homology of all atoms of the hinge region, 278SLS is fixed
The conformation of Lys53 which lies on the other side of the hydrophobic pocket I does
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not differ greatly among the models (see table 5.15). Therefore it has no influence on the
docking. Table 5.15 on the next page also presents the differences between the chosen PDBs
and 278SLS in the DFG area (in addition with Leu167).
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5.5. X-RAY CRYSTAL STRUCTURE 278SLS
PDB 1WBS has the highest average RMSD obviously, because here the DFG is in the DFG-
OUT conformation. PDB 2GTN has also a very high average RMSD. The loop in this PDB
structure is very unusual, because it lies in the ATP pocket. The other PDB structures are
very similar in the DFG region in comparison with 278SLS. The DFG region of 2IOH is the
most similar one when compared to 278SLS. The highest calculated RMSD values occur at
Phe169, however all conformations of Leu167 are rather the same. Asp168 which is directly
situated next of Phe169 has surprisingly low RMSD values. The highest concern the side
chain oxygens. At the backbone the nitrogen and the C-α atome have very low RSMD values.
Therefore here another ”flip” which concerns only a very local region can be observed. Figure
5.71 visualizes the alignment of the DFG atoms and Leu167.
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Figure 5.71.: Alignment by homology of all DFG atoms, 278SLS is fixed
Combining all facts so far PDB 2QD9 is the most similar to 278SLS, when regarding the
hinge- and DFG region. The only remaining problem is the Gly-rich loop. If it’s conformation
in the X-ray crystal structure 278SLS is the real state, but might cause problems with further
dockings. It may be therefore wise to use both, PDB 2QD9 together with 278SLS, for further
dockings to judge any poses correctly and not be wrongly influenced by the Gly-rich loop.
The ligand of 278SLS can not be compared to the generated molecules in the database. The
conformation of the ligand is as seen in figure 5.72 badly resolved. The state of ring B is
139
CHAPTER 5. RESULTS
obviously unusual.
Figure 5.72.: 278SLS (MOLCAD surface representation) with ligand (stick representation),
ring B marked with red arrow, shot taken in SYBYL7.2
In table 5.16 the WHAT IF report is presented. The values are not good. If this had been a
published structure it would not have been chosen for the docking studies. The X-ray structure
needs more refinement.
278SLS
2nd generation packing quality -1.755
Ramachandran plot appearance -2.779
χ-1/χ-2 rotamer normality -3.207
Backbone conformation -6.529
Resolution 1.95
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Bond lengths 0.537
Bond angles 0.612
Omega angle restraints 1.449
Side chain planarity 0.249
Improper dihedral distribution 0.521
B-factor distribution 0.349
Inside/Outside distribution 1.058
Table 5.16.: WHAT IF report of 278SLS; the first 5 values represent Structure Z-scores (posi-
tive is better than average) following represent RMS Z-scores (should be close to
1.0)
5.5.1. Docking studies with 278SLS
5.5.1.1. FlexX
FlexX was not used, because GLIDE and eHITS were found to be superior to FlexX. So
Flexidock was not used either to check the FlexX results.
5.5.1.2. GLIDE
The complete Suberone database was docked to 278SLS. REV4min occupied the first rank.
The carbonyl oxygen formed two H-bonds to Met109 and Gly110 (distance 2,001A˚ and 2,102
A˚) and the hydrophobic pocket I accommodated the amino-phenol (figure 5.73 on the next
page). The next ranks were also occupied by REV compounds (REV6min and REV5min)
which took up then same pose. SK468min had its carbonyl oxygen pointed to the side chain
hydroxyl group of Tyr35, whereas the nitrogen of the pyridine interacted with the backbone
-NH of of Gly110 (figure 5.74). This pose occurred when a compound had the pyridine alike
SK468min (e.g. SK383min (rank 74)). The other poses (most of them took up by REV
compounds) were alike the one of rank one or alike rank 22 where SK510 was posed alike,
but only formed an H-bond to Gly110 (see figure 5.75). On later ranks (from 200) some
more irrelevant poses occurred, but until then most of the poses were very similar to the X-ray
crystal structure.
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Figure 5.73.: Docking of 278SLS (green stick representation): REV4min; rank one (grey stick
representation)
Figure 5.74.: Docking of 278SLS (green stick representation): REV4min; rank one (grey stick
representation)
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Figure 5.75.: Docking of 278SLS (green stick representation): left SK539min; rank 50 (grey
stick representation), right SK508min; rank 77 (grey stick representation)
5.5.1.3. eHITS
Thus the ligand in 278SLS was so badly refined, as mentioned before, SYBYL7.2 was used to
determine the correct atom types, e.g. that in the carbonyl C and O are sp2 hybridised, so
that the correct number of hydrogens is added. The modified ligand was saved in the PDB
file. Two re-docking studies were started (water was kept), surprisingly disclosing that the
modified PDB file resulted in less good poses; sometimes lacking H-bonds to the hinge region
or even reversed. Figure 5.76 on the next page shows the differences between the re-dockings.
It also demonstrates that eHITS is unable to recognize the oxygen as sp2 hybridised.
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Figure 5.76.: Re-docking studies of 278SLS: docking result with unmodified ligand (left blue
stick representation original ligand) and result with modified ligand (right pink
stick representation docked ligand)
Docking of the Suberones placed MO38min on the first rank (just like the docking to PDB
2QD9). It had the oxygen of the seventh ring on the opposite side of the amino-phenol. But
this time the interaction-file revealed two H-bonds of the carbonyl oxygen to the NH of Met109
and Gly110 and an additional between NH2 and a side chain oxygen of Asp168 (figure 5.77 on
the next page). The pose is in agreement with the proposed binding mode of Revesz et al..
144
5.5. X-RAY CRYSTAL STRUCTURE 278SLS
Figure 5.77.: Docking of the Suberones to 278SLS: MO38min (rank one) has three H-bonds; to
Met109 distance: 2,9383A˚ to Gly110 distance: 2,3915A˚ and to Asp168 distance:
1,1317 A˚
GA4min (rank 36) and GA11min (rank 64) formed two H-bonds to Met109 and Gly110.
The two GA compounds have the oxygen of the seventh ring on the opposite side of the
aminophenyl. Several other compounds had at least one H-bond to Met109 (e.g. GA13min
(rank 43) and RN14amin (rank 48)) RN14amin is the SYBYL7.2 built ligand and very similar to
the ligand of 278SLS (figure 5.78 on the next page). The two carbons of the seven-membered
ring are only sp2 hybridised in the case of RN14amin. Here it formed no additional H-bond to
Asp168.
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Figure 5.78.: Docking of the Suberones to 278SLS: RN14amin (orange stick representation,
rank 48) has one H-bond to Gly110: distance 2,192A˚, and the ligand of 278SLS
(pink stick represenation)
All carbonyl oxygens of the other compounds did not form any H-bonds, but still pointed to
the hinge region. However the majority of the carbonyl oxygens pointed to the opposite site of
the hinge region. But all amino-phenyl substituents were situated in the hydrophobic pocket
I.
Thus SG ligands were added later to the database, they were docked exclusively in PDB
2QD9 (see also section eHITS) and 278SLS. On the first rank SK541min was situated. The
hydrophobic pocket I contained the amino-phenol substituent, but the carbonyl oxygen did
not point to the hinge region, but rather to Lys53. A single H-bond interaction was found
between the side chain oxygen of Asp168 and the -NH (distance 2,5408 A˚). Second ranked
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SK468min formed with its carbonyl oxygen an H-bond to Lys53 (distance 1,7600 A˚), whereas
the amino-phenol was situated in the hydrophobic region II. Figure 5.79 presents the two
proposed binding poses.
Figure 5.79.: Docking of the Suberones type SG in 278SLS; left rank one (SK541min) and
right rank two (SK468min)
Third ranked GA430min was a little shifted to the front (hear hydrophobic region II) and still
had its amino-phenol in hydrophobic region II. Just a few compounds were posed with their
carbonyl oxygen pointing to the hinge region (SK510min, SK318min, SK539min, SK558min).
All the rest of the compounds were posed alike SK541min. In the end the eHITS docking
results were not very good.
5.6. MORE2 compounds
The MORE2 compounds were built to test if the amine linker of the amino-phenol could
be replaced by an oxygen linker and if the -NH2 could be replaced by a methoxy group.
GLIDE was used for the docking, because due to the above described results it had proved
to deliver the best results. The three X-ray strucutures PDB 2I0H, PDB 2QD9 and 278SLS
were used, because their conformation mirror the actual induced-fit state during the presence
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of the Suberone compounds (278SLS of course is the actual induced-fit state). The docking
yielded to three different rankings:
• PDB 2I0H: MORE3min, MORE1min, MORE4min, MORE2min
• PDB 2QD9: MORE2min, MORE3min, MORE1min, MORE4min
• 278SLS: MORE4min, MORE2min, MORE1min, MORE3min
In case of PDB 2I0H all poses were alike. The carbonyl oxygen pointed to the hinge region, but
without any H-bonds. The amino-phenol occupied hydrophobic pocket I and only MORE1min
was anchored to it by an H-bond between the -NH2 to the backbone oxygen of Leu104. Two
of the results of the PDB 2QD9 ranking (MORE3min and MORE1min) differed , because they
had the carbonyl oxygen directed to Lys53, but maintained with their amino-phenol in the
hydrophobic pocket I. This also happened to all MORE compounds apart from MORE1min in
case of the docking to 278SLS. Figure 5.80 shows the two binding poses. Left is the reasonable
pose, whereas the right one with the bad contact between Lys53 and the oxygen, and the ugly
contact between Tyr53 and hydrogen (presented through the red dashed line) is rather unlikely.
Figure 5.80.: Docking of the MORE2 compounds to PDB 2QD9 and 278SLS (green stick
representation); left MORE2min (grey stick representation) in PDB 2QD9; rank
one, right MORE3min (grey stick representation) in 278SLS; rank 4
The docking supports the idea that an oxygen linker may also be acceptable in a Suberone
compound.
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The molecular modeling studies were able to propose a binding mode of the Suberones and
X-ray crystallography supplied the evidence. The Suberones bind in the pose proposed by
Revesz et al. (see figure 6.1 on the next page).
Both Revesz et al. and Ottosen et al. proposed that the carbonyl oxygen is bound to
hinge region via an H-bond to the backbone -NH of Met109. They were contradictory on
the position of the amino-phenol (ring C). According to Ottosen et al. it was situated in the
hydrophobic region II, whereas Revesz et al. proposed that it would occupy the hydrophobic
pocket I.
However, Revesz et al. and Ottosen et al. could not generate more details of the binding pose
that were actually observed in the X-ray structure (278SLS). The X-ray structure revealed
that the hinge region performs a ”flip” to be able to form two H-bonds. The backbone -NH
of Gly110 is turned towards the inside of the ATP binding site (the ”flip”), so that it can
interact with the carbonyl oxygen of the Suberones. The carbonyl oxygen also interacts
with the backbone -NH of Met109. So the concept of the previous mentioned Linear Binders
has to be enhanced. This class of Suberones does not only bind to the hinge region’s linker
residue Met109, but enforce the ”flip”. So not only due to the gatekeeper residue Thr106
which determines the width of the entrance of the hydrophobic pocket I, but also the hinge
region residue next to Met109 itself contribute to selectivity. Through the existence of Gly110
the φ-ψ-rotation is restricted to a certain conformation. Other residues like Asp150 in JNK3
may be unable to perform such a ”flip”, due to their side chains.
Docking is not able to predict such an interaction, because all programmes that were used (and
that also applies for the majority of the available docking programmes) only treat the ligand as
flexible, while keeping the protein structure rigid. Docking in a fully flexible protein would need
too much CPU- and calculation time. So it is of great consequence in which rigid PDB struc-
ture the ligands are docked (apart from the choosing of the applicable docking programme).
Choosing a suitable PDB structure was also part of this work. It was evident that there is
more to the quality of a structure than only one quality criteria (e.g the R-factor). It has to
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Figure 6.1.: Binding mode of the Suberones proposed by the modeling studies
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be a consensus of several aspects. The PDB structure which was used in the former Diploma
thesis (PDB 1YWR) e.g. failed the quality standards. Considering the above mentioned rigid
docking, the use of several PDB structures is of high importance. Several conformations of
the p38α MAP kinase were used here and it came out that different conformations yield to
different results (PDB 1W84 in comparison to PDB 2I0H). Thus the ligand determines the
induced-fit state of a protein, the native ligand and the database ligands have to be similar
and provoke the induced fit. Docking with just one PDB structure, which even may be the
unsuitable, may draw wrong conclusions. This was made clear by the use of the several con-
formations and highlights the need for careful preparations before such a docking study. For
example Ottosen et al. only proposed their binding mode through docking studies with PDB
1BL7 [46] whose ligand is SB220025 and does not share many constitutional similarities with
the Suberone compounds. In the end the Suberone X-ray crystal structure (278SLS) showed
that the ”flip” makes up about only 2A˚ in comparison to e.g. PDB 1W84.
The conformations of the ligands seemed not of that importance. The conformations which
were generated seemed to meet the requirements, which were needed for the dockings. Mea-
suring the dimensions of the Suberones revealed that active Suberones share certain angles
and such upstream calculations and considerations might help to meet a preselection before
the actual synthesis. That the calculated conformations of the Suberones completely agreed
with the confromation in the protein is not clearly secured, but can be assumed.
The GRID calculations strongly supported that the carbonyl oxygen binds to the hinge region.
The position of the -NH2 however was still unsure. It supported both binding poses by showing
that any -NH or -NH2 groups are favoured in hydrophobic pocket I and hydrophobic region
II. The results also depended on the conformation of the used PDB structure. In the end
GRID slightly favoured the hydrophobic pocket I, but did not hint to the later in the docking
studies observed H-bonds to Ala51 and Leu104.
The docking results strongly depended first on the algorithm of the used docking programme
and secondly on the PDB structure. The FlexX results were not as good as the others again.
More unlikely poses had to be sorted out. If just FlexX had been used, the proposed binding
mode would have been that according to Ottosen et al., because all dockings to the DFG-IN
conformations led to that conclusion. Only the docking to PDB 1OZ1 did not favour the one
or the other binding mode, while completely failing in proposing any suitable binding modes
in PDB 1W84 or PDB 2FSO. FlexX also had huge problems with ligands of smaller molecular
weight. It is again not considered to be applicable for docking studies with the p38α MAP
kinase. Flexidock could not be used, because of its inability to dock large databases and its
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complicated preparations. Docking has to be automatable to deliver good results in a short
period of time.
GLIDE was superior to FlexX and Flexidock and proposed many likely poses. It clearly favoured
the binding mode according to Revesz et al., apart from the docking to PDB 1OZ1. It also
had problems with PDB 1W84, implicating that the use of 1W84 for Suberone docking is not
recommendable, although PDB 1W84 is of good quality. eHITS, a not well known often used
programme with not so many possibilities to change any settings, yielded acceptable results.
It also favoured the binding mode according to Revesz et al. and even found the right docking
poses in PDB 1W84. Although the results were not preferring one of the two binding modes.
eHITS had problems with the dockings to the DFG-OUT conformations in PDB 1W82 and
PDB 1WBS. FlexX showed that the Suberone may bind to the DFG-OUT conformation as
well, but considering its other results, this could have been mistrusted, if GLIDE had not
supported it as well. This possibility was not supported by the X-ray crystallization studies.
However, [1] made clear that this can only be proofed by NMR studies.
More studies with JNK3 models were neglected to focus on the DFG-OUT conformation.
These might be a task for further studies.
Unfortunately some difficulties emerged, considering any activity predictions or explanations
for activity or inactivity. Any rankings of the dockings could not mirror the ranking according
to IC50 values. A variation of the docking parameters or the use of newer programmes which
consider flexibility of the residues may improve those results in further studies. The loss of
activity in the isomeres of the 3-amino-6,11-dihydro-dibenzo[b,e]oxepin-11-ones could not be
explained by the molecular modeling studies.
Thus water was not present in the docking studies, the observed water mediated H-bond could
not be foreseen. The docking studies often proposed H-bonds to Ala51 or Leu104, what could
not be observed in 278SLS.
Although now a X-ray crystal structure is available, the first docking studies showed that it
will not make the modeling much easier. The particular position of the Gly-rich loop influences
the docking results. More dockings should include PDB 2I0H and PDB 2QD9 as well to sort
out any results which were too much influenced by the Gly-rich loop.
In conclusion the following propositions can be given (see figure 6.2 on the next page) based
on the molecular modeling studies.
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Figure 6.2.: Possible modificatons of the Suberones proposed by the modeling studies
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Any variations in the aromatic rings (displayed by the letter Z) may be possible to improve
e.g. water solubility by introducing a nitrogen. Subsitituents on R3 should be rigid and
follow the other proposals made up by Revesz et al., as are subsituents at the R2 position.
Those substituents would point out of the ATP binding pocket and could have effects on drug
properties (such as bioavailability). Substituents on R1 if even should be rather small, so that
they would not collide with the hinge region. The same applies for substitutents at the R4
position. There, small substituents such as -NH2 may also be acceptable, maybe would form
an additional H-bond to Thr106. Furthermore it would improve selectivity, because Thr106 is
not always present there in other kinase structures (e.g. JNK3). The modeling studies showed
that the exchange of the amine liker with an oxygen may also head to good ligands.
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7.1. PDB structures
All PDB structures of p38α MAP kinase and JNK3 were downloaded from http://www.
rcsb.org. The website contains all published PDB structures since its opening in 1971
at Brookhaven National Laboratory. It is the depository of information about the three-
dimensional structures of large biological molecules, including proteins and nucleic acids. These
are the molecules of life that are found in all organisms including bacteria, yeast, plants, flies,
and mice, and in healthy as well as diseased humans [47].
7.2. Quality Check
The tools which were used for checking the quality of the PDB structures are described below.
7.2.1. WHAT IF
The WHAT IF programme [86], [87] can help the user to rapidly check the crystallographic
data. A generated document contains a report of findings during the analysis of the given
protein. Each reported fact has an assigned severity. Error terms requires immediate attention,
while warnings describe less severe problems or uncommon structural features, but still need
special attention. A note gives statistical values, plots, or other verbose results of tests and
analysis that have been performed. To indicate the normality of a values is expressed as a
Z-value or Z-score. This is the number of standard deviations that the score deviates from
the expected value. If a Z-score is used in WHAT IF, the accompanying text explains how
the expected value and standard deviation were obtained. The first feature that is checked, is
”Nomenclature”e. g. (Chain names), followed by ”Weight”or if there any missing atoms. Next
is ”Symmetry related problems”, such as rounded coordinates detected, crystallographic sym-
metry between molecules, extra crystallographic symmetry between the independent molecules
or the Matthews coefficient. The Matthews coefficient is defined as the density of the protein
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structure in cubic Angstroms per Dalton. Normal values are between 1,5 (tightly packed, little
room for solvent) and 4,0 (loosely packed, much space for solvent). The ”Geometry” check
contains chirality (values around -35 or +35 are expected for chiral atoms, around 0 for planar
atoms), bond lengths, bond angles, torsion angles (values for protein residues were taken from
Engh and Huber [88]), Ramachandran score and Ramachandran plot, omega check and χ-
1/χ-2 score. The cell scaling check finds significant systematic deviation. A reason might be
that the unit cell used in the refinement can be different from the best cell calculated. Or the
value of λ used for a synchrotron data set can be miscalibrated. Finally, the discrepancy can
be caused by a dataset that has not been corrected for significant anisotropic thermal motion.
”Rings and Planarity” checks include side-chain planarity and proline puckering (method of
Cremer and Pople [89]). The ”Structure” checks include inside/outside profile, bumps (if the
atoms are closer than the sum of their van der Waals radii minus 0,40 A˚), packing quality,
backbone (comparison with structures in the WHAT IF database show if they have alterna-
tive positions for the backbone) and peptide plane flip. The side chain or ”rotamer check” is
based on the 3D backbone database in WHAT IF. The position of the water molecules is also
checked. During the B-factors check low B-factors, an average B-factors and the distribution
are checked. The B-factor or atomic displacement parameter shows the fluctuation of an atom
around its average position. The distribution of B-factors of a protein is an important indicator
for flexibility and dynamic. An high B-factor indicates great mobility of side chains or single
atoms. Therefore B-factors give reliable information about the dynamic of a protein [90]. The
final report includes the following contents:
• Atom coordinate problems and/or unexpected atoms
– Rounded coordinates
• Symmetry related problems
– Crystallographic symmetry between molecules
– Matthews coefficient
• Nomenclature related problems
– Nomenclature
– Torsion convention problems
– Heavy atom naming
– Chirality deviations
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– Dihedral angle distribution
– Chain names
– Atomic occupancy factors
– Missing atoms
– Extra C-terminal groups
– Bond lengths
– Bond length variability
– Cell scaling
– Bond angles
– Bond angle variability
– Side chain planarity
– Atoms connected to aromatic rings
– Unusual PRO puckering amplitudes
– PRO puckering phases
– Unusual residues detected by torsion angle evaluation
– Unusual conformations detected by backbone torsion angle evaluation
– Ramachandran Z-score
– Omega angle restraint
– Chi-1/chi-2 angle correlation Z-score
– Ramachandran plot
• Accessibility related checks
– Inside/Outside residue distribution
– Inside/Outside RMS Z-score plot
• Secondary structure
– Secondary structure
• Bump checks
– All atoms away from symmetry axes
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– Interatomic distances
– Second generation packing environment
– Residues with abnormal new packing environment
– Structural average packing Z-score
• 3D-database related check
– Backbone oxygen evaluation
– Rotamers
– Backbone conformations
– Backbone conformation Z-score
• Water related checks
– Water contacts
– Waters which need moving
– Water molecules without hydrogen bonds
• B-factor analysis
– Average B-factor
– Number of buried atoms with low B-factor
– B-factor distribution
– B-factor plot
• Hydrogen bond related checks
– Side chain flips
– Histidine type assignments
– Buried unsatisfied hydrogen bond donors
– Buried hydrogen bond acceptors OK
• Final summary
– Summary report for users of a structure
– Summary report for depositors of a structure
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7.2.2. ProSA
ProSA [91, 92] is a webinterface for structure research. It is helpful for experimental structure
determinations and modeling studies. It helps the user to decide if the overall structure is
correct and to identify faulty parts (https://prosa.services.came.sbg.ac.at/prosa.php).
7.2.3. PDBSUM and PROCHECK
PDBsum [73] provides an at-a-glance overview of the of every macromolecular structure
deposited in the Protein Data Bank (PDB), giving schematic diagrams of the molecules
in each structure and of the interactions between them ( http://www.ebi.ac.uk/thornton-
srv/databases/pdbsum) PDBsum is linked to PROCHECK [93]. PROCHECK generates an
overview of the stereochemical quality of PDB structures, including the following reports :
1. Main Ramachandran plot
2. All-residue Ramachandran plots
3. All-residue chi1-chi2 plots
4. Main-chain parameters
5. Side-chain parameters
6. Residue properties plot
7. Main-chain bond lengths
8. Main-chain bond angles
9. RMS distances from planarity
10. Distorted geometry
A simple output offered by PDBsum generates firstly the Ramachandran Plot statistics, where
a good model would be expected to have over 90% the most favoured regions (based on an
analysis of 118 structures of resolution of at least 2,0 A˚ and R-factor no greater than 20,0)
and secondly the overall G-factors. Any G-factors below -1,0 may indicate properties that are
highy unusual. The main-chain bond-lengths and bond angles are compared with [88] ideal
values derived from small-molecule data. The Ramachandran Plot statistics and the overall
average G-factor taken from PDBsum are displayed in table 5.7.
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7.3. Modeling
7.3.1. SYBYL7.2
The modeling programme SYBYL7.2 [94] was used to inspect all the PDB files of the p38α
MAP kinase and JNK3. It visualizes the atom coordinates of the PDB files to create a three-
dimensional picture of a protein structure. The tool ”Align by Homology” in the ”Biopolymer”
option facilitates the identification of the conformational differences. One picked PDB struc-
ture stays fixed, while the other chosen structures are aligned to the fixed PDB structure.
These alignments can be carried out on the C-α atoms, the backbone atoms (N–α-C–O), the
side chains atoms or all atoms. A list of the calculated RMSD values is listed on the prompt.
7.3.1.1. Databases
SYBYL7.2 was used create to the databases used for the docking studies. The ligands of
the PDB structures where taken out from the PDB files and stored unvaried in a SYBYL
database file. All Suberone compounds where build by the Build/Edit panel of SYBYL. An
energy minimum was calculated by using the minimizing protocol for small molecule ligands
in figure 7.1.
Figure 7.1.: SYBYL minimization protocol
MMFF94s is the best force field for small molecules which is available in SYBYL7.2. The ”s”
MMFFF94s stands for the ”static” variant of the original force field MMFF94. The out-of-
plane and torsional parameters were modified to provide nearly planar structures for amide and
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unsaturated amine trigonal nitrogens. Terms in the MMFF94 energy equation:
• EMMFF94 =
∑
Estretch +
∑
Ebend +
∑
Estretch bend +
∑
EOOP +
∑
Etorsions +∑
EV DW +
∑
Eelect
The method is Conjugate gradient which is a good choice for small molecules. No Simplex
optimization was used. The Termination Citeria was set to 0,05 for complete minimization.
Max Iterations is set to determine the number of cycles before the minimizations stops. 10000
was used to reach the desired complete minimization. [94] The molecules of the database
were saved and exported as Mol2, SDF, MDB, HMTL and excel file formats for later usage.
7.3.2. GRID
GRID [95] is a computational procedure for determining energetically favourable interactions
between probes with various functional group characteristics and a protein surface (target).
The GRID method was first described by [96]. The package GRID2.2 involves the six pro-
grammes GREATER, GREAT, GRIN, GRID, GVIEW and GLUE. GREATER is a Graphical User
Interface (GUI) for the GRID package (figure 7.2).
Figure 7.2.: GREATER interface
So the user can access the programmes GRIN, GRID, GREATER and GVIEW. The primary
input for GRIN is the coordinates of the atoms in the target molecule. The secondary input for
GRIN is a set of ”energy variables” which are contained in the GRUB file. Therefore the main
function of GRIN is to check the PDB and GRUB files, and merge them so that appropriate
energy variables are specified for each atom in the target. The GRIN output file GRINKOUT
(GRIN Koordinate OUTput) is a list of target atoms in the correct sequence with their x, y, z
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coordinates and the energy variables. It is the input file for GRID. GRID determines where the
chosen probes would interact favourably with a protein. Table 7.1 displays the chosen GRID
probes, including a short description about the functional groups they represent.
Symbol Description
single atom
OH2 Water
DRY The hydrophobic Probe
H Neutral hydrogen atom
C3 Methyl CH3 group
C1= sp2 CH aromatic or vinyl
N2: sp3 NH2 with Ione pair
N2 Neutral flat NH2 eg amide
N1: sp3 NH with Ione pair
N: sp3 N with Ione pair
O sp2 carbonyl oxygen
O:: sp2 carboxy oxygen atom
OH Phenol or carboxy OH
OC= Ether oxygen
PO4 phosphate dianion
PO4H phosphate anion
STH Thiophen or thioether S
F Organic fluorine atom
MG+2 Magnesium cation
multi atom
AR.COO- Aromatic carboxylate
AR.CONH2 Aromatic amide
Table 7.1.: Chosen probes for the GRID calculations
GRID produces two output files called GRIDLONT and GRIDKONT. The last programme
of the package is GVIEW which visualizes the structure of the target and the results of the
GRID computation simultaneously. The user can check the calculated Molecular Interaction
Fields (MIF) and the GRID energy contributions due to atoms of the target. The calculations
were mostly carried out with default parameters. During the import of the PDB structures
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to GRIN the filtering level was set on semi-automatic. The GRIN warnings were ignored and
just accepted, because the errors occurred at atoms outside of the important regions of the
box size of the GRID calculation ran over the whole structure, but it the end only the MIF of
the ATP binding pocket or the DFG-OUT regions were checked. Before starting the run, the
values of the method keywords were varied as follows:
• LEAU determines the way in which water is treated during the computation. Default=
0. LEAU=1 GRID will find and take account of sites for bridging waters.
• MOVE directive controls the flexibility of the target. Default= 0. MOVE=1 as above
but flexible side chains are allowed to move.
• ALMD directive controls the printing in the GRIDKONT output file. Default= 0.0
The programme adds to the values of energy of interaction an extra column with the
sequential number of the atom interacting more strongly with the probe. When set to
-2 an extra record will be prefixed to the start of the GRIDKONT file and it is written
in a computer readable binary code [95].
Figure 7.3 gives an overview of the general GRID workflow.
Figure 7.3.: GRID workflow
All PDB structures with the obtained MIF were checked visually with GVIEW.
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7.4. Docking
7.4.1. FlexiDock
Flexidock is a docking programme of the SYBYL7.2 modeling package. It’s genetic algorithm-
based flexible docking provides a means of docking ligands into the active sites. FlexiDock
works in torsional space, keeping bond lengths and angles constant. As large van der Waals
interactions can only relax via bond rotations, optimization cannot alter chirality and bond
chemistry. FlexiDock works on a protein-ligand pair. The protein backbone atoms are fixed in
space, but the ligand is mobile. Both the protein side chains and the ligand contain a number
of flexible bonds. FlexiDock considers only non-ring single and amid bonds as rotable. But the
parameters can be modified. FlexiDock incorporates van der Waals, electrostatic, torsional and
constraint energy terms of the Tripos Force Field. With FlexiDock it is possible to determine
important atoms and fragments. Genetic algorithms are used by FlexiDock to determine the
optimal ligand geometry. Genetic algorithms are robust global optimizers, with performance
requirements which scale well with increasing system size. Its principle is to generate a initial
population of ligand conformations and interactions. The ”Chromosomes” contain sequences
of data describing the receptor-ligand interaction’s degree of freedom as ”genes”. After an
optimization all ligand poses are scored. Subsequent to the scoring follows the selection of
the preferentially good poses for creating the next generation. There the evolution is carried
out via genetic operators. During mutation the values of individual genes are changed, during
crossover a set of genes is exchanged between the chromosomes. Individual genes are moved
to another subpopulation during migration. In the end the fitness function uses a subset of the
Tripos Force Field and calculates the energy of the important atoms. Partial scoring is used, as
the fitness function improves when complementary site-points are near each other. When each
chromosome is scored, each site-point is checked against the set of complementary sites. If
the components of the pair are within the site-points radius, the full site score is added to the
fitness score (see figure 7.4 on the next page). Before docking a ligand into the protein with
FlexiDock, the complex needs charges. In this case the charges are computed with MMFF94s
for the small molecule inhibitor and with AmberForceField02 (AmberFF02) for the receptor.
In addition, the water molecules have to be removed before using the protein. The FlexiDock
input file defines the pocket. The pocket consists of the residues Val30, Ala51, Lys53, Glu71,
Leu75, Ile84, Leu86, Leu104, Thr106, Leu108, Met109, Gly110, Ala111, Asp112, Ser154,
Ala157, Leu167, Asp168 and Phe169. In the next step the structures are set up. After adding
the H atoms to the protein structure, the rotable bonds can be defined. For the receptor
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the flexible bonds are the side chains of Lys53, Glu71, Thr106, Met109 and Asp168. Now
FlexiDock creates an output-file with 20 solutions. The FlexiDock file contains the ligand and
the active site. [94]
Initial 
Population
Evaluate 
Fitness
Generation 
Limit
New
Population
Reproduce
Select for 
Reproduction
Report 
Fittest
Individuals
Answers
N
Y
Figure 7.4.: FlexiDock workflow
7.4.2. FlexX
FlexX flexible docking method uses incremental construction algorithmen to place ligands
into active sites. The automatically selected base fragment of the ligand is placed into the
active site using an algorithmic approach based on a pattern recognition technique called pose
clustering. Then the remainder of the ligand is built up incrementally from other fragments.
The new fragment is added in all possible conformations to all placements. But only the best
conformations are taken on to the next construction step. When adding a new fragment, FlexX
searches for matching interactions groups. Distance tolerances of 2A˚ and angle tolerances of
20 are used to make sure that no possible interactions are missed. The conformational
flexibility of the ligand is included by creating general conformations for each fragment and
including all in the ligand building step. Placement of the ligand is scored on the basis of
protein-ligand interactions (pairwise assignment of interaction geometries). Finally the binding
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energy is estimated and the placements are ranked [97]. Figure 7.5 shows the constitution of
the FlexX docking algorithm.
Figure 7.5.: FlexX docking algorithm (lecture slide by O.Kohlbacher)
In the so-called receptor description file (RDF) the docking site and the position of the ligand
will be defined. It contains the ionization states (Templates) of the charged amino acids and
the torsional angles of the amino acids, which affect the H-bonds in the active site. The
original pdb structure of the p38 MAP kinase is used to create the active site file. The defined
active site file contains the residues Val30, Ala51, Lys53, Glu71, Leu75, Ile84, Leu86, Leu104,
Thr106, Leu108, Met109, Gly110, Ala111, Asp112, Ser154, Ala157, Leu167 and Asp168.
The selection radius around the position of the ligand is 5.2A˚. For customizing the RDF, the
Templates are defined as follows. Asp 112, Asp168 and Glu71 have a negative charge, while
Lys53 is positive charged. For the residues Asp112, Asp168, Glu71, Lys53, Ser154 and Thr106
the standard torsions are used. For the ligand and the reference structure the prepared ligand
is used. Thus, ligands of PDB structures are often faulty, the atom types and the bonds
have to be manually checked, concluding with the addition of the hydrogens. The chosen
FlexX option is the serial CScore Calculation, where the relaxed and unrelaxed structures are
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calculated. This means that the ligand-protein-complex is minimized and then scored again.
The output file contains the 50 best scored conformations according to FlexX.
7.4.3. GLIDE
GLIDE (Grid-based Ligand Docking with Energetics) is a docking programme of Schro¨dinger
[98, 99]. GLIDE searches for favourable interactions between a small ligand molecule and a
protein by using a hierarchical series of filters to search for possible locations of the ligand in
the active-site region of the receptor. The shape and properties of the receptor are represented
on a grid by several different sets of fields that provide progressively more accurate scoring of
the ligand. The combination of position and orientation of a ligand relative to the receptor,
along with its conformation in flexible docking, is referred to as a ligand pose. Each ligand
must be a single molecule, while the receptor may include more than one molecule, e.g., a
protein and a co-factor. In this study GLIDE runs in the flexible docking mode, allowing
different conformations for the ligand. At first each ligand is divided into a core region and
a number of rotamer groups. Each rotamer group is attached to the core by a rotatable
bond, but does not contain additional rotatable bonds. The core is what remains when each
terminus of the ligand is severed at the ”last”rotatable bond. Carbon and nitrogen end groups
terminated with hydrogen (-CH3, -NH2, -NH
+
3 ) are not considered rotatable because their
conformational variation is of little significance. For each core conformation an exhaustive
search of possible locations and orientations is performed over the active site. The search
begins with the selection of ”site points” on an equally spaced 2A˚ grid that permeates the
active-site region. To make this selection, pre-computed distances from the site point to the
receptor surface, evaluated at a series of pre-specified directions and binned in 1A˚ ranges, are
compared to binned distances from the ligand center to the ligand surface. GLIDE positions
the ligand center at the site point if there is a good enough match, but skips over the site
point if there is not. The second part of the hierarchy begins by examining the placement of
atoms that lie within a specified distance of the line drawn between the most widely separated
atoms (the ligand diameter). This is done for a pre-specified selection of possible orientations
of the ligand diameter. If there are too many steric clashes with the receptor, the orientation
is skipped. Next, rotation about the ligand diameter is considered, and the interactions of a
subset consisting of all atoms capable of making hydrogen bonds or ligand-metal interactions
with the receptor are scored (subset test). If this score is good enough, all interactions with
the receptor are scored. The scoring in these three tests is carried out using Schro¨dinger’s own
version of ChemScore, an empirical scoring function [100]. ChemScore recognizes favorable
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hydrophobic, hydrogen-bonding, and metal-ligation interactions, and penalizes steric clashes
(greedy scoring). After that the poses are re-scored according to the top greedy-scoring via a
”refinement”procedure, in which the ligand as a whole is allowed to move rigidly by 1 A˚ in the
Cartesian directions. The best refined poses are passed on to the third stage in the hierarchy-
energy minimization. The energy minimization typically begins on a set of van der Waals and
electrostatic grids that have been ”smoothed”to reduce the large energy and gradient terms that
result from too-close inter-atomic contacts. It finishes on the full-scale OPLS-AA nonbonded
energy surface (”annealing”) which consists only of rigid-body translations and rotations when
external conformations are docked. When conformations are generated internally, however, the
optimization also includes torsional motion about the core and end-group rotatable bonds. In
the end a small number of the top-ranked poses are then subjected to a Monte-Carlo procedure
in which alternative localminima-vcore and rotamer-group torsion angles are examined to try
to improve the energy score. Finally, the minimized poses are re-scored using the GLIDEScore
scoring function. GLIDEScore is based on ChemScore, but includes another steric-clash term
and adds buried polar terms to penalize electrostatic mismatches. The best-docked structure
for each ligand is made using a model energy score (Emodel) that combines the energy grid
score, the binding affinity predicted by GLIDEScore, and the internal strain energy for the
model potential used to direct the conformational-search algorithm. GLIDE can also compute
a specially constructed Coulomb-van der Waals interaction-energy score that is formulated to
avoid overly rewarding charge-charge interactions at the expense of charge-dipole and dipole-
dipole interactions. The user can combine the computed GLIDEScore and ”modified”Coulomb-
van der Waals score values to give a composite score that usually helps improve enrichment
factors in database screening applications. Figure 7.6 on the next page gives an overview of
the GLIDE docking hierarchy. A GLIDE constraint is a ligand-receptor interaction requirement.
To use GLIDE constraints, the receptor sites for possible ligand interactions must be specify
when you set up a receptor grid generation job. To run a ligand docking job, the user has to
select GLIDE constraints to apply from the list of receptor constraint sites that were defined
for the receptor. In GLIDE constraint docking jobs, GLIDE incorporates satisfaction of these
constraints into several of its hierarchical filters, allowing prompt rejection of docked poses that
fail to meet the requirements. The XP (extra-precision) mode of GLIDE is a refinement tool
designed for use only on good ligand poses. The standard-precision (SP) mode is recommend
for the first screening of large databases. Only the top-scored ligands should be docked using
XP mode. The XP mode of GLIDE is able to identify ligand poses that would be expected to
have unfavorable energies. The presumption is that only active compounds will have available
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poses that avoid these penalties while at the same time securing a favorable scoring from the
terms in the scoring function that reward e.g. hydrophobic contact between the protein and
the ligand, appropriate hydrogen-bonding interactions. The chief purposes of the XP method
are to weed out false positives and to provide a better correlation between good poses and
good scores. Both modes were tested during this study.
Figure 7.6.: The GLIDE docking hierarchy
All following panels were carried out in Maestro, the unified interface for all Schro¨dinger
software. Before starting to generate the receptor grids for ligand docking, the protein has to
be prepared. After deleting the water molecules and the identification of the ligand the protein
preparation panel is started.
• Automatic protein preparation is divided into two steps:
– preparation adds hydrogens and neutralizes side chains that are not close to the
binding cavity and do not participate in salt bridges.
– refinement component performs a restrained impact minimization of the co-crystallized
complex, which re-orientates side chain hydroxyl groups and alleviates potential
steric clashes
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For the PDB 2FSO and PDB 2PKJ, which do not contain a small molecule ligand, the identi-
fication of a ligand was enabled through a little indirection. Both PDB structures were loaded
in SYBYL and aligned by homology to PDB 2EWA. The ligand of PDB 2EWA was merged
into the files of PDB 2FSO and PDB 2PKJ, and saved for the the further usage with GLIDE.
This was necessary, because a ligand is required for the later described Receptor Grid Gener-
ation. The preparation panel was carried out by default. Just the button of ”Neutralization
zone around the ligand”was unchecked. The ligands prepared in SYBYL were imported to the
workspace and all the hydrogens were added. The structures were stored in a maestro file.
Another ligand database was generated by using the LigPrep tool. LigPrep process consists
of a series of steps that perform conversions, apply corrections to the structures, generate
variations on the structures, eliminate unwanted structures, and optimize the structures. The
settings were used by default, apart from ”stereoisomers: generate all combinations”and ”ion-
ization: generate possible states at target pH 7,4 (0,5)” The last step before the actual
docking is the Receptor Grid Generation. The Receptor Grid Generation panel has three tabs,
which specify the settings for the receptor grid generation job:
• Receptor, where the user picks the ligand molecule, which excludes the ligand from
receptor grid generation.
• Site, where an enclosing box is generated around the picked ligand to ensure that the
database ligands will be confined to the enclosing box.
• Constraints enable Glide to screen out ligands, conformations, or poses that do not meet
these criteria early on in their evaluation for docking suitability.
For each PDB structure a file with and a file without contraints were generated. The chosen
contraints were:
• Positional
– Atoms of the ligand which form H-bonds to the hinge region (e.g. 1W84: N-pyridin)
• H-bond
– The atoms of a residue with forms H-bonds to the ligand (e.g. 1W84: bb NH of
Met109-N pyridin)
• Hydrophobic
– Identification of hydrophobic cells (e.g. 1W84: 14 hydrophobic cells situated in the
hydrophobic region I)
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To use Glide constraints they have to be applied during the docking setup. All other options
were used by default. The actual docking the Ligand Docking panel has five tabs:
• Settings: the user has to chose the Receptor Grid base name (the generated file of the
Receptor Grid Generation)and the docking precison (SP or XP). All ligands were docked
flexibly in the receptor grid.
• Ligands: here the source of the ligands is specified and some other parameters which
were used by default.
• Constraints: the contraints are activated here; just the hydrophobic contraints were used
in the end.
• Similarity: was used by default.
• Output: the user defines the structure of the output; in this study a pose viewer file was
generated to check both ligand and receptor and for each ligand at most 50 poses per
ligand were written out in the output file. Other options were used by default.
The results were visualized with the help of the pose viewer in maestro.[101] Any lengths of
H-bonds or contacts was used by default. All used Schro¨dinger programmes (Maestro, GLIDE,
LigPrep) were from the Schro¨dinger7.0 version.
7.4.4. eHITS
eHITS by SimBioSys [102, 103] uses a systematic docking algorithm. The ligand is divided
into fragments and flexible chains. The fragments are docked independently in the receptor
side. The poses of the fragments are found by a fast graph match algorithm. eHITS keeps a
number of pre-defined poses and reconnects them with the flexible chains. To obtain the final
ligand pose, the programme executes an optimization by using a local energy minimization
algorithm. In the end the poses are scored to obtain the final ranking. eHITS’ visualizer is
called CheVi (Chemical visualizer). After loading the docking the user can decide if he want
to keep the water during the docking. If the PDB file contains a ligand the programme needs
to know that as well (highlighting complex). The parameters were all used in default. Just the
accuracy was varied during the Re-docking and Cross-docking approaches, identifying standard
as the most useful one in comparison to accurate and fast. The receptor can be displayed in
a surface option which can be colored due to the 25 surface points types (figure 7.7).
The ligand can be displayed in stick representation with or without ligand. The interactions
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Figure 7.7.: eHITS surface points
between the ligand and the protein are saved in a separate interaction file which contains e.g.
the scores, distances and type of interaction. These interactions can be labeled with numbers
and are visualized by coloured hyphens.
7.4.5. Pictures
All pictures of results of FlexX, GLIDE and eHITS were obtained with ”The Gimp”(http://gimp.org)
and later treated with ”Paint.net”(http://getpaint.net). Any 2-D structures of the compounds
were created with ”IsisDraw(2.4)”and the rest of the 3-D protein structures were made up with
”PyMOL” (http://pymol.sourceforge.net).
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A. Databases
A.1. Ligands for docking
This chapter includes the used ligands for the Docking evaluation.
No. Structure Name PDB MW EN (kcal/mol) IC 50 nM
1.
N
H
N
H
N
O OH
N
H
O Cl
N
AIZ501 2B1P 491.9720 60.8832 903
2.
N S
N
H
OO
N
N
COM2000 2O0U 472.6048 141.8275 4.8 1
3.
N
OH N
F FPH 1OZ1 305.3074 93.3378 1
4.
NH
N
L12 1W84 222.2864 22.5271 n. t.
5.
N
N
N
N
O
FF
NH
F
LIE301 2GTN 399.3710 71.9225 n. t.
1(pIC50corresponds to -log IC50, higher values indicate exponentially greater potency)
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6.
O
O
OH
OH
N
N
F
NH2
PQB1 2GFS 371.3641 32.9947 200
7.
N
N OO
N
N
Cl
O
Cl
F
Q222-400 2I0H 537.3720 121.1298 9
8.
Cl
Cl
N
N
N
H
N
N N
H
Q880-501 1PMQ 513.508 173.0708 4
9.
Cl
Cl
N
N
N
N
N N
H
Q984-501 1PMN 485.4546 352.9408 0.2
Table A.1.: Ligands for docking evaluation
186
A.2. COMPOUNDS FOR DOCKING: SUBERONES, REVESZ AND OTTOSEN
COMPOUNDS
A.2. Compounds for docking: Suberones, Revesz and
Ottosen compounds
A.2.1. Suberone scaffold type GA
No. Structure Name MW EN (kcal/mol) IC 50µM
1.
O
O
N
H
NH2
GA1min 316.3551 99.808 3.06 2
2.
O
O
N
H
NH2
F
GA2min 319.3308 87.010 -
3.
O
O
N
H
NH2
GA3min 316.3551 81.046  5 3
4.
O
O
N
H
NH2
GA4min 366.4141 108.700 -
5.
O
O
N
H
NH2
GA5min 366.4141 110.669 -
2SB203580 0.064
3SB203580 0.064
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6.
O
N
N
O
N
H
NH2
GA6min 368.3901 144.582 -
7.
O
N
N
O
N
H
NH2
GA7min 368.3901 140.649 -
8.
O
O
N
H
NH2
N
GA8min 367.4021 111.865 -
9.
O
O
N
H
NH2
N
GA9min 367.4021 113.312 -
10.
O
N
O
N
H
NH2
GA10min 367.4021 110.452 -
11.
O
O
N
H
NH2
N
GA11min 367.4021 110.036 -
188
A.2. COMPOUNDS FOR DOCKING: SUBERONES, REVESZ AND OTTOSEN
COMPOUNDS
12.
O
O
N
H
NH2
N
GA12min 367.4021 109.950 -
13.
O
N
O
N
H
NH2
GA13min 367.4021 107.960 -
14.
O
O
N
H
NH2
N
N
GA14min 368.3901 115.378 -
15.
O
O
N
H
NH2
GA15min 368.3901 118.621 -
16.
O
O
N
H
NH2
F
N
N
N
N
GA16min 384.3927 123.728 - 4
17.
O
O
N
H
NH2
F NH
OH
OH
GA17min 405.4486 149.507 -
Table A.2.: Suberone scaffold type GA
4Di-fluoro: 3 SB203580 0.064
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A.2.2. Suberone scaffold type JH
No. Structure Name MW EN (kcal/mol) IC 50µM
1.
O
O
N
H
NH2 JH30min 316.3551 100.784 1.430  0.676 5
2.
O
O
N
H
NH2
F
JH31min 334.345 95.963 0.038  0.016 6
3.
S
O
N
H
NH2 JH46min 332.4211 97.637 1.2  0.315 7
4.
O
O
N
HNH2 JH126min 316.3551 85.660 7.47  0.160 8
Table A.3.: Suberone scaffold type JH
A.2.3. Suberone scaffold type MORE
No. Structure Name MW EN (kcal/mol) IC 50
1.
N
O
O
N
HNH2
MO1min 317.3430 113.598 -
5SB203580 0.4276; n=3
6SB203580 0.0631; n=3
7SB203580 0.4171; n=3
8SB203580 0.4168; n=2
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2.
N
O
O
N
HNH2
MO2min 317.3400 133.101 -
3.
N
O
N
H
O
NH2
MO3min 317.3430 103.053 -
4.
N
O
N
H
O
NH2
MO4min 317.3430 85.990 -
5.
N
O
O
N
H
F
NH2 MO5min 349.3602 149.028 -
6.
N
O
O
N
H
NH2
F
MO6min 349.3602 129.448 -
7.
N
O
O
N
H
NH2
F
MO7min 385.3925 139.185 -
8.
N
O
O
N
H
NH2
F
MO8min 385.3925 121.838 -
191
APPENDIX A. DATABASES
9.
N
O
O
NH
NH2
F MO9min 411.4300 179.010 -
10.
N
O
O
NH
NH2
F MO10min 411.4300 159.793 -
11.
N
O
O
N
H
NH2
NH2 MO11min 332.3577 114.795 -
12.
N
O
O
N
H
NH2
NH2 MO12min 332.3577 96.674 -
13.
O
O
NH2
N
H
MO13min 316.3551 99.433 -
14.
O
O
NH2
N
H
MO14min 316.3551 100.790 -
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15.
O
O
NH
F
NH2
MO15min 410.442 124.550 -
16.
O
O
NH
F
NH2
MO16min 410.442 123.790 -
17.
O
O
N
H
NH2
NH2 MO17min 331.3697 105.168 -
18.
O
O
N
H
NH2
NH2 MO18min 331.3697 105.401 -
19.
O
O
N
H
NH2
NH2 MO19min 381.4287 115.174 -
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20.
O
O
N
H
NH2
NH2 MO20min 381.4287 114.382 -
21.
O
O
NH
NH2
MO21min 442.5105 139.424 -
22.
O
O
NH
NH2
MO22min 442.5105 137.698 -
23.
O
O
NH
F
NH2
MO23min 348.3722 99.866 -
24.
O
O
NH
F
NH2
MO24min 348.3722 98.643 -
25.
O
O
N
H
NH2
F
O
MO25min 364.3710 98.305 -
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26.
O
O
N
H
NH2
F
O
MO26min 364.3710 97.048 -
27.
O
O
N
H
NH2
F
O
MO27min 364.3716 95.876 -
28.
O
O
N
H
NH2
F
O
MO28min 364.3716 93.711 -
29.
O
O
N
NH
F
MO29min 362.3989 116.061 -
30.
O
O
N
NH
F
MO30min 362.3989 110.064 -
31.
O
O
N
H
NH
F
MO31min 348.3722 102.033 -
32.
O
O
N
H
NH
F
MO32min 348.3722 97.201 -
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33.
O
O
N
NH2
F
MO33min 348.3722 108.972 -
34.
O
O
N
NH2
F
MO34min 348.3722 107.918 -
35.
O
O
N
H
NH2
F
MO35min 348.3722 102.158 -
36.
O
O
N
H
NH2
F
MO36min 348.3722 100.932 -
37.
O
O
N
H
NH2
F
Cl
MO37min 368.7908 108.817 -
38.
O
O
N
H
NH2
F
Cl
MO38min 368.7908 107.378 -
39.
O
O
N
H
N
F
MO39min 362.3989 107.358 -
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40.
O
O
N
H
N
F
MO40min 362.3989 106.452 -
Table A.4.: Suberone scaffold type MORE
A.2.4. Suberone scaffold type MORE2
No. Structure Name MW EN (kcal/mol) IC 50µM
1.
O
O
NH2 MORE1min 315.3671 118.501 -
2.
O
O
NH2
F
MORE2min 333.3575 114.152 -
3.
O
N
H
O MORE3min 329.3937 112.540 0.5 9
4.
O
N
H
O
F
MORE4min 347.3842 104.690 - 10
Table A.5.: Suberone scaffold type MORE2
9SB203580 0.015; with 3-amino subsituent 0.5; SB203580 0.064
10without 3-amino subsituent 0.592; SB203580 0.064
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A.2.5. Scaffold type OTTO
No. Structure Name MW EN (kcal/mol) IC 50nM
1.
O
N
H
NH2
Cl
OTTO1min 336.8168 92.262 10 3
2.
O
N
H
NH2 OTTO2min 316.3982 99.596 13 3
3.
O
O
N
H
Cl
NH2 OTTO3min 352.8160 94.007 5 2
4.
O
N
H
NH2
Cl
OTTO4min 336.8168 86.192 574 16
Table A.6.: Scaffold type OTTO
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A.2.6. Scaffold type REV
No. Structure Name MW EN (kcal/mol) IC 50nM
1.
Cl
O
N
H
F
F
REV1min 343.7563 81.762 11
2.
O
N
H
O
F
F
NH2 REV2min 420.4534 76.404 14
3.
O
N
H
O
F
F
N
OH
REV3min 478.5329 95.065 1
4.
O
N
H
Cl
F
F NH
N
REV4min 397.8072 67.146 0.7
5.
O
N
H
O
F
F NH
N
REV5min 393.3881 84.582 5
6.
N
O
N
H
Cl
F
F NH
N
REV6min 398.795 41.062 8
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7.
N N
N
H
F
F
N
NH
O
NH2
REV7min 434.4434 109.643 10
8.
N
N
N
H
F
F
N
NH
O
NH2
REV8min 434.4434 3.277 12
9.
O
N
H
O
F
F
NH2
REV9min 424.4852 100.780 113
10.
N
N
H
F
F
O
Cl
REV10min 344.7443 55.583 100
Table A.7.: Scaffold type REVESZ
A.2.7. Suberone scaffold type RN
No. Structure Name MW EN (kcal/mol) IC 50 µM
1.
O
N
H
NH2 RN13amin 314.3823 104.047 0.087 11
11SB203580 0.049; n=4
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2.
O
N
H
NH2 RN14amin 312.3664 132.157 1.06 12
3.
O
N
H
NH2 RN14min 328.4090 93.944 3.58 13
4.
O
N
H
NH2 RN15min 314.3823 100.326 31.9 14
Table A.8.: Suberone scaffold type RN
A.2.8. Suberone scaffold type SK
No. Structure Name MW EN (kcal/mol) IC 50
1.
N
O
O
NH2 SK1min 226.2319 87.045 -
2.
N
O
O
NH2 SK2min 226.2319 103.145 -
12SB203580 0.049; n=4
13SB203580 0.015; n=4
14SB203580 0.049; n=4
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3.
N
O
O
NH2 SK3min 226.2319 67.662 -
4.
N
O
O
NH2 SK4min 226.2319 60.587 -
5.
N
O
O
NH2 SK5min 226.2319 50.400 -
6.
N
O
O
NH2
SK6min 226.2319 64.784 -
7.
N
O
O
NH2
SK7min 226.2319 81.210 -
8.
N
O
O
NH2 SK8min 226.2319 54.035 -
9.
N
O
O
NH2
SK9min 226.2319 82.888 -
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10.
N
O
O
NH2
SK10min 226.2319 102.746 -
11.
N
O
O
NH2
SK11min 226.2319 63.556 -
12.
N
O
O
NH2
SK12min 226.2319 60.220 -
13.
N
O
O
NH2
SK13min 226.2319 46.291 -
14.
N
O
O
NH2
SK14min 226.2319 64.427 -
15.
N
O
O
NH2
SK15min 226.2319 77.091 -
16.
N
O
O
NH2
SK16min 226.2319 53.753 -
17.
O
N
O
NH2
SK17min 225.2240 125.337 -
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18.
O
N
O
NH2 SK18min 226.2319 108.229 -
19.
O
N
O
NH2 SK19min 226.2319 23.684 -
20.
O
N
O
NH2 SK20min 226.2319 26.219 -
21. ON
O
SK21min 211.2172 75.796 -
22.
O
N
O
SK22min 211.2172 59.118 -
23.
ON
O
NH2 SK23min 226.2319 17.159 -
24.
O
N
O
NH2 SK24min 226.2319 39.881 -
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25. O
N
O
NH2
SK25min 226.2319 61.871 -
26.
O
N
O
NH2
SK26min 226.2319 45.073 -
27. O
N
O
SK27min 211.2172 71.595 -
28.
O
N
O
SK28min 211.2172 76.375 -
29. ON
O
NH2
SK29min 226.2319 23.920 -
30.
O
N
O
NH2
SK30min 226.2319 8.839 -
31.
ON
O
NH2
SK31min 225.2240 82.363 -
32.
O
N
O
NH2
SK32min 226.2319 102.060 -
Table A.9.: Suberone scaffold type SK
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A.2.9. Suberone scaffold type SG
No. Structure Name MW EN (kcal/mol) IC 50µM
1.
ONH
O
NH2
NH2
GA425 331.3697 89.778 0.5 15
2.
ONH
O
NH2
NH2F
GA430 349.3602 84.954 0.5 16
3.
ONH
O
NH2
O
GA553 346.3812 98.304 n.t.
4.
N
O
O
N
H
O
SK288 332.3545 117.665 5
5.
N
O
O
N
H
NH2 SK316 317.343 109.166 1 17
6.
N
O
N
H
NH2 SK318 334.3206 121.536 1 18
15SB203580 0.064
16SB203580 0.064
17SB203580 0.058
18SB203580 0.035
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7.
N
O
O
N
H
F
F
SK345 338.3093 103.493 1
8.
N
O
O
N
H
NH2
F
SK362 335.3335 104.375 0.5
9.
N
O
N
H
NH2 SK383 315.3703 97.914 0.5 19
10.
N
O
N
H
NH2
SK436 313.3544 123.494 1 20
11.
N
O
N
H
F
F
SK468 336.3365 92.189 0.5 21
12.
N
O
N
H
NH2
F
SK508 333.3607 93.107 0.5 22
13.
O O
N
H
F
F
SK510 363.3588 96.193 - 23
19SB203580 0.033
20SB203580 0.033
21SB203580 0.046
22SB203580 0.046
2310% inhibition at 1µM; SB203580 0.059
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14.
O
N
H
F
F
SK539 335.3485 98.236 0.5 24
15.
O
N
H
F
NH2 SK541 332.3728 99.260 0.5 25
16.
O
O
N
H
F
F
SK558 365.3746 98.130 0.5 26
17.
O
O
N
H
F
NH2 SK568 362.3989 99.177 0.5 27
Table A.10.: Suberone scaffold type SG
24SB203580 0.059
25SB203580 0.046
26SB203580 0.059
27SB203580 0.024
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A.2.10. Suberone scaffold type GA
Compound a in A˚ b in A˚ c in A˚ d in A˚ e in A˚ f in A˚
GA1min 1.494 1.422 1.367 1.413 1.401 12.706
GA2min 1.494 1.422 1.367 1.406 1.405 12.696
GA3min 1.494 1.422 1.367 1.405 1.404 12.696
GA4min 1.494 1.423 1.367 1.413 1.401 12.739
GA5min 1.368 1.422 1.494 1.413 1.400 12.640
GA6min 1.368 1.422 1.494 1.413 1.400 12.648
GA7min 1.494 1.423 1.366 1.413 1.401 12.711
GA8min 1.368 1.422 1.495 1.413 1.400 12.659
GA9min 1.368 1.422 1.495 1.413 1.400 12.651
GA10min 1.368 1.423 1.494 1.413 1.400 12.680
GA11min 1.494 1.423 1.367 1.413 1.401 12.723
GA12min 1.494 1.423 1.367 1.413 1.401 12.795
GA13min 1.494 1.423 1.367 1.413 1.401 12.755
GA14min 1.494 1.423 1.367 1.413 1.400 12.718
GA15min 1.368 1.422 1.495 1.413 1.400 12.721
GA16min 1.366 1.425 1.504 1.413 1.402 12.753
GA17min 1.364 1.426 1.499 1.413 1.402 12.730
Table A.11.: Distances of the Suberone scaffold type GA
A.2.11. Suberone scaffold type JH
Compound a in A˚ b in A˚ c in A˚ d in A˚ e in A˚ f in A˚
JH30min 1.368 1.423 1.494 1.413 1.400 12.645
JH46min 1.794 1.809 1.496 1.413 1.400 12.486
JH126min 1.368 1.423 1.494 1.407 1.404 12.660
JH31min 1.368 1.423 1.494 1.413 1.401 12.639
Table A.12.: Distances of the Suberone scaffold type JH
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A.2.12. Suberone scaffold type MORE
Compound a in A˚ b in A˚ c in A˚ d in A˚ e in A˚ f in A˚
MO1min 1.367 1.423 1.489 1.414 1.405 12.059
MO2min 1.494 1.423 1.365 1.413 1.405 11.517
MO3min 1.364 1.423 1.495 1.405 1.390 12.082
MO4min 1.488 1.422 1.368 1.405 1.391 11.534
MO5min 1.365 1.423 1.495 1.413 1.403 11.794
MO6min 1.489 1.423 1.368 1.413 1.403 11.678
MO7min 1.365 1.423 1.495 1.413 1.400 15.017
MO8min 1.489 1.422 1.368 1.413 1.401 14.682
MO9min 1.365 1.423 1.494 1.412 1.407 11.779
MO10min 1.489 1.423 1.368 1.411 1.407 11.742
MO11min 1.365 1.423 1.494 1.409 1.404 11.847
MO12min 1.489 1.423 1.368 1.409 1.405 11.830
MO13min 1.366 1.423 1.494 1.414 1.405 12.475
MO14min 1.494 1.423 1.367 1.413 1.405 11.715
MO15min 1.367 1.423 1.494 1.412 1.409 11.831
MO16min 1.494 1.423 1.367 1.412 1.409 11.809
MO17min 1.367 1.422 1.494 1.409 1.407 11.877
MO18min 1.494 1.423 1.367 1.409 1.407 11.891
MO19min 1.367 1.422 1.494 1.409 1.407 11.958
MO20min 1.493 1.423 1.367 1.409 1.407 11.930
MO21min 1.367 1.422 1.494 1.412 1.408 11.857
MO22min 1.494 1.424 1.367 1.409 1.412 11.895
MO23min 1.367 1.423 1.494 1.413 1.404 11.851
MO24min 1.494 1.422 1.367 1.413 1.405 11.731
MO25min 1.368 1.422 1.495 1.413 1.401 12.629
MO26min 1.494 1.423 1.369 1.413 1.401 12.726
MO27min 1.368 1.423 1.494 1.413 1.401 12.663
MO28min 1.494 1.423 1.367 1.413 1.401 12.706
MO29min 1.367 1.422 1.494 1.425 1.409 11.182
MO30min 1.494 1.423 1.367 1.425 1.408 11.164
MO31min 1.368 1.422 1.494 1.412 1.399 11.907
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MO32min 1.494 1.423 1.367 1.415 1.401 11.927
MO33min 1.368 1.422 1.494 1.423 1.408 11.125
MO34min 1.494 1.423 1.367 1.422 1.409 11.203
MO35min 1.368 1.422 1.494 1.414 1.401 11.476
MO36min 1.494 1.423 1.367 1.414 1.401 11.451
MO37min 1.368 1.422 1.494 1.416 1.401 11.536
MO38min 1.494 1.423 1.367 1.415 1.402 11.527
MO39min 1.368 1.422 1.494 1.413 1.398 11.936
MO40min 1.494 1.422 1.367 1.413 1.399 12.060
Table A.13.: Distances of the Suberone scaffold type MORE
A.2.13. Suberone scaffold type MORE2
Compound a in A˚ b in A˚ c in A˚ d in A˚ e in A˚ f in A˚
MORE1min 1.510 1.522 1.499 1.381 1.376 12.042
MORE2min 1.510 1.522 1.500 1.381 1.376 12.044
MORE3min 1.510 1.522 1.500 1.412 1.400 12.634
MORE4min 1.510 1.522 1.500 1.412 1.400 12.635
Table A.14.: Distances of the Suberone scaffold type MORE2
A.2.14. Scaffold OTTOSEN compounds
Compound d in A˚ e in A˚ f in A˚
OTTO1min 1.413 1.401 12.177
OTTO2min 1.413 1.401 12.224
OTTO3min 1.413 1.401 11.717
OTTO4min 1.413 1.401 11.675
Table A.15.: Distances of the scaffold type OTTOSEN
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A.2.15. Scaffold REVESZ compounds
Compound d in A˚ e in A˚ f in A˚
REV1min 1.408 1.403 12.471
REV2min 1.408 1.404 12.485
REV3min 1.408 1.403 12.443
REV4min 1.408 1.403 12.449
REV5min 1.408 1.403 12.493
REV6min 1.408 1.404 12.481
REV7min 1.408 1.409 12.797
REV8min 1.399 1.391 12.885
REV9min 1.408 1.403 12.475
REV10min 1.408 1.404 12.483
Table A.16.: Distances of the scaffold type REVESZ
A.2.16. Suberone scaffold type RN
Compound a in A˚ b in A˚ c in A˚ d in A˚ e in A˚ f in A˚
RN13amin 1.510 1.522 1.500 1.413 1.400 12.606
RN14min 1.509 1.522 1.500 1.452 1.377 13.264
RN14amin 1.463 1.341 1.463 1.413 1.401 12.910
RN15min 1.509 1.522 1.500 1.412 1.401 12.610
Table A.17.: Distances of the Suberone scaffold type RN
A.2.17. Suberone scaffold type SG
Compound a in A˚ b in A˚ c in A˚ d in A˚ e in A˚ f in A˚
GA425min 1.358 1.423 1.494 1.413 1.400 12.684
GA430min 1.368 1.423 1.494 1.413 1.401 12.685
GA553min 1.368 1.423 1.494 1.412 1.400 12.721
SK288min 1.366 1.425 1.497 1.412 1.400 12.691
SK316min 1.366 1.425 1.497 1.413 1.400 12.653
SK318min 1.463 1.342 1.462 1.408 1.403 12.822
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SK345min 1.366 1.426 1.496 1.408 1.402 12.669
SK362min 1.366 1.426 1.497 1.413 1.401 12.654
SK383min 1.511 1.519 1.497 1.413 1.400 12.537
SK436min 1.464 1.342 1.464 1.413 1.401 12.863
SK468min 1.511 1.519 1.497 1.408 1.402 12.552
SK508min 1.511 1.519 1.497 1.412 1.400 12.538
SK510min 1.466 1.338 1.465 1.408 1.403 12.490
SK539min 1.500 1.522 1.510 1.408 1.403 12.663
SK541min 1.500 1.522 1.510 1.413 1.402 12.638
SK558min 1.500 1.522 1.510 1.408 1.403 12.670
SK568min 1.500 1.522 1.510 1.413 1.401 12.640
Table A.18.: Distances of the Suberone scaffold type SG
A.2.18. Suberone scaffold type SK
Compound a in A˚ b in A˚ c in A˚ e in A˚
SK1min 1.369 1.432 1.489 1.382
SK2min 1.494 1.423 1.365 1.382
SK3min 1.368 1.432 1.492 1.382
SK4min 1.495 1.424 1.367 1.382
SK5min 1.368 1.423 1.487 1.382
SK6min 1.494 1.423 1.363 1.382
SK7min 1.367 1.425 1.497 1.382
SK8min 1.497 1.420 1.362 1.381
SK9min 1.368 1.423 1.489 -
SK10min 1.494 1.423 1.365 -
SK11min 1.366 1.423 1.492 -
SK12min 1.495 1.424 1.367 -
SK13min 1.367 1.423 1.487 -
SK14min 1.494 1.423 1.363 -
SK15min 1.365 1.425 1.496 -
SK16min 1.497 1.420 1.362 -
SK17min 1.367 1.423 1.494 1.382
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SK18min 1.489 1.423 1.369 1.381
SK19min 1.367 1.424 1.495 1.377
SK20min 1.492 1.423 1.367 1.377
SK21min 1.363 1.423 1.495 -
SK22min 1.487 1.423 1.367 -
SK23min 1.363 1.420 1.498 1.377
SK24min 1.496 1.425 1.366 1.376
SK25min 1.363 1.423 1.495 -
SK26min 1.488 1.422 1.368 -
SK27min 1.367 1.424 1.495 -
SK28min 1.492 1.423 1.367 -
SK29min 1.362 1.423 1.495 -
SK30min 1.486 1.423 1.367 -
SK31min 1.362 1.420 1.498 -
SK32min 1.496 1.425 1.366 -
Table A.19.: Distances of the Suberone scaffold type SK
A.3. Comparisons of the different Suberone scaffolds;
Angles
A.3.1. Suberone scaffold type GA
Compound α in  β in  γ in  δ in   in  & in 
GA1min 120.44 108.52 113.80 113.30 118.81 119.15
GA2min 120.53 108.56 113.90 113.30 118.88 118.98
GA3min 120.50 108.53 113.87 113.28 119.06 118.96
GA4min 120.40 108.44 113.66 113.34 118.84 119.20
GA5min 113.12 114.38 108.63 120.67 118.74 119.31
GA6min 113.12 114.26 108.38 120.77 118.77 119.33
GA7min 120.46 108.61 114.20 113.45 118.80 119.13
GA8min 113.22 114.18 108.54 120.61 118.77 119.34
GA9min 113.21 114.19 108.52 120.67 118.78 119.34
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GA10min 113.29 114.12 108.50 120.49 118.81 119.40
GA11min 120.47 108.50 113.94 113.22 118.79 119.14
GA12min 120.45 108.46 113.91 113.23 118.81 119.15
GA13min 120.31 108.47 113.69 113.49 118.79 119.15
GA14min 120.43 108.57 114.00 113.22 118.77 119.16
GA15min 113.42 113.63 108.39 120.42 118.75 119.32
GA16min 116.59 109.60 111.11 117.97 118.90 119.46
GA17min 116.44 109.19 110.87 117.67 119.18 119.19
Table A.20.: Angles of the Suberone scaffold type GA (α-&)
Compound η in  θ in  ι in  κ in 
GA1min 132.20 117.03 118.82 124.12
GA2min 131.79 117.02 118.90 124.06
GA3min 131.87 117.05 118.88 124.05
GA4min 132.11 116.95 118.73 124.30
GA5min 132.35 119.09 117.22 123.66
GA6min 132.26 119.20 117.00 123.77
GA7min 132.22 117.18 118.68 124.12
- GA8min 132.24 119.10 117.01 123.85
GA9min 132.26 119.09 117.06 123.82
GA10min 132.13 119.08 116.94 123.95
GA11min 132.22 117.12 118.66 124.19
GA12min 132.19 117.09 118.70 124.18
GA13min 132.23 117.10 118.48 124.39
GA14min 132.20 117.20 118.54 124.23
GA15min 132.33 118.91 116.98 124.29
- GA16min 132.32 116.74 117.96 125.26
GA17min 131.61 116.84 118.23 124.87
Table A.21.: Angles of the Suberone scaffold type GA (η-κ)
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A.3.2. Suberone scaffold type JH
Compound α in  β in  γ in  δ in   in  & in 
JH30min 113.15 114.24 108.66 120.66 118.75 119.31
JH46min 112.68 102.65 109.90 120.87 118.77 119.29
JH126min 113.18 114.14 108.66 120.61 118.92 119.18
JH31min 113.15 114.32 108.75 120.67 118.78 119.38
Table A.22.: Angles of the Suberone scaffold type JH (α-&)
Compound η in  θ in  ι in  κ in 
JH30min 132.33 119.00 117.19 123.77
JH46min 132.33 119.81 117.18 122.87
JH126min 131.97 118.95 117.16 123.86
JH31min 132.11 118.98 117.22 123.77
Table A.23.: Angles of the Suberone scaffold type JH (η-κ)
A.3.3. Suberone scaffold type MORE
Compound α in  β in  γ in  δ in   in  & in 
MO1min 113.12 115.43 108.72 122.18 113.43 114.77
MO2min 120.94 108.89 114.80 113.60 113.47 114.66
MO3min 113.82 114.94 109.01 120.81 116.24 111.70
MO4min 122.25 108.61 115.12 113.00 116.30 111.39
MO5min 113.64 114.78 108.88 120.78 113.34 116.38
MO6min 122.10 108.68 115.34 112.99 111.41 116.38
MO7min 113.65 114.83 108.83 120.79 111.57 116.05
MO8min 122.34 108.70 115.40 135.99 111.57 116.13
MO9min 113.64 114.81 108.81 120.76 111.81 115.30
MO10min 122.08 108.58 115.31 113.05 111.94 115.32
MO11min 113.57 115.09 108.90 120.89 113.13 113.53
MO12min 121.93 108.54 115.15 113.02 113.33 113.55
MO13min 113.35 114.14 108.61 120.59 113.37 114.93
MO14min 120.58 108.55 113.74 113.36 113.47 114.73
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MO15min 113.30 114.02 108.56 120.52 111.79 115.12
MO16min 120.54 108.53 114.03 113.31 111.89 115.10
MO17min 113.35 113.92 108.51 120.48 113.32 113.86
MO18min 120.35 108.48 113.75 113.37 113.51 113.86
MO19min 113.52 113.55 108.53 120.29 113.35 113.92
MO20min 120.07 108.32 113.18 113.49 113.52 113.90
MO21min 113.36 113.97 108.51 120.50 111.73 115.37
MO22min 120.02 108.38 112.99 113.65 111.73 115.33
MO23min 113.42 113.72 108.52 120.43 111.51 116.08
MO24min 120.59 108.56 114.14 113.21 111.66 116.12
MO25min 113.12 114.40 108.67 120.64 111.49 115.93
MO26min 120.45 108.45 113.77 113.17 111.71 116.07
MO27min 113.19 114.18 108.65 120.73 111.57 115.95
MO28min 120.53 108.54 113.94 113.32 111.70 116.01
MO29min 113.45 113.72 108.54 120.41 111.44 119.77
MO30min 120.35 108.60 113.85 113.34 112.07 120.08
MO31min 113.23 114.04 108.58 120.57 110.34 115.91
MO32min 120.42 108.56 113.95 113.27 111.65 116.03
MO33min 113.39 113.90 108.57 120.46 112.08 119.83
MO34min 120.41 108.62 113.91 113.31 112.23 119.88
MO35min 113.22 114.20 108.63 120.62 112.29 116.52
MO36min 120.31 108.52 113.69 113.39 112.43 116.40
MO37min 113.18 114.27 108.73 120.64 112.60 116.46
MO38min 120.29 108.45 113.73 113.31 112.53 116.19
MO39min 113.23 113.96 108.56 120.52 109.73 116.09
MO40min 120.37 108.59 113.89 113.28 109.83 115.91
Table A.24.: Angles of the Suberone scaffold type MORE (α-&)
Compound η in  θ in  ι in  κ in 
MO1min 130.78 118.90 119.19 121.90
MO2min 130.66 116.59 120.66 122.72
MO3min 131.98 120.48 116.86 122.62
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MO4min 132.30 118.87 118.86 122.26
MO5min 132.13 120.52 116.76 122.68
MO6min 132.03 119.09 118.96 121.94
MO7min 132.15 120.53 116.76 122.67
MO8min 132.16 119.12 119.02 121.85
MO9min 132.69 120.49 116.73 122.74
MO10min 132.50 119.01 119.07 121.91
MO11min 133.29 120.60 116.84 122.52
MO12min 133.06 118.95 118.83 122.20
MO13min 130.73 118.89 117.12 123.96
MO14min 130.75 116.92 118.81 124.25
MO15min 132.77 118.81 117.07 124.09
MO16min 132.65 117.00 119.01 123.97
MO17min 132.82 118.81 117.02 124.15
MO18min 132.62 117.03 118.76 124.19
MO19min 132.70 118.60 116.89 124.50
MO20min 132.58 116.89 118.46 124.63
MO21min 132.40 116.82 117.40 124.13
MO22min 132.64 116.78 118.41 124.80
MO23min 132.24 118.72 117.03 124.23
MO24min 131.97 117.10 119.03 123.84
MO25min 132.29 119.09 117.27 123.61
MO26min 132.01 117.01 118.80 124.17
MO27min 132.27 118.91 117.26 123.81
MO28min 132.10 116.95 119.00 124.03
MO29min 125.79 118.65 117.11 124.21
MO30min 125.73 116.98 118.88 124.11
MO31min 133.71 118.86 117.15 123.96
MO32min 132.13 117.02 118.95 124.00
MO33min 125.85 118.72 117.15 124.11
MO34min 125.94 116.99 118.91 124.08
MO35min 130.46 118.87 117.22 124.88
MO36min 130.45 116.94 118.80 124.24
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MO37min 130.77 118.92 117.21 123.85
MO38min 131.00 117.01 118.78 124.18
MO39min 134.02 118.82 117.12 124.03
MO40min 134.02 117.05 118.89 124.03
Table A.25.: Angles of the Suberone scaffold type MORE (η-κ)
A.3.4. Suberone scaffold type MORE2
Compound α in  β in  γ in  δ in   in  & in 
MORE1min 115.63 115.86 110.13 119.96 118.32 116.7
MORE2min 115.63 115.9 110.18 119.98 118.22 116.69
MORE3min 115.67 115.96 110.28 120.01 118.61 118.91
MORE4min 115.69 115.97 110.28 120.01 118.54 118.93
Table A.26.: Angles of the Suberone scaffold type MORE2 (α-&)
Compound η in  θ in  ι in  κ in 
MORE1min 116.8 119.18 116.94 123.8
MORE2min 116.81 119.14 116.98 123.8
MORE3min 133.38 119.23 117.00 123.65
MORE4min 133.37 119.21 117.03 123.65
Table A.27.: Angles of the Suberone scaffold type MORE2 (η-κ)
A.3.5. Scaffold type OTTOSEN
Compound α in  β in  γ in  δ in   in  & in 
OTTO1min - - - - 118.73 118.99
OTTO2min - - - - 118.78 119.11
OTTO3min - - - - 118.76 119.02
OTTO4min - - - - 118.76 119.02
Table A.28.: Angles of the scaffold type OTTOSEN (α-&)
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Compound η in  θ in  ι in  κ in 
OTTO1min 132.33 119.83 119.59 120.34
OTTO2min 132.32 120.86 118.75 120.34
OTTO3min 132.36 117.97 119.62 122.41
OTTO4min 132.29 118.02 120.57 121.37
Table A.29.: Angles of the scaffold type OTTOSEN (η-κ)
A.3.6. Scaffold type REVESZ
Compound α in  β in  γ in  δ in   in  & in 
REV1min - - - - 118.86 118.69
REV2min - - - - 118.89 118.71
REV3min - - - - 118.92 118.70
REV4min - - - - 118.89 118.73
REV5min - - - - 118.90 118.73
REV6min - - - - 118.62 118.04
REV7min - - - - 118.67 118.34
REV8min - - - - 118.41 113.92
REV9min - - - - 118.88 118.68
REV10min - - - - 118.69 118.10
Table A.30.: Angles of the scaffold type REVESZ (α-&)
Compound η in  θ in  ι in  κ in 
REV1min 132.95 120.47 118.12 121.36
REV2min 132.93 120.27 117.92 121.79
REV3min 132.83 120.46 118.04 121.49
REV4min 132.80 120.43 118.04 121.47
REV5min 132.87 120.06 117.92 121.99
REV6min 131.56 120.17 118.23 121.54
REV7min 131.31 111.05 121.88 127.03
REV8min 134.75 110.88 120.61 128.49
REV9min 132.96 120.15 118.06 121.77
220
A.3. COMPARISONS OF THE DIFFERENT SUBERONE SCAFFOLDS; ANGLES
REV10min 131.41 120.11 118.37 121.48
Table A.31.: Angles of the scaffold type REVESZ(η-κ)
A.3.7. Suberone scaffold type SG
Compound α in  β in  γ in  δ in   in  & in 
GA425min 113.21 114.04 108.66 120.48 118.79 119.34
GA430min 113.21 114.07 108.68 120.49 118.71 119.33
GA553min 113.34 113.78 108.57 120.40 118.53 118.90
SK288min 113.61 113.29 109.37 116.65 118.59 118.98
SK316min 113.42 113.70 109.44 116.80 118.79 119.37
SK318min 119.26 111.51 112.24 114.98 118.89 118.80
SK345min 113.50 133.53 109.37 116.76 118.93 119.00
SK362min 113.42 113.71 109.46 116.79 118.73 119.36
SK383min 115.69 115.51 109.82 116.12 118.82 119.37
SK436min 119.12 111.64 111.52 119.57 118.80 119.18
SK468min 115.71 115.4 109.76 116.07 118.92 118.96
SK508min 115.69 115.52 109.84 116.12 118.75 119.35
SK510min 116.94 127.66 127.64 116.96 118.90 118.79
SK539min 120.14 110.27 116.14 115.63 118.95 118.77
SK541min 120.13 110.32 116.21 115.65 118.73 119.12
SK558min 120.15 110.28 116.16 115.72 118.90 118.72
SK568min 120.14 110.3 116.22 115.72 118.72 119.1
Table A.32.: Angles of the Suberone scaffold type SG (α-&)
Compound η in  θ in  ι in  κ in 
GA425min 132.29 118.87 117.14 124
GA430min 132.27 118.84 117.16 124
GA553min 133.65 118.78 117.07 124.1
SK288min 133.42 118.46 116.62 124.9
SK316min 132.26 118.62 116.67 124.7
SK318min 132.81 116.73 116.57 126.70
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SK345min 132.81 118.52 116.70 124.8
SK362min 132.25 118.60 116.69 124.70
SK383min 132.14 119.34 116.71 123.8
SK436min 132.21 116.99 116.58 126.43
SK468min 132.73 119.27 116.69 123.9
SK508min 132.13 119.31 116.72 123.9
SK510min 132.72 119.14 119.40 121.1
SK539min 132.70 116.98 119.40 123.50
SK541min 132.18 117.03 119.37 123.5
SK558min 132.76 116.90 119.47 123.5
SK568min 132.20 116.97 119.47 123.5
Table A.33.: Angles of the Suberone scaffold type SG (η-κ)
A.3.8. Suberone scaffold type SK
Compound α in  β in  γ in  δ in   in  & in 
SK1min 113.01 115.37 108.70 122.18 - 120.80
SK2min 120.81 108.94 114.98 113.51 - 120.59
SK3min 113.63 113.24 108.34 120.68 - 120.81
SK4min 120.32 108.98 114.03 113.63 - 120.63
SK5min 113.51 113.45 108.45 121.04 - 120.82
SK6min 120.40 108.81 114.01 114.92 - 120.62
SK7min 113.52 113.49 109.34 116.75 - 120.83
SK8min 118.94 107.94 110.08 112.65 - 120.69
SK9min 113.04 115.63 108.87 122.27 - -
SK10min 121.08 108.98 115.09 113.47 - -
SK11min 113.59 113.53 108.40 120.80 - -
SK12min 120.64 109.01 114.26 113.52 - -
SK13min 113.46 113.74 108.48 121.17 - -
SK14min 120.64 108.80 114.01 114.91 - -
SK15min 113.53 113.65 109.35 116.81 - -
SK16min 119.16 107.90 110.12 112.62 - -
SK17min 113.45 115.17 108.35 121.23 - 121.09
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SK18min 122.12 108.79 115.57 112.93 - 120.91
SK19min 113.90 113.64 108.91 120.19 - 120.20
SK20min 120.70 108.49 113.63 113.63 - 121.00
SK21min 114.92 114.03 108.83 120.49 - -
SK22min 120.98 108.44 113.29 113.29 - -
SK23min 112.61 110.14 107.97 119.69 - 116.69
SK24min 116.60 109.39 113.42 113.53 - 116.59
SK25min 113.71 115.02 109.01 120.89 - -
SK26min 122.29 108.68 115.29 112.96 - -
SK27min 113.56 114.22 109.04 120.46 - -
SK28min 120.73 108.38 113.35 113.55 - -
SK29min 115.00 114.27 108.95 120.55 - -
SK30min 121.24 108.40 113.47 113.44 - -
SK31min 112.76 109.94 107.95 118.93 - -
SK32min 116.86 109.37 113.62 113.44 - -
Table A.34.: Angles of the Suberone scaffold type SK (α-&)
Compound η in  θ in  ι in  κ in 
SK1min 120.18 118.96 119.17 121.86
SK2min 120.14 116.80 120.70 122.46
SK3min 120.20 118.71 116.81 124.47
SK4min 120.13 117.51 118.63 123.83
SK5min 120.26 118.74 116.72 124.53
SK6min 120.14 117.34 118.62 124.01
SK7min 120.33 118.57 116.63 124.78
SK8min 120.05 117.42 116.99 125.58
SK9min - 119.09 119.24 121.65
SK10min - 116.86 120.78 122.32
SK11min - 118.93 116.73 124.33
SK12min - 117.61 118.75 123.61
SK13min - 118.96 116.67 124.35
SK14min - 117.37 118.61 123.99
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SK15min - 118.73 116.56 124.70
SK16min - 117.46 116.95 125.59
SK17min 120.35 120.87 116.99 122.12
SK18min 120.44 119.27 119.02 121.70
SK19min 112.73 118.41 117.49 124.08
SK20min 112.51 116.72 118.79 124.49
SK21min - 118.64 117.35 123.98
SK22min - 113.52 116.68 118.68
SK23min 119.05 117.00 117.42 125.58
SK24min 118.75 116.58 118.59 124.81
SK25min - 120.70 116.82 122.44
SK26min - 119.11 118.84 122.03
SK27min - 118.74 117.56 123.67
SK28min - 116.79 118.78 124.42
SK29min - 118.81 117.36 123.80
SK30min - 116.82 118.69 124.47
SK31min - 116.89 117.43 125.67
SK32min - 116.65 118.58 124.76
Table A.35.: Angles of the Suberone scaffold type SK (η-κ)
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